A Trial of Intra-pleural bacteriaL immunoTherapy in mesothelioma (TILT) – a feasibility study using the trial within a cohort methodology. by Bibby, Anna C
                          
This electronic thesis or dissertation has been





 A Trial of Intra-pleural bacteriaL immunoTherapy in mesothelioma (TILT) – a feasibility
study using the trial within a cohort methodology.
General rights
Access to the thesis is subject to the Creative Commons Attribution - NonCommercial-No Derivatives 4.0 International Public License.   A
copy of this may be found at https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode  This license sets out your rights and the
restrictions that apply to your access to the thesis so it is important you read this before proceeding.
Take down policy
Some pages of this thesis may have been removed for copyright restrictions prior to having it been deposited in Explore Bristol Research.
However, if you have discovered material within the thesis that you consider to be unlawful e.g. breaches of copyright (either yours or that of
a third party) or any other law, including but not limited to those relating to patent, trademark, confidentiality, data protection, obscenity,
defamation, libel, then please contact collections-metadata@bristol.ac.uk and include the following information in your message:
•	Your contact details
•	Bibliographic details for the item, including a URL
•	An outline nature of the complaint
Your claim will be investigated and, where appropriate, the item in question will be removed from public view as soon as possible.
 
 
A Trial of Intra-pleural bacteriaL immunoTherapy in 
mesothelioma (TILT) – a feasibility study using the trial 
within a cohort methodology 
 
Anna Claire Bibby 
 
 
A dissertation submitted to the University of Bristol in 
accordance with the requirements for award of the degree of 
Doctor of Philosophy in the Faculty of Health Sciences 
 









Malignant pleural mesothelioma (MPM) is an incurable, asbestos-related 
cancer of the chest cavity.  Treatment options are limited, although 
immunotherapy has shown promise in recent trials.  This research explored 
bacterial immunotherapy in MPM, specifically the feasibility and 
acceptability of a trial of intra-pleural bacterial agents, using an innovative, 




Mixed methods were used.  The existing literature on intra-pleural 
bacterial agents in pleural malignancy was summarised.  Subsequently, a 
population-based cohort study was undertaken to examine whether 
bacteria in the pleural space due to infection were associated with survival 
in mesothelioma.  This was followed by a feasibility study of two intra-
pleural bacterial agents in MPM, using the trial within a cohort (TwiC) 
methodology.  Qualitative interviews with participants and their relatives 




Previous studies of intra-pleural bacterial agents were methodologically 
heterogenous and at risk of bias, rendering data synthesis impossible.  In 
contrast to the original hypothesis, pleural infection was associated with 
shorter survival in mesothelioma, although confounding could have 
affected this finding. 
 
The trial did not meet the pre-specified recruitment criteria and was 
therefore deemed unfeasible.  Additionally, it was not possible to maintain 
blinding of control participants and post-randomisation attrition was 
problematic.  Bacterial agents generated significant inflammatory 
responses but, despite this, the trial processes and methodology were 
generally acceptable to participants and relatives. 
 
Qualitative interviews revealed that MPM patients sought certainty and 
absolutes in response to anxiety about their future.  This affected their 




The efficacy of intra-pleural bacterial immunotherapy in MPM remains 
unproven, but future trials should not employ the TwiC design.  Given the 
importance of quality of life to people with MPM, effective communication 
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1. Chapter 1 - Introduction 
1.1. Background 
Mesothelioma is an aggressive cancer caused by previous exposure to asbestos.(1)  It 
affects the outer lining of the lung (malignant pleural mesothelioma, MPM) most 
frequently, but can also be found in the abdomen (peritoneal mesothelioma), the lining 
of the heart (pericardial mesothelioma) and rarely the genitals (tunica vaginalis 
mesothelioma).(1-3)  Mesothelioma is incurable, with limited treatment options and a 
median survival of less than 12 months from diagnosis.(1-3)  The current standard of 
care consists of combination platinum-based chemotherapy alongside pemetrexed, 
which extends median survival by approximately 2-3 months compared with single 
agent platinum regimens.(4, 5)  Adding bevacizumab to chemotherapy provides a 
further 3 month survival benefit, but this agent is not currently recommended by the 
National Institute of Health and Clinical Excellence (NICE) for use in MPM in the UK.(6) 
 
Immunotherapy is a form of treatment which uses the individual’s immune system to 
attack cancer cells.  It has revolutionised the treatment of several refractory 
malignancies, including malignant melanoma and non-small cell lung cancer (NSCLC).(7-
10)  There is a sound immunological rationale for the use of immunotherapy in 
MPM,(11-13) and early phase trials have shown promising results.(14-17)  Full-scale, 
phase III, randomised trials are underway.   
 
Before the current era of engineered immunotherapeutic agents, bacterial agents were 
used to stimulate the immune response.  Although rudimentary, as bacterial agents 
tend to stimulate a widespread and non-specific immune response compared to modern 
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targeted agents, bacterial immunotherapy has the benefit of being able to be 
administered locally, potentially reducing the risk of side effects.(18)  In MPM, bacterial 
immunotherapy agents can be delivered directly into the pleural cavity via an indwelling 
pleural catheter – a semi-permanent silicone tube inserted into the chest to drain fluid 
and ameliorate symptoms in patients with MPM. In the context of drug administration, 
the pleural cavity tends to act as a “closed box”, with minimal absorption of the 
therapeutic agent into the systemic circulation.(18, 19) This could potentially maximise 
drug effectiveness by concentrating the therapeutic agent in the immediate tumour 
environment, whilst limiting side effects elsewhere in the body. 
 
The overall aim of the work described in this thesis was to explore the role of intra-
pleural bacterial immunotherapy in MPM, to determine whether a full-scale trial was 
warranted, feasible and acceptable to patients.  The research used a mixed methods 
approach, culminating in a feasibility trial using an innovative, pragmatic methodology. 
 
1.1.1. Thesis structure 
The research aim was addressed via four separate work-streams.  Workstream 1 is 
described in Chapter 2 and comprised a systematic review of the existing data relating 
to survival outcomes for intra-pleural bacterial agent usage in pleural malignancy.  
Chapter 3 contains the methods, results and discussion of Workstream 2, a population-
based cohort study that used data from Hospital Episode Statistics (HES) to evaluate 
whether bacteria in the pleural space as a result of pleural infection were associated 
with survival in mesothelioma.  Workstream 3 consisted of a feasibility trial of two intra-
pleural bacterial immunotherapy agents in MPM and is reported in Chapter 4.  The trial, 
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called TILT, was based on the trial within a cohorts (TwiC) design, with the primary 
objective of determining whether the methodology was practical and achievable in this 
patient population.  The acceptability of the trial to participants and their family 
members was explored in qualitative interviews, undertaken in Workstream 4 and 
summarised in Chapter 5.  Workstream 4 also explored the experience of living with 
MPM and of receiving the trial agents.  Chapter 6 contains a discussion of the findings of 
all four Workstreams, interpreted in relation to the existing literature and each other, 
with a view to informing future research trials.  
 
The remainder of this chapter will provide an overview of mesothelioma (section 1.2), 
including pathogenesis, clinical presentation and prognosis.  This will be followed by a 
description of immunotherapy in MPM (section 1.3), culminating in a description of the 
two bacterial agents used in the subsequent trial, OK432 and Bacillus Calmette–Guérin 
(BCG).  The chapter will then describe the TwiC methodology and its benefits and 
limitations (section 1.4), before closing with an outline of the overall research plan and 




Malignant pleural mesothelioma (MPM) is an aggressive cancer of the outer lining of the 
lung (Figure 1.1). Mesothelioma can also affect the peritoneum, pericardium and tunica 
vaginalis, although these forms of disease are less common.(1)  There are three main 
histological sub-types: epithelioid, sarcomatoid and biphasic or mixed, with prognosis 
varying depending on type. 
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1.2.2. Pathogenesis 
The majority of mesothelioma cases are caused by previous exposure to asbestos.  
Asbestos, a naturally occurring silicate mineral, was once considered an ideal 
construction material due to its high tensile strength, ability to withstand high 
temperatures and low cost.(20)  Indeed its very name is a derivation from an ancient 
Greek word, ἄσβεστος, meaning “inextinguishable”.  It was widely used in several 
industries throughout the 1960s, 70s and 80s.  Asbestos has two different structural 
forms - curly, serpentine fibres of chrysotile, or ‘white’ asbestos and sharp, needle-like 
fibres of amphibole asbestos.  The latter is further divided into crocidolite (blue), 
amosite (brown), and anthophyllite, actinolite and tremolite asbestos. Heavy or 
prolonged exposure to any type of asbestos fibre increases the likelihood of developing 
MPM, however, the risk is highest following exposure to amphibole fibres.(1, 21)  
 
 
Figure 1.1 Malignant pleural mesothelioma 
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The mechanism of carcinogenesis in mesothelioma is multifactorial.  Asbestos fibres are 
inhaled and migrate to the pleura.  Within the pleural space, fibres cause irritation and a 
repeated cycle of tissue damage and repair is established. The presence of oxygen free 
radicals, released by asbestos fibres when phagocytosed by macrophages, causes intra-
cellular DNA damage and abnormal repair.(22)  Asbestos fibres also penetrate 
mesothelial cells, where they interfere with mitosis, cause mutations in DNA and alter 
chromosome structure. Asbestos-exposed mesothelial cells release inflammatory 
cytokines, including transforming growth factor β (TGF β), platelet-derived growth factor 
(PDGF) and vascular endothelial growth factor (VEGF).(22) This creates a favourable 
micro-environment for tumour growth. Finally asbestos induces the phosphorylation of 
various protein kinases, leading to increased expression of proto-oncogenes and further 
promotion of abnormal cellular proliferation.(23) 
 
1.2.3. Epidemiology  
The ancient Roman scholar and natural scientist, Pliny the Younger was the first to 
notice the potential harmful effects of asbestos.  He observed that people who worked 
in asbestos mines would often suffer from a mysterious respiratory illness that he called 
the “disease of slaves”.(24)  To protect against this, he advocated the use of a goat or 
lamb bladder as a rudimentary respiratory filter, although history does not relate 
whether this was an effective intervention.  
 
The link between asbestos and cancer was first reported in 1935, but it took another 20 
years before MPM was described and a direct causal link was determined.(25-27)  
Attempts to reduce exposure to asbestos dust date back to the Asbestos Industry 
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Regulations document of 1931, but guidelines were poorly followed and several 
companies continued to wilfully expose their workers to asbestos whilst fully aware of 
the risk to their health.(20)  In October 1965, this shameful practice was exposed via a 
front-page article in the Sunday Times, entitled “Scientists track down killer dust 
disease”, which clearly articulated the link between exposure to asbestos and the 
development of MPM.  In the article, it was stated that companies had known about the 
dangers of asbestos for years and should have taken steps to protect their workforce.  
This, combined with a change in legislation relating to the period of limitation, resulted 
in the first successful legal claim for damages in 1967.(28)  A voluntary industry ban on 
blue (crocidolite) asbestos was introduced the same year in the UK, with a similar 
voluntary ban on brown (amosite) asbestos following in 1980.  However, a formal ban of 
the import and use of crocidolite and amosite asbestos was not imposed until 1985 and 
it took a further 14 years before white (chrysotile) asbestos was banned outright in 
1999.  Sadly, many countries around the world, including the US, Russia and Brazil 
continue to use, mine and export asbestos, despite its harmful effects. 
 
There is a latency period of 30 to 50 years between exposure to asbestos and 
presentation with MPM.(1, 22, 29-31)  As a result, despite the legislation described 
above, UK and global incidence of mesothelioma has risen steadily over the past 4 
decades and continues to do so.  Precise numbers are difficult to determine as the 
disease is likely to be underreported in areas of low incidence and in low and middle 
income countries.  However, an estimate based on 2008 data suggested an average of 
14,200 new cases worldwide each year.(32) 
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The UK has one of the highest mesothelioma mortality rates in the world, with 2542 
people dying from the disease in 2015.(33)  Incidence is predicted to peak in the UK this 
year (Figure 1.2), however the ongoing, unregulated use of asbestos in countries with 
high population densities, such as India, China and Russia, means that mesothelioma will 






The industrial nature of mesothelioma means that there is a male predominance, with a 
male to female ratio of approximately 4:1.(38)  Many women with mesothelioma have a 
history of para-occupational exposure, for example washing their husband’s overalls, 
although some have been exposed directly from buildings during their schooling or 
through their own work. 
Figure 1.2 Mesothelioma deaths, actual and predicted, in the UK until 2030.  
Figure reproduced from the UK Health & Safety Executive - Mesothelioma 
mortality in Great Britain 1968-2015.(33) 
8 
1.2.4. Clinical presentation 
Over 85% of people with MPM present with a pleural effusion, where fluid has built up 
around the outside of the lung.(39)  This causes breathlessness in most, and chest pain 
in many.  Symptoms caused by pleural effusions can be managed by chemical 
pleurodesis (instilling an inflammatory agent into the pleural space to promote adhesion 
of the two pleural surfaces) or insertion of an IPC (Figure 1.3).(40)  If an IPC is inserted, it 
creates the possibility of delivering therapeutic agents directly into the pleural cavity via 
the catheter.(41, 42)  
 
 
Figure 1.3 An indwelling pleural catheter (IPC) 
 
Breathlessness can also arise as a result of the tumour impeding respiratory dynamics, 
particularly in late disease when the tumour encases the lung.  Extensive tumour or 
bulky disease can also lead to “trapped” or non-expandable lung (NEL), where the lung 
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is unable to inflate fully to fill the hemi-thorax, and fluid build-up is inevitable.(39)  Chest 
pain can also occur as a result of direct tumour invasion into the chest wall.   
 
Extra-pulmonary symptoms such as weight loss and fatigue are often present in MPM 
and occur as a result of tumour cytokines in the systemic circulation and the host’s 
response to the tumour.  Fevers and sweats, also due to tumour cytokines and host 
response, are common in MPM and are particularly difficult to manage. 
 
1.2.5. Prognosis 
Prognosis is poor in MPM, with median survival ranging from 8 to 14 months from 
diagnosis.(29, 30, 38, 43) Of the different histological sub-types, sarcomatoid MPM is 
associated with the worst outcomes, with median survival just 4 months.  In contrast, 
epithelioid sub-type has the most favourable prognosis with a median survival of 13.1 
months.(29, 38, 43)  These median values do not tell the whole story, however, as there 
are some people with remarkably long survival, up to ten years or longer.  Female 
gender, younger age at diagnosis and good functional status are some of the factors 
associated with longer survival, however there is no reliable biomarker or test that can 
identify “long survivors” at initial presentation.  The most useful prognostic tool is a 
decision tree developed by Brims et al (Figure 1.4) that uses readily-available clinical 
factors to separate patients into four groups, with varying estimates of life-expectancy 




Figure 1.4 Prognostic decision tree for malignant pleural mesothelioma. Figure reproduced from 
Brims et al - A novel clinical prediction model for prognosis in malignant pleural mesothelioma 
using decision tree analysis.(44) 
 
1.2.6. Treatment options 
Treatment options are limited in MPM, and none are curative.  Systemic anti-cancer 
therapy is the only treatment modality that has been shown to improve survival in 
randomised controlled trials (RCT).(4, 5) However, prior to 2003 the evidence was poor, 
with one large RCT demonstrating that chemotherapy offered no survival benefit and no 
improvement in quality of life (QoL) compared with active symptom control.(45)  The 
lack of available treatment options led to widespread medical nihilism – an attitude that 
has fortunately changed over the past decade as the increased number of MPM trials 
has yielded more options and a more hopeful outlook. 
 
1.2.6.1. Chemotherapy  
In 2003, two pivotal phase III trials were published that changed the landscape of 
chemotherapy in MPM.(4, 5)  The trials investigated, respectively, two third-generation 
anti-folate agents, pemetrexed and raltitrexed, which inhibit DNA synthesis and prevent 
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tumour proliferation. Both trials combined the anti-folate agent with cisplatin and found 
that the combination regimen was associated with a survival benefit of approximately 3 
months compared with cisplatin alone.  As a result, Pemetrexed was approved by global 
marketing authorities for use in MPM in combination with cisplatin.   
 
Over 15 years later, pemetrexed and cisplatin doublet remains the standard first-line 
chemotherapy regimen. This is despite the fact that overall response rates to 
chemotherapy were low – approximately 40% in the trials and just 26% when the drugs 
were rolled out in the US as part of an expanded access programme.(4, 46, 47)  
Awareness of the marginal benefits alongside concern about potential side effects may 
explain the variation in chemotherapy uptake around the UK, with less than 50% of 
eligible people choosing to receive it in some UK centres.(38, 48)  
 
1.2.6.2. Targeted therapy 
More recently, the VEGF antagonist, bevacizumab, was shown to prolong survival when 
used alongside standard chemotherapy in MPM.(6) The multicentre, phase III MAPS trial 
randomised 448 participants to receive cisplatin and pemetrexed with or without 
bevacizumab. Patients who received bevacizumab had a median survival of 18.8 months 
(95% confidence interval (CI) 15.9-22.6) compared with 16.1 months (14.0-17.9) in the 
chemotherapy alone arm (p=0.017). Bevacizumab treatments was also associated with 
longer progression-free survival (PFS) and similar adverse event rates, leading the 
authors to conclude bevacizumab is warranted alongside first-line standard 
chemotherapy in patients with unresectable MPM.  However, in the UK, bevacizumab 
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has not been recommended by NICE and access is limited.  It is available in Europe since 
gaining marketing authorisation from the European Medicines Agency for use in MPM. 
 
New treatment options are desperately needed for MPM and immunotherapy has 




In 2013, immunotherapy was declared the scientific breakthrough of the year by Science 
Journal.(55)  However, the concept of harnessing the immune system to target tumours 
was not a new one, indeed as far back as 1890, Dr William Coley was injecting 
osteosarcomas with Erysipelas (a bacterium that causes skin infections, now known as 
Streptococcus pyogenes) in the earliest recorded attempt at cancer immunotherapy.(56)  
Working in the pre-antibiotic age, his success rates were compromised, predictably, by 
sepsis-related adverse events.  However, the theory behind his work endured, with 
interest in immunotherapy re-emerging periodically throughout the following 
century.(57, 58) 
 
The modern era of cancer immunotherapy is dominated by a group of drugs known as 
immune checkpoint inhibitors (ICI).  These agents stimulate T lymphocyte activity by 
blocking inhibitory receptors (“checkpoints”) on the T cell surface, thus preventing the 
cell from being downregulated (Figure 1.5).  Specific checkpoints that have been 
targeted are the programmed death 1 (PD-1) receptor and its ligand, PD-L1, as well as 
the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).  ICI agents that block PD-1, 
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PD-L1 or CTLA-4 have been shown to improve survival in malignant melanoma, NSCLC 
and renal cell carcinoma, and are now included in the standard care pathways for these 
tumours.(8, 10, 59-66)   Fittingly, given the impact these agents have had on several 
poor-prognosis malignancies, the two scientists who identified the immune checkpoints 
and enabled the development of ICI, Drs Tasuku Honjo and James P. Allison, were jointly 
awarded the Nobel Prize in Medicine in 2018. 
 
Figure 1.5 The immune checkpoint pathway and targets of checkpoint inhibition 
 
1.3.2. The rationale for immunotherapy in mesothelioma 
Immunotherapy is an appealing concept in mesothelioma, as it is a tumour with certain 
immuno-evasive properties.  Mesothelioma’s propensity to aggressively invade local 
structures stems, in part, from its ability to suppress local immune cell populations that 
usually protect against tumour progression.  For example, Cytotoxic T Lymphocytes 
(CTL) and Natural Killer (NK) cells usually respond to tumour antigens, limit tumour 
growth and enhance tumour killing, however these cells are depleted in the pleura of 
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patients with MPM.(11, 12, 67, 68)  The ability to overcome this local 
immunosuppression and maintain functional lymphocyte populations in the tumour 
environment is associated with longer survival in MPM.(13, 69, 70) 
 
1.3.3. Immune checkpoint inhibition in mesothelioma 
Several ICI have been investigated in MPM, the first of which was the CTLA-4 antagonist, 
tremelimumab.  Although phase II data looked promising, a subsequent RCT 
demonstrated no difference in overall survival (OS) between patients treated with 
tremelimumab or placebo.(50, 51)  A potential explanation for this disappointing result 
lies in the different functions of the CTLA-4 and PD-1 receptors.  CTLA-4 is involved in 
priming CD4 + memory and helper T cells, whilst PD-1 is predominantly expressed on, 
and involved in the inhibition of, CD8+ effector T cells.(71, 72)  It is possible, therefore, 
that PD-1 blockade may be more effective than targeting CTLA-4, particularly in PD-L1 
expressing tumours such as mesothelioma.   
 
ICI targeting the PD-1 receptor or its ligand PD-L1 have also been investigated in MPM.  
Like tremelimumab, early phase studies were encouraging.  The phase 1b KEYNOTE-028 
saw pembrolizumab (a PD-1 inhibitor) given to 25 patients who had previously received 
chemotherapy.  Disease control, defined as a partial response or stable disease 
following treatment, was seen in 18 (72%) of participants.(14)  Another single-arm study 
of pembrolizumab (NCT02399371) demonstrated similar disease control rates (DCR) of 
66% (41/65), with median PFS of 4.5 months (95% CI 2.3 to 6.2) and median OS of 11.5 
months (95% CI 7.6 to 14) in previously-treated MPM patients.(73)  However, 
subsequent clinical data from 93 patients treated with pembrolizumab off-label 
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reported slightly lower DCR of 48%, and median OS of 7.2 months compared with 18 
months in KEYNOTE-028.(74)  A phase III RCT of pembrolizumab in the second line 
setting (PROMISE, NCT02991482) reported initial results at the European Society for 
Medical Oncology Conference in October 2019.  The trial failed to meet its primary 
endpoint of improved PFS compared with second-line chemotherapy.  PFS was 2.5 
months (95% CI 2.1-4.2) in patients treated with pembrolizumab, compared with 3.4 
months (95% CI 2.2-4.3) in those treated with gemcitabine or vinorelbine.(75) Full 
publication of the results is awaited. 
 
Another PD-1 inhibitor, nivolumab has been investigated in MPM in three phase II trials, 
NivoMes, MAPS2 and MERIT.  In the former, 16 patients out of 34 (47%, 95% CI 30%–
65%) demonstrated disease control at 12 weeks after treatment with single agent 
nivolumab, with an acceptable toxicity profile.(16)  Similarly, in the nivolumab arm of 
MAPS2, 24 of 54 (44%, 95% CI 31–58) patients treated with single-agent nivolumab had 
disease control at 12 weeks.(17)  More recently, the Japanese MERIT study 
demonstrated DCR of 68% (95% CI, 50.8–80.9) in 34 patients treated with nivolumab in 
the second- or third-line setting.(76)  Reponses persisted with a median duration of 
response of 11.1 months and median OS 17.3 months.  Randomised comparative data is 
awaited from the phase III CONFIRM trial (NCT03063450), which is expected to report in 
the final quarter of 2021.(77) 
 
A single PD-L1 antagonist has been trialled in MPM, in a phase 1b, dose expansion 
cohort study called JAVELIN.  Fifty-three, heavily pre-treated patients with pleural and 
peritoneal MPM were given avelumab, with the aim of evaluating safety and initial 
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efficacy.(78)  Five patients had a complete or partial response, giving an overall 
response rate of 9% (5/53, 95% CI, 3.1%-20.7%).  Responses were long-lasting, with a 
median duration of response of 15.2 months (95% CI 11.1–not estimable).  A further 26 
patients (49%) had stable disease, generating a DCR of 58%.  Median PFS was 4.1 
months (95% CI 1.4 to 6.2) and median OS 10.7 months (95% CI 6.4 to 20.2).  The drug 
had an acceptable toxicity profile with only 5 treatment related adverse events and no 
treatment related deaths. 
 
The only ICI that has been used in the first-line setting for MPM is durvalumab.  In the 
single-arm, phase II DREAM study, 54 treatment-naïve patients were treated with 
durvalumab alongside standard pemetrexed and cisplatin chemotherapy.(79)  The 
overall radiological response rate was 48% (26/54, 95% CI 35-61%), with disease control 
achieved in 87% (47/54).  Median PFS was 6.9 months (95% CI 5.5-9.0) with an 
estimated 1-year survival rate of 65% (95% CI 54-79) after 24.6 months follow-up.  
However, side effects were common, with 36/54 participants experiencing one or more 
adverse event of grade 3 or higher.  
 
Given the distinct immunological functions of the PD-1 and CTLA-4 receptors, it is 
possible that the effect of blocking one in isolation is limited if the other pathway 
remains uninhibited.  Experience in the melanoma field supports this hypothesis, with 
evidence that the combination of ipilimumab (a CTLA-4 antagonist) and nivolumab 
produced a synergistic effect on survival outcomes compared with either agent 
alone.(61-63)   
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The same combination of agents were trialled in MPM in the CHECKMATE-743 trial. This 
randomised, open-label, phase III trial compared the survival benefit of nivolumab plus 
ipilimumab with standard chemotherapy in the front-line setting.  The results were 
presented for the first time at the Virtual Presidential Symposium at the World 
Conference on Lung Cancer in August 2020.  The primary outcome, overall survival, was 
18.1 months in the ipilimumab and nivolumab arm, compared with 14.1 months in the 
standard chemotherapy arm, producing an adjusted hazard ratio for mortality of 0.74 
(95% CI 0.6-0.9).(80)  Combination therapy appeared to be most effective in patients 
with greater than 1% tumour PDL1 expression and in people with sarcomatoid disease, 
although these analyses were unadjusted.  There were a similar number of adverse 
events in the two arms, although the nature of the events differed in accordance with 
the known side effects of the different regimens.  There were more serious adverse 
events and a higher number of treatment discontinuations in the immunotherapy arm, 
but these participants had a longer duration of treatment overall, which may explain 
this finding.  The full report of the trial is awaited, and is likely to change practice with 
regard to the frontline standard of care in MPM. 
 
The combination of ipilimumab and nivolumab has also been investigated in previously 
treated MPM in phase II trials.  In the MAPS2 study, patients randomised to the 
combination arm were treated with ipilimumab plus nivolumab.(17) Twenty-seven 
patients of 54 (50%, 95% CI 37–63) exhibited disease control at 12 weeks, with a median 
OS of 15·9 months (95% CI 10·7–not reached).  For a drug regimen given in the second- 
and third-line setting, where the best recorded median OS for chemotherapy is 10.5 
months, this potentially represents a clinically meaningful benefit.(81) Published 
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simultaneously, the INITIATE trial was a single arm study of nivolumab plus ipilimumab 
also in the second- or third-line setting.  Twelve-week DCR was higher than in MAPS2 at 
23 out of 34 patients (68%, 95% CI 50–83) with median survival not attained after 14.3 
months of follow up.(15)  Phase III trials are planned. 
 
Tremelimumab has also been tested in a combination regimen, alongside durvalumab.  
Phase II data showed the combination to be safe and potentially effective, but an RCT is 
required to confirm this observation.(82) 
 
1.3.4. Intra-pleural bacterial immunotherapy 
Like chemotherapy, ICI are intra-venous agents, with the potential to cause systemic 
side effects, including potentially fatal complications.(17)  The increased use of IPCs in 
MPM (and other malignancies) offers an opportunity to deliver drugs directly into the 
tumour environment, which may limit systemic absorption and lead to fewer side 
effects.(18, 19)  Further laboratory and animal studies are necessary to ascertain 
whether intra-pleural use of ICIs is safe in humans. 
 
As mentioned previously, the earliest attempts at cancer immunotherapy used bacteria 
to stimulate the immune response.  Bacterial agents - commercial products made up of 
altered or attenuated bacterial components - have been delivered into the pleural space 
for decades as pleurodesis agents.   In the UK, Corynebacterium parvum, a gram positive 
aerobic bacillus, was used as a pleurodesis agent for malignant pleural effusions (MPE) 
between 1970 and the late 1990s.(83-87) Some clinicians believed C. Parvum exerted an 
additional, anti-tumour effect, although others disputed this.(88-91)  Eventually the 
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commercial preparation (which was never actually licensed for use in humans) ceased 
production. 
 
There is a scientific rationale supporting the hypothesis that bacterial agents may have 
antic-cancer activity.  As part of the inflammatory process that results in pleurodesis, 
bacterial agents stimulate effector immune cells.(92)  Some of these cells, specifically 
CTL and NK cells have concomitant anti-cancer activity. In addition, bacterial agents 
induce the release of multiple cytokines, including tumour necrosis factor α (TNF-α) and 
TGF-β, which have tumour suppressive effects.(93)  
 
Based on this theory, research groups in Asia rekindled an interest in intra-pleural 
bacterial immunotherapy for pleural malignancy.  Clinical trials were undertaken using 
Staphylococcus superantigen, Lactobacillus casei and killed Streptococcal preparations in 
patients with MPE secondary to lung cancer.(94-96)  Results were encouraging, but 
participant numbers were small.  To date, the effect of bacterial agents in MPM has not 
been studied.  
 
This research focussed on two bacterial agents; OK432 and BCG, administered intra-
pleurally via an IPC to patients with MPM. 
 
1.3.5. OK432 
OK432 is a heat- and penicillin-killed, freeze-dried preparation of Streptococcus 
pyogenes.  Preparation involves heating live streptococci to 37°C in the presence of 
penicillin. This temperature is maintained for 20 minutes before being raised to 45°C for 
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30 minutes.(97)  This eliminates the proliferative ability of the organism and inactivates 
its capacity to produce toxins.  Thus, while bacterial cell structure remains intact, active 
streptococcal infection following administration is not possible. 
 
 In vitro, OK-432 induced lymphocyte-mediated tumour killing in pleural fluid, whilst in 
vivo, it has been associated with longer survival in several cancer types.(98-100)  In non-
small cell lung cancer, meta-analysis of trial data demonstrated longer survival in 
patients treated with OK432, with an odds ratio (OR) of 0.70 (95% CI 0.56 to 0.87) for 
mortality.(100)  However, whilst the studies included in the meta-analysis delivered 
OK432 intra-tumourally, sub-cutaneously or intra-venously, intra-pleural administration 
was not included.  
 
Five randomised trials compared intra-pleural OK432 with other intra-pleural or intra-
venous chemotherapy agents in people with MPE.(96, 101-104)  All five focussed on 
control of the pleural effusion rather than survival or other cancer-specific outcomes, 
however, two reported longer survival in patients treated with OK432 and 
chemotherapy compared with either agent in isolation.(101, 104)  Neither study was 
adequately powered for this outcome though, and both were at high risk of bias in at 
least one area of their methodology. 
 
Intra-pleural OK432 has been demonstrated to be an excellent pleurodesis agent and 
has been used in the routine management of MPE in Japan since the 1980s.(96)  
Adverse events are rare. In phase IV data from 26,027 patients treated with OK432 prior 
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to 1984, inflammation at the injection site and fever were the most frequent and severe 
toxicities seen.  These occurred in 23% and 15% of patients respectively.   
 
1.3.6. BCG 
BCG is a live, attenuated, low-virulence strain of Mycobacterium bovis, currently used as 
a vaccine against tuberculosis.  In addition to stimulating CD4+ and CD8+ cytotoxic T 
lymphocytes and eliciting the production of anti-cancer cytokines, BCG produces a 
delayed type IV hypersensitivity reaction, mediated by T helper cells, which enables 
sustained anti-tumour activity alongside the acute inflammatory response.(105-107).  
 
BCG has been shown to have anti-tumour activity in skin and bladder cancer, and has 
been used as an intra-cavity anti-cancer agent in bladder cancer since 1976.(108)  Meta-
analysis of RCT data demonstrated that intra-vesical BCG reduced the risk of progression 
in non-invasive bladder cancer compared with no treatment or other intra-vesical 
therapies.(109-113)  Bladder biopsies taken from patients treated with intra-vesical BCG 
demonstrated induction of antigen presenting cells and macrophages, with associated T 
cell-predominant inflammation for up to 6 months after treatment.(114)    
 
In malignant melanoma, BCG injected into the tumour was associated with regression of 
up to 90% of the targeted lesion, and an abscopal effect of over 15% tumour reduction 
in non-treated lesions.(115)  This occurred in conjunction with significant prolongation 
of disease-free periods and longer overall survival, even in patients with metastatic 
disease.  In recent years, however, BCG has been superseded by ICI in melanoma 
treatment.(62, 63, 66)   
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Finally, observational data from a 60-year follow up study of 2963 patients who 
participated in an RCT of BCG vaccination as children, suggested a possible protective 
effect from lung cancer later in life.  Lung cancer rates were 18.2 per 100,000 person 
years in people vaccinated with BCG, compared with 45.4 per 100,000 person years in 
the group who received placebo (hazard ratio (HR) 0.38, 95% CI 0.20-0.74).(116)  The 
authors hypothesise that generation of CD4+ memory and natural killer cells following 
BCG vaccination enables later activation of these immune cells with smaller stimulus, 
and therefore enhanced anti-cancer detection and activity. 
 
Intra-pleural BCG was investigated as an adjuvant therapy to surgery and chemo-
radiotherapy in the 1970s.  Early studies demonstrated that it was feasible and safe to 
deliver BCG intra-pleurally.(58, 117, 118) Furthermore, intra-pleural BCG was associated 
with a reduction in recurrence rates, and an overall survival benefit compared with 
placebo.(58, 118-123) The evidence was conflicting however, with a similar number of 
trials demonstrating no difference in survival following intra-pleural BCG.(124-129)  A 
small number of studies suggested intra-pleural BCG was associated with worse 
outcomes,(117, 130) although in one of these BCG (without chemotherapy) was 
compared with standard chemotherapy – a design that would be deemed unethical in 
the current day, as it entailed withholding an established efficacious treatment from a 
proportion of participants.(130)  Additionally several of the negative studies were non-
randomised,(125, 126) and many involved small participant numbers and were likely 
underpowered to detect differences in survival.(117, 127, 128)  
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Another explanation for the different outcomes observed in BCG trials may lie in the 
different BCG strains used. It has been established that TICE strain is more effective than 
Connaught strain, and of the lyophilised vaccines, Pasteur is more effective than 
Glaxo.(131, 132)  It may be relevant, therefore, that three of the six trials that 
demonstrated a positive effect of BCG used the TICE strain.(58, 119) For this reason, 
TICE strain was selected for use in this research.   
 
Whether or not intra-pleural BCG was effective in lung cancer, there remains a strong 
case for potential efficacy in MPM.  Mesothelioma is similar to melanoma, both in terms 
of histological appearance and certain genetic mutations driving the tumours.(133, 134)  
In addition, as a localised tumour affecting a discreet body cavity, MPM resembles early-
stage bladder cancer and offers a similar opportunity for targeted delivery of anticancer 
drugs directly into the tumour environment.  Animal studies have shown that proximity 
of BCG to tumour was an important factor in producing an effective response.(135)  
Unlike lung cancer, where intra-pleural administration was anatomically distant from 
the original site of disease, intra-pleural administration in MPM delivers the drug into 
direct proximity with the tumour, thus creating immune stimulation in the very area it 
will be most effective. 
 
1.4. The trial within a cohort (TwiC) design 
1.4.1. What are TwiCs? 
This research used the trial within a cohort (TwiC) design to investigate intra-pleural 
bacterial immunotherapy in MPM.(136) This is a highly pragmatic methodology that 
aims to replicate real-life clinical practice, with several potential benefits. 
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Figure 1.6 Schematic representation of the TwiC methodology 
 
The TwiC design, also known as the cohort multiple randomised controlled trial (cmRCT) 
methodology, uses data from an established, longitudinal, observational cohort study to 
screen cohort participants for their eligibility to participate in the trial.  Eligible cohort 
participants are randomly selected to be offered the trial intervention, at which point 
they are provided with further information about the trial and, with their consent, 
enrolled. Cohort participants who are eligible for the trial but not randomly selected 
remain in the cohort and are not informed about the trial or the intervention.  Their 
data is used as control data for the trial.  Figure 1.5 shows a schematic representation of 
the TwiC design.  
 
1.4.2. Ethical considerations of TwiCs 
One of the most frequently stated concerns about the TwiC design relates to whether it 
is ethical.   Experienced clinical trial methodologists recognise its similarities to the 
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historic Zelen design – a trial methodology in which participants were randomised 
before they provided consent.(137)  Since randomisation is inarguably a research 
activity, this constituted a breach of patient autonomy based on both the Declaration of 
Helsinki, which states that “subjects must be volunteers and informed participants in 
the research project”, and the United Nations International Covenant on Civil and 
Political Rights statement that “no one shall be subjected without his free consent to 
medical or scientific experimentation.”(138)  
 
There are, however, certain situations where it may be necessary to conduct a trial 
without consent, e.g. in emergency settings, where the process of obtaining consent 
would delay treatment and therefore not be in the patient’s best interests, or where it 
may not be possible to obtain consent due to the patient’s clinical condition e.g. 
unconsciousness. Scott Kim, a prominent American bioethicist, described five conditions 
where conducting a trial without consent could be potentially ethically justified.(139)  
These conditions were: 
1. Scientific necessity, where the process of obtaining consent undermines the 
scientific validity of the results or make the trial impossible to conduct.  
Examples of this include where there is high potential for contamination 
between arms or a high risk of the Hawthorne effect (where participants’ 
behaviour changes once they are aware they are in a trial). 
2. Low risk, where participating in the trial exposes participants to no or minimal 
risk of harm compared to standard treatment.  Such trials usually amount to 
comparisons of different usual care regimens. 
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3. Analogous clinical situations, where the intervention would not usually be 
consented for in clinical practice.  There are several settings where this may be 
the case, including 
a. clinical constraints, e.g. emergency settings as described above, 
b. therapeutic non-disclosure, e.g. where the process of obtaining consent 
would create psychological harm, 
c. package deal, where the trial intervention is inherently related to other 
processes and would not usually be consented for e.g. ventilator settings 
in intensive care, and  
d. cluster trials, where interventions are implemented at a higher level e.g. 
treatment pathways in general practitioner (GP) services, or impact on 
aspects of care in which patients do not usually have involvement e.g. 
medical staffing. 
4. Meaningful preference, where there is no clear patient preference for an 
intervention, or the outcomes under study are not of value to participants. 
 
However, many of these conditions are subjective, for example the assessment of “low 
risk” for criteria 2, or evaluation of potential psychological harm in criteria 3b.  
Ultimately, Kim rejected most of the above criteria, believing that only scientific 
necessity, clinical constraints and certain cluster trials were ethically justifiable to 
conduct without consent.  He concluded that the sole reason to conduct a trial without 
consent was if the “research cannot practicably be carried out” with consent, the 
corollary being that if consent can be obtained, it should be.(139)   
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The Zelen design has been used in some circumstances that meet the criteria described 
by Kim, e.g. a randomised trial of extra-corporeal membrane oxygenation (ECMO) in 
neonates who had an 85% likelihood of dying without treatment.(140)  In that trial, it 
was thought to be too distressing to raise parents’ hopes by discussing a potential 
treatment with them during the consent process and then denying them the treatment 
if their child was randomised to usual care. In that situation, the Zelen design appeared 
to be a reasonable and justifiable methodology.(141)  However, in other situations, by 
failing to obtain consent from people who were (usually) able to provide it, the Zelen 
design breached Kim’s principle.(138, 142)  It was, therefore, concluded to be an 
unethical approach and one that was potentially harmful to the researcher/participant 
relationship, and often the doctor/patient relationship too.(137, 138, 143)  .   
 
Similar to Zelen, it could be said that randomisation without consent is inherent to the 
TwiC methodology.  With an awareness of the potential ethical pitfalls of the design, its 
creators organised an international symposium on the ethics of TwiCs in 2016, attended 
by clinical triallists, bioethicists, research regulators and myself.(144)  It was noted that 
the majority of RCTs failed to recruit to time and target, and there was an ethical 
consideration to be made relating to inefficiency, wasted resource and squandered 
participant effort if trials were abandoned or failed to recruit adequate numbers to 
power the primary outcome.  By adopting a radically different approach to participant 
identification and enrolment, TwiCs could overcome these issues.   
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Discussion at the symposium included anecdotal concerns that patients in the control 
arm could be seen as being “deceived” because they were not informed about the trial 
and “exploited” as their data was used without their knowledge. (142, 144, 145) An 
elegant solution to this issue was suggested by Dr Danny Young-Afat from Utrecht 
Medical Centre. He proposed a two-stage consent model in which, on enrolling in the 
cohort, patients were asked to consent to be screened for future trials, to be randomly 
selected for the trial and to allow their data to be used as comparison data if they were 
not selected, without being further informed of this at the time.(146)  Trial participants 
were then approached to give further consent if and when they were randomly selected 
to join the trial.  With this approach, the second consent process was highly specific, as 
the participant was essentially asked whether they wish to receive the trial intervention 
or not.  This pleasingly addressed another ethical issue that is often overlooked in 
clinical trials, that of overburdening participants with information, discussed in more 
detail in the next section.(144)  
 
The two-stage consent process removed the issue of randomisation without consent 
and of potential deception or exploitation of control patients.(144)  It allowed every 
participant, whether in the cohort or the trial, to give their consent for the exact 
research processes they would undergo, thus maintaining, indeed enhancing, their 
autonomy. As discussed in the next section, this approach supported the highly 
pragmatic nature of TwiCs by replicating real-life clinical care as closely as possible.  
Following discussion with the trial team and patient involvement groups during the 
design period, the two-stage consent model was chosen as the most ethically and 
individually acceptable approach for TILT.  In addition, as discussed in section 4.2.1., it 
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became clear that the two-stage consent model was a pre-requisite if the trial was to be 
compliant with European Union Clinical Trials Regulations.  
 
1.4.3. Benefits of the TwiC design 
The TwiC methodology offered certain benefits over the traditional RCT design.(136)  
The presence of a cohort allows simultaneous collection of observational data that 
provides information on the natural history of the disease.  Additionally, because cohort 
studies tend to have broader eligibility criteria than clinical trials, they can recruit more 
quickly and often enrol participants with more diverse characteristics.(136, 147) This is a 
significant potential benefit in MPM research, where recruitment can be slow and 
participant diversity narrow.(50, 148) 
 
The TwiC methodology is highly pragmatic in nature and aims to replicate real life 
clinical care to a greater degree than occurs with a standard RCT.  As a result, TwiCs tend 
to have high external validity, and are an excellent method of evaluating effectiveness, 
rather than efficacy.(149)  This is particularly pertinent in MPM, where trial populations 
are often not representative of real-world patients.  Indeed, in one observational study 
of consecutive MPM patients from a single Australian hospital, 55 of 109 patients 
evaluated (50.5%) did not meet the eligibility criteria for the MAPS study and 42/105 
(40%) were ineligible for KEYNOTE-028.(150)  This selection bias causes disparity 
between the efficacy of a drug as reported in clinical trials and the effectiveness of the 
same agent when rolled out into real-world clinical care.  For example, response rates in 
the original pemetrexed and cisplatin trial were approximately 40%, but only 26% when 
the drug began to be used in clinical care.(4, 47) 
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The similarity of TwiCs to real-life clinical practice is most obvious in relation to sharing 
information with participants.  In an RCT, participants are given information about the 
trial interventions and then randomly allocated to one, meaning that a proportion of 
people (those allocated to the control arm) have been informed about a treatment or 
intervention that they do not ultimately receive. In contrast, in clinical practice, patients 
are provided with information about a specific treatment when it is indicated for their 
clinical care and, if they agree to it, they will definitely receive said treatment.  The 
patient may choose to decline treatment, based on individual preference or following an 
evaluation of risks and benefit, but the option to receive treatment is not withdrawn 
from them. Conversely, patients are not told about treatment that they are not going to 
receive. TwiCs replicate this by providing information about the intervention solely to 
participants who have been selected to receive it.  As well as making TwiCs pragmatic, 
this creates a patient-centred or “personalised” consent process, whereby each 
participant provides consent for the exact research process or intervention that they will 
undergo, and none that they will not.(136)  
 
The personalised consent process has several specific benefits.  Firstly, it can reduce 
disappointment.  In conditions like MPM where treatment options are limited, people 
may choose to participate in clinical trials in the hope of gaining access to a treatment 
that is not otherwise available.  However, if the trial includes a standard care arm (and is 
unblinded), participants who were hoping to receive a novel treatment may be 
disappointed if they are allocated to this arm.  They may withdraw from the trial, or the 
disappointment may be so great it impacts on their quality of life or affects other 
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patient-reported outcomes. By blinding controls to the existence of the trial and the 
intervention, the TwiC design removes this issue, and may therefore reduce attrition 
bias and reporting bias.(136) 
 
The second benefit of person-centred consent is that it can reduce anxiety associated 
with uncertainty.  When invited to participate in an RCT, people are asked to make a 
decision without knowing what the consequence of that decision is, i.e. they may or 
may not receive the trial intervention depending on subsequent randomisation.  This 
uncertainty renders the decision-making process harder and more stressful.(151)  In 
contrast, the TwiC design provides patients with a more straightforward choice.  
Patients are only offered the intervention once they have been selected to receive it, so 
their decision is simplified to whether they want to receive the intervention or not.  The 
outcome of the decision is known at the point that the decision is made.  This relieves 
the burden of decision-making and reduces anxiety and confusion.(145)  It also releases 
control participants from making additional decisions and avoids them being burdened 
with unnecessary information.   
 
This is of particular importance in MPM research, as patients are often approached to 
participate in research studies soon after receiving their diagnosis. They are likely to be 
dealing with a number of uncertainties, such as “what does the future hold?”, and “how 
long will I live?”.  Adding further uncertainty at this time could be considered unethical 
or at the very least, unkind.(145) 
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The TwiC methodology respects patients’ choices to decline an intervention and allows 
data to be collected on non-participants.  In an RCT, if an eligible person chooses not to 
participate when approached about the trial, no data can be collected on them.  In 
contrast, because TwiC participants are already enrolled in a longitudinal cohort, even if 
they choose not to join a trial, they will have already contributed data to the cohort and, 
presumably, will continue to do so.  This provides useful information about the 
characteristics of people who choose not to participate in trials and whether their 
outcomes differ in any way to the trial participants.  The data can also be used to assess 
the representativeness of the trial population with respect to the cohort and, 
consequently, the generalisability of results. 
 
Once participants have completed the trial, they return to the cohort for ongoing 
longitudinal follow-up.  This enables collection of long-term outcomes relating to the 
trial intervention, e.g. survival or delayed adverse reactions, without the need for an 
extended trial period.   
 
Using the TwiC design, multiple trials can be embedded within the same cohort, 
meaning that participants have repeated opportunities to participate in trials.(136)  This 
is most useful in diseases where different interventions or treatments are needed at 
different stages in the disease pathway.  Caution is required, however, if multiple trials 
with the same primary outcome are running in the cohort, as contamination is likely to 
occur between the trials.(152) 
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1.4.4. Limitations of the TwiC design 
All trial methodologies have strengths and weaknesses and the TwiC design is no 
different.  It is important to appreciate the limitations of the methodology and to 
evaluate whether this approach is suitable and appropriate for the research question 
being asked.  Specifically, there are several considerations relating to the control arm of 
TwiCs that make them unsuitable for certain types of research. 
 
Firstly, because the TwiC methodology is fundamentally pragmatic, the use of a non-
placebo-controlled arm means the design is not suitable for early phase trials aiming to 
determine whether an intervention works, and how.(136)  These questions are best 
answered by blinded, placebo-controlled efficacy trials. 
 
Secondly, the control arm in a TwiC is, by definition, standard care.  It is not suitable, 
therefore, for conditions where a standard of care has not been established, or where 
there is wide variability in the usual management of a condition.  In this situation, the 
heterogeneity of treatment in the control arm could make statistical analysis impossible 
or render the results meaningless.   
 
Whilst embedding a trial within a cohort affords several benefits related to collection of 
additional cohort data, it is recognised that cohort studies can be time consuming and 
expensive to set up.(147)  Maintaining the cohort can also be demanding in terms of 
resources, but is of the utmost importance to ensure optimal data quality and low rates 
of loss to follow-up.(153)  Additionally, for the control arm to provide valid comparison 
data, follow-up visits for controls in the cohort must match those of the trial, both in 
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terms of content and timing.  For this to be manageable, a degree of flexibility is 
required within the cohort.  This is only achievable if the cohort protocol is designed 
pragmatically, without an overly proscriptive follow-up schedule.   
 
Similarly, for cohort participants to be effectively screened for their eligibility to 
participate in a TwiC, the cohort must collect data relating to the trial inclusion and 
exclusion criteria.  A recent TwiC of an exercise intervention in patients with breast 
cancer highlighted this issue when 48% (62/130) of patients randomly selected to 
receive the intervention were subsequently found to be unsuitable on further 
investigation.(154)  To prevent the study being underpowered, the sample size had to 
be increased, although fortunately one of the benefits of the TwiC design came into 
play, and recruitment was completed swiftly, with the existing cohort providing a 
resource for potentially suitable participants. 
 
There is an important statistical point to be aware of with TwiCs.  Because control 
participants are blinded to the existence of the trial and are not asked to give further 
consent after randomisation, they do not have the opportunity to decline participation.  
This is ethically acceptable, since they have consented to provide control data for trials 
when they enrolled in the cohort, however it may lead to problems with differential 
attrition.   As long as controls continue to participate in the cohort and are not lost to 
follow-up, they will provide complete data, with no attrition in the control arm.  In 
contrast, patients selected for the intervention are given the participant information 
sheet (PIS) and given time to consider whether they would like to receive the 
intervention, before being asked to provide consent for the trial.  There is potential for 
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some patients to choose not to enrol at this point.  Equally, if the trial intervention 
consists of multiple processes, e.g. repeat doses of a drug, a participant may decide not 
to complete the full course, either due to side effects or a change of heart.  Differential 
attrition could bias the observed effect of intervention in the final results.(155, 156)  
Arguably, however, the result will be a realistic reflection of the effectiveness of the 
drug in the real-world setting, which will inevitably include patients who decline to take 
it or who do not complete the prescribed course.  This reflects the pragmatic nature of 
the TwiC design. 
 
If the potential bias introduced by differential attrition is of concern, various statistical 
approaches can be employed to adjust for compliance.  One such approach is 
compliance-adjusted causal effects (CACE) modelling, which is a form of instrumental 
variable analysis.(157, 158)  By assuming that a similar proportion of control participants 
would have been non-compliant given the opportunity, and that the characteristics of 
the non-compliant populations would be the same in the control and intervention arms, 
CACE analysis adjusts the effect size in the control arm for conceptual non-
compliers.(158)  This, as well as other forms of instrumental variable analysis, may 
reduce the risk of attrition bias in TwiCs.(156)  Importantly, CACE analysis produces a 
result that applies only to compliers, i.e. it yields efficacy data rather than information 
on effectiveness, and arguable detracts from the pragmatic focus of the TwiC design. 
 
Another consideration for TwiC trials is the potential for contamination if multiple trials 
are run within the same cohort, especially if the trials are evaluating the same primary 
outcome.(152)  One way of avoiding this is to allow cohort participants to only 
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participant in one trial, although this removes one of the benefits of the TwiC 
methodology, namely the opportunity for patients to participate in multiple trials.  
Additionally, unless there is a rapid turnover within the cohort, preventing patients from 
participating in more than one trial may lead to selection bias and reduced external 
validity as fewer and fewer people are eligible to be randomised for sequential trials. An 
alternative solution would be to ensure that each trial running within the cohort 
focusses on a different element or stage of the disease pathway with different primary 
outcomes.  For example, in MPM, a trial examining fluid management techniques could 
co-exist with a trial of an oncological treatment or a trial of palliative care interventions, 
as the outcome of one trial is unlikely to be affected by the intervention of the other. 
 
At the time of designing TILT, the TwiC design had never been used in the MPM 
population, nor had it been applied to a clinical trial of an investigational medicinal 
product (CTIMP).  Many of the potential benefits seemed relevant to this patient group, 
and the potential to facilitate recruitment was attractive.  However, there was 
uncertainty about whether it would be possible to deliver a TwiC in the MPM setting, 
and whether the design would be acceptable to patients.  Consequently, TILT was 
designed as a feasibility study, aiming to explore these factors and to determine 
whether a full-scale TwiC of intra-pleural bacterial immunotherapy would be possible in 
people with MPM. 
 
1.5. Overall study design 
This research was developed to test the hypothesis that intra-pleural bacterial 
immunotherapy may be an effective treatment for MPM, with better tolerability and 
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fewer side effects that systemically delivered therapies.  The hypothesis was 
investigated from several angles, including a systematic review of the literature relating 
to intra-pleural bacterial agents in pleural malignancy. This was followed by a cohort 
study that used population-level data to test the validity of previous “natural 
experiments”, that reported pleural infection was associated with longer survival in 
pleural malignancy.(159-161)  Ultimately an RCT is required to determine whether intra-
pleural bacterial agents prolong survival in MPM, and for the reasons described in 
section 1.4.3., the TwiC design appeared attractive.  However, with no such trials having 
been undertaken in MPM patients before, a feasibility study was necessary to establish 
whether certain facets of the design would be possible in this population, and whether it 
was acceptable to participants.  Additionally, since the bacterial agents of interest – 
OK432 and BCG – had not previously been administered to patients with MPM, a 
feasibility study would provide initial information on tolerability and acceptability and 
help inform whether a full-scale RCT would be achievable.  
 
1.5.1. Aims 
The overall aim of the work described in this thesis was to explore the role of intra-
pleural bacterial immunotherapy in MPM, in order to determine whether a full-scale 
trial of intra-pleural BCG or OK432 in MPM was warranted, feasible and acceptable.  The 
research was designed in response to a James Lind Alliance Priority Setting Partnership 
for mesothelioma, undertaken in 2015.(162)  During that process, a group of clinicians, 
patients, charities and other stake-holders ranked the top 50 research priorities for 
mesothelioma in order of importance.  The 8th most important research question was 
whether there is “a role for intrapleural immunostimulants (a drug designed to 
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stimulate an anti-cancer immune response, such as corynebacterium parvum extract)”.  
The intention was for the findings from this research to contribute to the design of a 
future randomised trial aiming to answer this question definitively.  
 
To achieve the research aim, four specific sub-questions relating to intra-pleural 
bacterial immunotherapy were asked.  Corresponding workstreams were developed, to 
address each sub-question, with the intention that, viewed collectively, the results 
would answer the overall research question.   
 
1.5.2. Objectives 
This research had four objectives, based on the four research sub-questions.  
• To determine whether the existing evidence supported the hypothesis that intra-
pleural bacterial agents are associated with longer survival in patients with 
pleural malignancy.  
• To examine whether bacteria that arose spontaneously in the pleural space, i.e. 
pleural infection, were associated with altered survival in MPM. 
• To explore the feasibility of a randomised trial of two intra-pleural bacterial 
agents – OK432 and BCG – in MPM, using the TwiC methodology. 
• To evaluate the acceptability of the TwiC design and of receiving intra-pleural 
OK432 and BCG to trial participants and their families. 
 
The objectives were addressed sequentially, by four workstreams: 
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Workstream 1 was a systematic review that summarised the existing literature relating 
to intra-pleural bacterial agents in pleural malignancy.  It focussed on oncological 
outcomes, specifically survival and tumour response rates.  Information on adverse 
events was also collated, to inform design of the subsequent feasibility trial.   
 
Workstream 2 was a population-based cohort study that used historic data from 
Hospital Episode Statistics for all patients with mesothelioma seen in English hospitals 
over a 10-year period.  Linked mortality data was obtained from the Office of National 
Statistics (ONS). This workstream was designed to determine whether bacteria that arise 
spontaneously in the pleural space as a result of pleural infection were associated with 
altered survival in patients with mesothelioma, as had been reported in previous 
observational studies.(159-161) 
 
Workstream 3 was a prospective, multi-centre, randomised, three arm trial of intra-
pleural OK432 vs intra-pleural BCG vs usual care in MPM.  The trial, called TILT, was a 
feasibility study based on the TwiC methodology, aiming to determine whether the TwiC 
design could be utilised in this setting, whether intra-pleural OK432 and BCG could be 
delivered practically and safely, and whether a full-scale trial would be possible. 
 
Workstream 4 was a qualitative study comprised of semi-structured, face-to-face 
interviews with trial participants and separate face to face interviews with their family 
members or carers.  The study was designed to provide an understanding of the 
experience of participating in TILT, as well as to explore the knowledge, beliefs and 
decision-making processes relating to treatment decisions and research participation.  
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The aim was to determine whether TILT was acceptable to patients and their family 
members, and to use the insight afforded by the interviews to refine the design of 
subsequent trials. 
 
1.5.3. Mixed methods research 
To tackle the overarching research question, this thesis employed both quantitative and 
qualitative methods, combining the results to generate more informative findings.  This 
type of research, which is often referred to as “mixed methods”, merges diverse 
methodological approaches from different scientific backgrounds, based on contrasting 
research paradigms.   
 
Quantitative research was developed from an ontological standpoint, i.e. “the study of 
being”.(163)  It assumes an objective reality that exists independent to the researcher 
and the researcher is simply revealing that reality or investigating how it works, i.e. 
“what can be known about X?”  An extension of ontology is epistemology, which can be 
defined as the theory of knowledge, exploring how knowledge is formed and how it 
relates to reality, i.e. “how do we know this about X?”(163)  Quantitative research 
adopts a “positivist” approach, drawing on the ontological and epistemological premise 
of an objective and independent reality, to test a hypothesis using empirical data.  The 
hypothesis is generated based on existing information, and assessed using observed 
“facts”, collected by an impartial researcher.  The findings obtained are intended to 
describe the observed reality and are therefore considered generalisable.  
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In contrast, qualitative research methods, which arose from the social science 
disciplines, assume a more subjective state.  They generally argue that reality is not 
fixed, but rather is individually constructed.(164)  Each object or event has a different 
meaning depending on a person’s experience or interpretation of it, which often relate 
to a social or cultural context.  This is referred to, in different contexts, as a “relativism”, 
“interpretivism” or “constructivism”.  The aim of qualitative research is to develop an 
understanding of this subjective reality by attempting to understand an individual’s 
experience.  Typically, this requires an inductive approach, in which observations are 
collated to formulate a hypothesis or theory.  
 
Additionally, with qualitative methods, the researcher brings their own individual 
experience to the research, which informs the way in which they collect and interpret 
information, and contributes to the ultimate findings. Undertaken well, good qualitative 
research should yield rich and believable evidence (internal validity or credibility), that 
has relevance and utility to other people in other situations (external validity or 
transferability), based on research processes that can be replicated to produce similar 
findings (reliability or dependability).(165, 166) 
 
The difference between a positivist approach and a relativist approach to research can 
be demonstrated using a tree as a simplified example.  The quantitative researcher 
would accept the reality that the tree is a tree, regardless of who is examining it, and 
would aim to describe the tree by collecting objective data, e.g. the height, number of 
branches, presence of fruit etc.  In contrast, a qualitative researcher would recognise 
that the tree has a greater meaning that is shaped by people’s interactions with it and 
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would seek to explore this.  The researcher may discover that the tree bears fruit that 
feeds the village or serves as an important landmark.  The researcher themselves may 
have a perspective on the tree, perhaps they played beneath it in childhood.   
 
Clearly, neither approach is “right” or “wrong”, although historically, purists considered 
the two methodologies to be incompatible and based on opposing research 
paradigms.(167)  A more pragmatic standpoint recognises the merit in both methods 
and appreciates that multiple different descriptions can exist for the same 
phenomenon, with all being valid.(168)  Understanding the theory behind each 
approach and recognising the appropriateness of each for a specific task allows the 
correct approach to be selected for the research that is planned.  Building on this, 
Teddlie and Tashakkori suggested that the two approaches could be complementary 
and proposed an “integrationist approach”.(169)  After all, in the example above, if the 
research aims to understand the tree in its entirety, the use of both methods is the only 
way to obtain a complete picture, including the tree in its objective state and its 
meaning to those who interact with it.   
 
In the context of clinical trials, the addition of qualitative research methods can identify 
and help address potential methodological issues.(170)  For a pilot or feasibility study, 
mixed methods can provide vital information to inform the subsequent full-scale trial 
that could not be obtained from quantitative data alone.  Previous qualitative research 
undertaken alongside RCTs has revealed modifiable barriers to participant enrolment, 
including understanding of randomisation, willingness to receive the allocated 
intervention and appreciation of clinician equipoise.(170, 171)  In one longitudinal MPM 
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study, semi-structured interviews were undertaken with participants in the pilot phase 
of a surgical trial that was perceived as difficult to recruit to.(172)  The results 
highlighted the challenges of communicating complex information about research trials 
to patients and emphasised the importance of maintaining equipoise when describing 
treatment options. Having been informed by the qualitative data, the subsequent full-
scale trial has consistently recruited above target. 
 
There are several techniques for combining quantitative and qualitative research, which 
vary depending on the emphasis placed on each method, the chronology of the research 
and the timing and strategy of combining the findings.(168)  In this doctoral work, the 
qualitative content of Workstream 4 was embedded within the feasibility trial of 
Workstream 3, with equal weight placed on the two methodologies.  The qualitative 
data was analysed contemporaneously with direct interaction on the trial, as well as 
being integrated with quantitative outcomes at the end of the trial, based on a parallel, 
concurrent, interactive model with subsequent convergence.(173)  This approach, 
shown graphically in Figure 1.6, allows simultaneous implementation of qualitative and 
quantitative methods, with the former directly influencing the latter, before the results 
of both are mixed to provide an overall interpretation. 
 
Participants took part in qualitative interviews on completion of the 12-week trial 
period.  The interviews explored their experiences of participation and aimed to gain 
insight into their views about trial design and specific research processes, including 
acceptability.  If a qualitative theme was identified relating to a particular element of the 
trial and if that element could be changed without affecting the scientific quality of the 
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trial, the protocol was adapted in light of the qualitative finding.  Once the trial finished, 
the qualitative findings were integrated with the quantitative results to create an overall 
assessment of whether the trial was feasible and acceptable to participants and their 
relatives.  The qualitative results were also used to identify what elements of the trial 
were not acceptable and how they could be changed or improved for future trials. 
 
Previous qualitative research in patients with MPM highlighted that people with the 
condition tended to be stoical in relation to their symptoms and the terminal nature of 
the disease.(174) In contrast, relatives and family members were often more vocal, 
especially about the emotional and practical burden of the disease and, as a result, 
tended to act as advocates on behalf of the patients.  For this reason, relatives and 
carers of trial participants were also invited to take part in qualitative interviews to 
ascertain their views on trial participation and overall impact on their family member.  
 
1.5.4. Co-production and patient & public involvement 
The methods and resources used during this thesis, specifically in Workstreams 3 and 4 
were chosen and developed using co-production techniques with input from a 
dedicated patient and public involvement (PPI) group.  This ensured that the research 
was informed by a range of perspectives and benefitted from a combination of different 
knowledge and skills, including those of the people at the heart of the research, i.e. 
people with MPM.(175)  Co-production was a dynamic process, with regular dialogue 
between the study team and members of the PPI group, supported by resources 
obtained from NIHR’s INVOLVE network.  
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Figure 1.7 Mixed methods research design – a parallel, concurrent, interactive model with subsequent convergence. Adapted from Creswell, JW and Plano 
Clark, VL. Chapter 3. Choosing a Mixed Methods Design. Designing and conducting mixed methods research.(173)
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2. Chapter 2 - A systematic review of intrapleural bacterial 
products in pleural malignancy 
 
The work in this chapter has been published:   
Bibby AC, Walker S & Maskell NA. Are intra-pleural bacterial products associated with 
longer survival in adults with malignant pleural effusions? A systematic review.  Lung 
Cancer 2018: 122:249-256.(176) 
 
ACB devised the concept and designed the study, developed and performed the 
literature search, screened abstracts and full-text articles for inclusion and performed 
data extraction.  ACB also evaluated included studies for risk of bias, analysed pooled 
study data and wrote the first draft of the paper.  SW was the second reviewer of 
abstracts and full-text papers, and independently performed data extraction.  NAM 
assisted with development of the study idea and design, resolved any disagreements 
between the independent reviewers and reviewed the final analysis.  All authors 
reviewed and refined the paper prior to publication.  
 
2.1. Background 
As described in Chapter 1, bacterial products have been used intra-pleurally for decades 
to induce pleurodesis in patients with MPE.  Several researchers and clinicians 
postulated that they exerted additional, anti-tumour effects via cytokine release and 
induction of effector immune cell responses.(84-90)  However, the research focus has 
always been on the efficacy of these products to control pleural fluid and no RCT has 
been undertaken with survival as the primary endpoint. 
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More recently, the anti-cancer activity of several alternative intra-pleural bacterial 
products has been studied in stand-alone, early phase clinical trials of patients with 
MPE.  These trials yielded encouraging results, but the small participant numbers and 
methodological limitations inherent to early phase trials limited their interpretation.(94-
96) 
 
Whilst patients with MPM were included in some of these studies, none have 
specifically examined the effect of the products in MPM.  For the reasons outlined in 
Chapter 1, there is a strong scientific rationale for investigating bacterial products in 
MPM.  Prior to undertaking the proposed work in this thesis, a systematic review was 
performed to evaluate and summarise the existing evidence on the anti-tumour effect 
of intra-pleural bacterial products in MPE, including MPM.   
 
2.2. Methods 
The aim of the systematic review was to answer the question “Are intra-pleural bacterial 
products associated with longer survival in adults with MPE?”  The review was 
registered on PROSPERO International Prospective Register of Systematic Reviews, 
registration number 50867.  A summary of the protocol is available at 
https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017058067. 
 
2.2.1. PICOS criteria 
Systematic reviews of quantitative data, particularly those involving clinical trials, are 
often based on pre-specified PICOS criteria: 
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• P – Population 
• I – Intervention 
• C – Comparators 
• O – Outcomes 
• S – Study design 
For this systematic review, the population of interest was adults with MPE. The 
intervention was intra-pleural administration of any bacterial preparation, including live 
or attenuated whole organisms, bacterial toxins or antigens, and bacterial cell 
components.  Comparators included no treatment, alternative non-bacterial intra-
pleural agents or placebo. The outcomes of interest were anti-cancer activity, primarily 
overall survival, but studies that reported 1-year survival rates, tumour response rates 
and adverse events were also included.  Control of MPE and pleural fluid response rates 
were not included as outcomes, as these have been covered in a recent Cochrane 
systematic review and meta-analysis.(83)  RCTs and non-randomised comparative 
studies were included. 
 
Based on these PICOS criteria, the systematic review aimed to assess and summarise 
survival outcomes following administration of an intra-pleural bacterial product 
compared with other intra-pleural treatments, placebo or no treatment in adults with 
MPE.   
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2.2.2. Study selection 
Research papers in all languages were included.  Foreign language papers were 
translated into English using an online translation service.  No date limitations were 
placed on the search.  Studies where no abstract was available were excluded.  Where 
clinical trial registers suggested a trial had been completed but not reported, the 
authors were contacted and asked to provide the data.   The full eligibility criteria for 
studies included in the systematic review are presented in Table 2.1. 
 
2.2.3. Data sources and search strategy 
An electronic literature search was undertaken using the following databases: 
• MEDLINE (1946 to 2017 week 09) 
• EMBASE (1974 to 2017 week 09) 
• Cochrane Database of Systematic Reviews 
• Cochrane CENTRAL Register of Controlled Trials 
• International Clinical Trials Registry (ISRCTN) 
• EU Clinical Trials Register 
• US NIH Clinical Trials Register  
• Open Grey (System for Information on Grey Literature in Europe – SIGLE).   
 
Once the electronic search was complete, a manual search was undertaken to review 
the references of included papers and systematic reviews to ensure no relevant papers 
had been missed.    
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• Age ≥ 18 years. 
• Malignant pleural effusions due 
to any underlying tumour. 
• Can include mixed malignant and 
non-malignant effusions if results 
reported separately. 
• Can include pleural, pericardial 




• Age < 18 years. 
• ‘Operable’ lung cancer. 
• Non-malignant pleural disease or 
mixed populations where results 
















Combination therapy with other 
concurrent treatments delivered 
via any route. 
 
 
• Intravenous, intra-dermal, sub-
cutaneous delivery of bacterial 
products. 
• Viral vectors for gene therapy. 
• Vaccine therapy.  
• Passive immunotherapy (i.e. 
primed immune cells, cytokine 
therapy) 






• Any other intra-pleural agent 







• Survival (overall or rates at 
specific time points). 
• Tumour response rates. 
• Adverse events. 
 
 
• Pleurodesis or pleural fluid 





• Any language 
• Full-text article  
 
• Randomised controlled trials 
• Case control studies 
• Comparative cohort studies 
• Cohort studies with historic 
control groups. 
 
• Studies without a comparison 
group. 
• Early phase clinical trials. 
• Case series/case reports. 
• Review articles. 
• Letters/ editorials/ commentaries. 
• Conference abstracts. 
• Animal studies/ in vitro lab studies. 
• Studies with no abstract available. 
 
Table 2-1 Eligibility criteria for systematic review based on PICOS criteria 
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The search strategy was developed with support from an information scientist at the 
University of York and is shown in Appendix A.  The strategy included exploded MeSH 
headings for MPE, combined with keyword or title word searches for intra-pleural 
bacteria, immunotherapy and specific products.  The initial search was run on 27th 
February 2017, with the manual search completed on 3rd March 2017.  The search was 
repeated on 22nd February 2018, prior to publication of the systematic review, to 
identify any studies published in the intervening year. 
 
2.2.4. Data extraction and risk of bias assessment 
The titles and abstracts of all studies identified by the search were screened for 
relevance by myself (Dr Anna Bibby, AB) and by a second, independent reviewer (Dr 
Steve Walker, SW).  Studies were included in the review if they met the eligibility criteria 
for the PICO variables, as stated above.  Potentially eligible studies were obtained in full-
text format and further screened by the reviewers, independently. Discrepancies 
between the reviewers were resolved by discussion, or if resolution could not be 
reached, by consultation with a third party (Prof Nick Maskell, NM).   
 
Data were extracted from eligible studies by the two independent reviewers (AB and 
SW).  If a study stated in its methodology that data relevant to the PICO criteria was 
collected but did not report this data in the results section, the authors were contacted 
and asked to provide the data. 
 
Randomised trials that met the inclusion criteria were evaluated using the Cochrane tool 
for assessing risk of bias, whilst non-randomised studies were assessed using the Risk Of 
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Bias In Non-randomised Studies of Interventions (ROBINS-I).(177, 178)  With the 
Cochrane tool, risk of bias was assessed over the pre-specified domains of random 
sequence generation, concealment of allocation, blinding of participants and personnel, 
blinding of outcome assessment, completeness of outcome data, selective reporting and 
other potential sources of bias.  Domains were judged to be at high, low or unclear risk 
of bias.  Using ROBINS-I, risk of bias was assessed in relation to confounding, selection of 
participants, classification of intervention, adherence to intended intervention, missing 
data, measurement of outcomes and reporting of results.  Studies were deemed to be at 
low, moderate, serious or critical risk of bias in each of these areas, or not to have 
sufficient information available to assess.  Risk of bias was assessed independently by 
the same two reviewers (AB & SW), with differences of opinion resolved by discussion or 
involvement of a third party (NM).   
 
2.2.5. Data synthesis and analysis 
Where possible, raw data was extracted from studies to calculate the outcomes of 
interest i.e. overall survival, 1-year survival rates and tumour response rates.  Overall 
survival was calculated using time-to-event analysis (Cox proportional hazards model) to 
generate a hazard ratio for mortality, with 95% CI.  Proportional outcomes (i.e. rates) 
were calculated as OR with 95% CI.  
 
Meta-analysis was planned if two or more RCTs with the same outcome were identified. 
Heterogeneity would be assessed visually with Forest plots and quantitatively using the 
I2 statistic.(179)  Since heterogeneity was expected to be high, a random effects model 
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was expected to be required.  Ultimately, however, meta-analysis was not possible, due 
to variable reporting of outcomes and high heterogeneity between studies. 
 
Univariable meta-regression and Fisher's exact test were used to explore the 
relationship between the likelihood of the study reporting a positive effect and study 
design; year of publication; patient population; and bacterial product. 
 
2.3. Results 
2.3.1. Study selection 
Results of the search are shown in Figure 2.1, in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.(180) 
Six hundred and thirty-one articles were identified by the search, once duplicates had 
been removed.  Of these, six hundred and two were excluded at screening.  Fifteen 
manuscripts were excluded at full-text review, for the following reasons: full-text was 
unavailable for five; survival outcomes were not reported or not reported separately in 
six; two publications reported duplicate data (the paper with the least amount of data 
was excluded); one article had no data on pleural effusions and one manuscript was a 
review article. Further information on excluded papers is shown in Appendix 2.  In total, 
fourteen studies were included in the final review. 
 
2.3.2. Characteristics of included studies 
Of the fourteen included papers, eight were RCTs,(84, 94, 96, 101-104, 181) and six 
were non-randomised comparison studies,(90, 95, 122, 123, 182, 183) most commonly 
cohort studies with historic comparators.  Studies were published between 1979 and 
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2007.    The most frequent population was patients with MPE due to lung cancer (all 
sub-types),(94, 96, 122, 123, 181) or NSCLC specifically.(95, 101-103, 183)  Other studies 
included patients with MPE due to any underlying tumour,(84, 90) MPE due to 
MPM,(182) and MPE secondary to lung and gastrointestinal tumours.(104) Study 






Figure 2.1 Result of search, content screening and full-text review of papers investigating 
intra-pleural bacterial products in malignant pleural effusion 
 
Full text retrieved 
(n=29) 
Excluded at screening 
(n=602) 




Full text unavailable (n=5) 
Survival not reported, 
authors contacted (n=6) 
No pleural effusion (n=1) 
Duplicate data (n=2) 
Review article (n=1) 





Identified from grey 
literature & clinical 
trials registers (n=336) 
Identified from 
manual search & 
snowballing (n=7) 




Table 2-2 Summary of randomised trials included in the systematic review (nb all agents were delivered intra-pleurally unless otherwise stated) 
Abbreviations: 95% CI – 95% confidence intervals; C. Parvum – Corynebacterium parvum; GI – gastrointestinal; HR – hazard ratio; I/P – intra-pleural; I/V 
– intravenous; KE – Klinische Einheit; kg – kilogram; mcg – microgram; mg – milligram; MST – median survival time; MPE – malignant pleural effusion; 
NS – non-significant; NSCLC – non-small cell lung cancer   
*where reported 
Authors Publication date N 
Study 
population, 
MPE 2⁰ to: 
Intervention (dose) Comparator (dose) 
MST 
intervention, 
days (95% CI*) 
MST 
comparator, 
days (95% CI*) 
P value 
Ishida et al 
(101) 2006 49 NSCLC 
OK423 (5KE) 
Cisplatin alone (50mg) 
131 
152 p=0.55 OK432 (5KE) + cisplatin 
(50mg) 256 
Kasahara et 
al   (103) 2006 40 NSCLC OK432 (10KE) OK432 (1KE) 235 158 
Not 
reported 
Luh et al (96) 1992 55 Lung cancer OK432 (10KE) Mitomycin C (8mg) 177 156 NS 
Yoshida et al  
(102) 










Nio et al 
(104) 1999 42 
Lung or GI 
cancer 
OK432 (1-10KE) 





OK432 (1-10KE) + I/P 
chemotherapy (various) 115 p=0.080 
Masuno et al 
(94) 1991 95 Lung cancer 
Lactobacillus casei 
(0.2mg) + doxorubicin 
(40mg) 
Doxorubicin alone 
(40mg) 232 125 p=0.0061 
Millar et al 
(84) 
1980 21 Any tumour C. Parvum (7mg) Mustine (20mg) 80 (mean) 86 (mean) NS 
Yamamura 
et al (181) 1983 68 Lung cancer 
Nocardia rubra (400mcg) 
+ doxorubicin (40mg) 
Doxorubicin alone 




Authors Publication date Study design 
Study 
population, 
MPE 2⁰ to: 





months (95% CI*) 
MST comparator, 
months (95% CI*) P value 
Ren et al 
(95) 2004 
Case series with 








al (90) 1985 
Cohort with 
historic controls Any tumour 67 
C. Parvum 

















al  (183) 2005 
Retrospective 




(80mg/m2) 14 18 NS 
Yamamura 
et al (123) 1979 
Cohort with 
historic controls Lung cancer 87 
BCG cell wall 
skeleton (200-
400mcg) 
Usual treatment 10 6 p=0.016 
Yasumoto 
et al  (122) 1979 
Cohort with 
historic controls Lung cancer 30 
BCG cell wall 
skeleton (5mg) 
+ chemotherapy 




Table 2-3 Summary of non-randomised studies included in the systematic review (nb all agents were delivered intra-pleurally unless otherwise stated) 
Abbreviations: 95% CI – 95% confidence intervals; C. Parvum – Corynebacterium parvum; GI – gastrointestinal; HR – hazard ratio; I/P – intra-pleural; I/V – 
intravenous; KE – Klinische Einheit; kg – kilogram; mcg – microgram; mg – milligram; MST – median survival time; MPE – malignant pleural effusion; NS – 
non-significant; NSCLC – non-small cell lung cancer. 
*Where reported   **Calculated by the author of this thesis
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Different bacterial products were used, including OK432 in six studies,(96, 101-104, 183) 
Corynebacterium parvum in three,(84, 90, 182) BCG cell wall skeleton in two,(122, 123) 
and Lactobacillus casei,(94) Staphylococcus aureus superantigen,(95) and Nocardia 
rubra cell wall skeleton(181) in one apiece.  Comparators included intra-pleural 
chemotherapy,(84, 90, 94, 96, 101, 102, 104, 181, 183) usual treatment,(122, 123) talc 
poudrage,(95) or alternative pleurodesis agents(182).  One RCT compared two different 
doses of the same bacterial product.(103)  Two studies employed a three-arm design, 
comprising bacterial product alone, chemotherapy alone and bacteria/chemotherapy 
combination.(101, 104)  
 
2.3.3. Risk of bias assessment 
Risk of bias was high or unclear in at least one domain for all eight randomised trials 
included in the systematic review (Table 2.4).  Half the RCTs were published prior to the 
development and publication of the Consolidated Standards of Reporting Trials 
(CONSORT) guidance in 1996, and much of the information required to assess risk of 
bias was missing.(184)  Information on random sequence allocation and concealment of 
allocation was provided in only three trials, whilst information on blinding of 
participants and outcome assessments was lacking in all but two.  Selective reporting 
and incomplete outcome data were commonplace, with only three RCTs including all 
participants in the final analysis and reporting all the outcomes stated in the 
methodology.  
 
All non-randomised studies were at high risk of confounding, with several using historic 
controls or patient groups with differing baseline characteristics (Table 2.5).  Selection 
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bias was also a risk for non-randomised studies, with many failing to state how eligible 
participants had been identified or selected.  Description of the intervention and 
adherence to it was relatively well reported, however outcome measures were 
frequently not pre-stated, not defined or not assessed by blinded assessors.   
 
Individual studies and their limitations are described in sections 2.3.5 for RCTs and 2.3.6 




















Ishida et al (101)        
Kasahara et al (103)        
Luh et al (96)        
Yoshida et al (102)        
Nio et al (104)        
Masuno et al (94)        
Millar et al (84)        
Yamamura et al (1983) (181)        
Table 2-4 Risk of bias assessment for randomised trials included in the systematic review, 
assessed using Cochrane Risk of Bias Tool.  Red = high risk of bias, green = low risk of bias,  




Selection of participants 










Reporting of result 
Ren et al (95)        
McLeod et al (90)        
Senyigit et al (182)        
Shimizu et al (183)        
Yamamura et al (1979) (123)        
Yasumoto et al (122)        
 
Table 2-5 Risk of bias assessment for non-randomised studies included in the systematic review, 
assessed using ROBIN-I Tool. Black = critical risk of bias, red = serious risk of bias, yellow = 
moderate risk of bias, green = low risk of bias, grey = no information. 
 
2.3.4. Synthesis of results 
Six of the fourteen included studies reported an overall survival benefit associated with 
intra-pleural bacterial immunotherapy.(90, 94, 95, 122, 123, 181)  This ranged from a 
median survival benefit of 2.5 to 5.4 months from the date of drug administration.  
However, limited reporting of confidence intervals meant that the precision of most 
estimates could not be evaluated.  The remaining eight studies demonstrated no 
difference in survival between patients treated with intra-pleural bacteria and 
comparators.(84, 96, 101-104, 182, 183)   
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Only two papers provided measures of variance for the survival estimate, specifically 
95% CI.(95, 102)  One paper provided patient-level data, and I performed survival 
analysis using this data.(122)  No other measures of variance were available and 
requests for raw data were unsuccessful, therefore meta-analysis was not possible.   
Additionally, heterogeneity within and between populations, interventions and 
comparators meant meta-analysis was inappropriate, even using a random-effects 
model, as a pooled effect estimate would not be applicable to specific populations or 
products.  Consequently, narrative synthesis was undertaken. 
 
2.3.5. Results of individual studies – randomised trials 
Five RCTs investigated OK432, a heat- and penicillin-killed Streptococcus pyogenes 
preparation.   An initial dose-finding trial found that 10 Klinische Einheit (KE) of OK432 
was associated with longer survival than a dose of 1KE (33.6 weeks vs 22.6 weeks) but 
interpretation of these results was difficult without a non-OK432 comparator 
group.(103)   
 
Other trials compared OK432 with intra-pleural chemotherapy.  The most 
methodologically reliable was a three-armed study that compared OK432 at a dose of 
0.2KE/kg with two different intra-pleural chemotherapy regimens in MPE due to 
NSCLC.(102)  No survival difference was seen across the three groups.  Similarly, Luh et 
al found no difference in survival between lung cancer patients treated with intra-
pleural mitomycin C or OK432 (10KE).(96)  However, this paper was at risk of reporting 
bias as outcomes were not stated a priori and some participants were excluded from the 
analysis due to early death.  
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Ishida et al reported a trend towards longer survival in patients with MPE secondary to 
NSCLC treated with OK432 in a three-armed trial that compared 5KE of OK432 plus 
intra-pleural cisplatin with OK432 alone or cisplatin alone.(101)  Median survival was 8.3 
months in the combination arm, compared with 5 months for cisplatin and 4.3 months 
for OK432 alone. Statistical significance was not achieved (p=0.55), however, the trial 
was underpowered with just 49 participants – a sample size that was based on time 
constraints rather than a formal calculation.  
 
The final study to evaluate OK432 compared multiple regimens of intra-venous and 
intra-pleural chemotherapy with varying doses of OK432, either alone or in combination 
with intra-pleural chemotherapy.(104)  The heterogeneity of interventions made 
interpretation difficult, and the use of an comparator with a proven survival benefit 
(intravenous chemotherapy) in one arm must be taken into account when considering 
the results.   No survival difference was seen between the arms, however the 
combination of OK432 and intra-pleural chemotherapy was associated with longer 
survival compared with OK432 alone (115 days vs 51 days).  Given survival was similar 
for people treated with OK432 and patients treated with intra-venous chemotherapy, 
the study could be interpreted to mean intra-pleural OK432 is as effective as standard of 
care chemotherapy.  However, the study was not designed as a non-inferiority trial and 




Yamamura et al also combined intra-pleural chemotherapy with a bacterial product, 
using Nocardia rubra cell wall skeleton in conjunction with doxorubicin versus 
doxorubicin alone in 68 participants with MPE secondary to lung cancer.(181)  The 
nocardia group had a median survival of 266 days, compared with 190 days for single-
agent doxorubicin (p<0.05).  However, patients who died within 30 days of 
randomisation were excluded from the analysis, risking attrition bias.  Furthermore, this 
outcome was the result of a sub-group analysis of data from a larger trial in which 
multiple analyses were undertaken, without pre-specification in the analysis plan.  
Therefore there is a risk of multiple testing and of reporting bias.  
 
Another RCT randomised 95 participants with lung cancer MPE to receive intra-pleural 
Lactobacillus casei and doxorubicin or doxorubicin alone.(94)  Patients who received 
Lactobacillus had a median survival of 232 days compared with 125 days in controls 
(p=0.0061).  However, 19 patients were excluded from the final analysis, creating a high 
risk of attrition bias.  Interestingly, no further trials were undertaken using either 
Lactobacillus casei or Nocardia rubra despite these positive results. 
 
The final RCT investigated Corynebacterium parvum, randomising 21 participants to 
either Corynebacterium or intra-pleural mustine.(84)  No survival difference was seen in 
this small study, with mean survival of 80 days for Corynebacterium and 86 for mustine.  
No information was provided about the distribution of the data, so it is unclear whether 
use of mean survival values was appropriate.  Additionally, outcomes were not specified 
a priori, creating a risk of reporting bias.   
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2.3.6. Results of individual studies – non-randomised studies 
Two non-randomised studies evaluated BCG cell wall skeleton (BCG-cws) alongside 
standard care in patients with lung cancer.(122, 123) The first reported median survival 
of 10 months in 55 patients treated with BCG-cws, compared with 6 months in 32 age-
matched historic controls (p=0.016).(123)  The second presented patient-level data for 
13 patients with MPE given BCG-cws and 17 historic controls.(122)   These data were 
analysed to reveal median survival of 8 months in the BCG-cws group and 4 months in 
controls, with a hazard ratio of 0.374 (95% CI 0.168-0.833, p=0.016).  However, it was 
unclear how participants were selected for these studies, and the latter included a 
greater proportion of women in the BCG-cws group, a factor known to be associated 
with longer survival in lung cancer.(185)  Additionally the use of historic controls may 
have introduced confounding due to potential advances in care between the two time 
periods. 
 
Two observational studies investigated Corynebacterium parvum.(90, 182)  McLeod et al 
retrospectively analysed data from 67 patients with MPE treated with Corynebacterium 
parvum or intra-pleural mustine at a single UK centre.(90) Mean survival was 251 days in 
the Corynebacterium group compared with 119 days in the mustine group (p<0.01). 
However, 14 patients died within 30 days of treatment and were excluded from the final 
analysis, introducing potential bias for survival outcomes.  Additionally, patients who 
received mustine were treated prior to 1980, whilst the majority of Corynebacterium 
patients were treated after this, raising the possibility of temporal confounding.  
Furthermore, 6 patients who failed pleurodesis with mustine were excluded from the 
analysis, generating potential bias due to differential attrition.   
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Senyigit et al also investigated Corynebacterium parvum, but in patients with MPM.(182)  
They described 117 patients who received intra-pleural Corynebacterium, 
oxytetracycline or nitrogen mustard.  No survival difference was detected between the 
three groups, with mean survival of 10 months in Corynebacterium patients, 11 months 
in oxytetracycline patients and 9 months in patients treated with nitrogen mustard.  The 
study was at risk of attrition bias as 21 participants were excluded from the final analysis 
due to death, disease progression or loss to follow up.  In addition, time-to-event 
modelling was not employed for survival analysis and thus censored data was not taken 
into account.   
 
Shimizu and colleagues evaluated 32 patients with NSCLC treated with either intra-
pleural OK432 or cisplatin between 2000 and 2004.(183)  They found no difference in 
mortality, with median survival of 14 weeks in OK432 patients and 18 weeks in the 
cisplatin cohort.  However, the two groups were markedly dissimilar, with worse 
prognostic characteristics in the OK432 group and less systemic chemotherapy 
administered to these patients.  These differences could have attenuated a potential 
survival benefit associated with OK432, although the lack of observed survival difference 
is consistent with previous RCT data.(96, 101-104) 
 
Finally, Ren and colleagues gave intra-pleural staphylococcus superantigen (SSAg) to 14 
patients with MPE secondary to NSCLC, six of whom also received intra-venous SSAg.  
Outcomes were compared with 18 historic controls from up to 10 years earlier.  Median 
survival was 7.9 months in SSAg patients, compared with 2 months in controls 
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(p=0.0023), leading the authors to conclude that SSAg had anti-neoplastic effects.  
However, the study was vulnerable to a number of confounding factors, mainly relating 
to the differences between the two treatment groups.  As well as the temporal divide 
between cases and controls, controls were treated in the USA whilst cases were 
recruited and treated in Japan.  Differences in epidemiology, tumour and population 
genetics, healthcare systems, and treatment approaches between the 2 countries mean 
the population are unlikely to be comparable.  
 
2.3.7. Meta-regression 
More non-randomised studies reported favourable survival with bacterial products than 
RCTs (4/6; 66.7% vs 2/8; 25%) but the relationship was not confirmed by meta-
regression (OR 0.17, 95% CI 0.16-1.72, p=0.132).   A greater number of studies published 
prior to 1996, i.e. before the first iteration of the CONSORT reporting guidelines were 
produced, were positive compared with studies published after that date (6/8; 75% vs 
1/6; 16.7%). Meta-regression supported this association (OR 15, 95% CI 1.03-218.3, 
p=0.047), albeit with an imprecise estimate of the relationship due to the small number 
of studies.  Studies involving lung cancer patients were more likely to be positive (4/6; 
66.7%), compared to studies of MPE secondary to NSCLC (1/5; 20%), any tumour (1/2; 
50%) or MPM (0/1; 0%) but regression analysis did not demonstrate a convincing 
association (OR 0.47, 95% CI 0.18-1.21, p=0.116). 
 
No specific bacterial product appeared more effective, although patients treated with 
Lactobacillus casei and Nocardia rubra had longer survival in two respective RCTs, whilst 
BCG cell wall skeleton was associated with a four-month extension to median survival in 
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both non-randomised studies that utilised it.(94, 122, 123, 181)  OK432 was associated 
with no survival benefit in 5 RCTs and 1 non-randomised study,(96, 101-104, 183) 
although in one of those studies the comparator was intra-venous chemotherapy, i.e. 
standard care.(104)  Corynebacterium parvum was associated with longer survival in one 
non-randomised study,(90) but no effect in 2 others (1 randomised and 1 non-
randomised),(84, 182) whilst Staphylococcus aureus superantigen was associated with 
longer survival in a single observational study.(95) 
 
2.4. Summary of findings 
The existing evidence was mixed regarding the potential survival benefits associated 
with intra-pleural bacterial products in pleural malignancy.  All eligible studies were of 
low quality and were at high or unclear risk of bias in at least one domain.  Synthesis of 
data was limited due to the heterogeneity of bacterial products, underlying diseases and 
outcome measures studied.  Additionally, few studies presented measures of variance, 
which precluded meta-analysis. 
 
There is, therefore, no reliable evidence at present to support the use of intra-pleural 
bacterial products to prolong survival in pleural malignancy.  Well-designed, suitably 
powered RCTs are needed, but choosing the appropriate bacterial product and target 
population is likely to prove challenging.   
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3. Chapter 3 – A population-level cohort study examining the 
association between pleural infection and survival in 
mesothelioma 
 
The work described in this chapter has been published:   
Bibby AC, de Fonseka D, Carslake DJ & Maskell NA. Is pleural infection associated with 
longer survival in mesothelioma? A population-based cohort study using data from 
Hospital Episode Statistics. Cancer Epidemiology 2019;59:75-82. 
 
ACB conceived the study, designed the methodology, cleaned & analysed the data, 
interpreted the results and wrote the manuscript. DDF helped refine the methodology, 
assisted with data analysis and contributed to manuscript writing. DJC developed the 
statistical analysis plan, assisted with data analysis, interpreted the results and helped 
write the manuscript. NAM developed the study concept, reviewed the analysis plan, 
assisted with interpretation of results and refined the manuscript.  
 
3.1. Background 
Whilst the evidence for directly administered intra-pleural bacterial products is limited 
in malignant pleural disease, bacteria can also occur spontaneously in the pleural space 
as a result of pleural infection.  Small studies have reported longer survival in patients 
with malignancy who developed pleural infection, although the majority of these were  
in patients who had undergone curative surgical resection of lung tumours and were 
theoretically cancer-free at the point of developing pleural infection.(159-161)  In 
mesothelioma, a single observational study reported longer survival in people who 
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developed pleural infection with an IPC in situ, compared with those without 
infection.(186)  Patient numbers were small, however, and confidence intervals wide, 
such that the true mortality benefit may have been extremely small and, therefore, not 
clinically relevant.   
 
This study was designed to investigate whether pleural infection was associated with 
survival in mesothelioma, using a national clinical dataset.  This would inform the overall 
thesis hypothesis regarding bacteria in the pleural space and survival in mesothelioma.  
 
3.2. Methods 
3.2.1. Study Design  
This was a population-based cohort study using historic data from Hospital Episode 
Statistics (HES) linked to Office of National Statistics (ONS) mortality data.  The research 
was approved by the Proportionate Review Sub-Committee of the National Research 
Ethics Committee London – Central (14/LO/1258).   
 
3.2.2. Study population & data sources 
The study population consisted of all patients with mesothelioma seen in a hospital in 
England between 01/01/2005 and 31/12/2014.  Participants were identified from HES, a 
database containing details of every hospital stay, emergency attendance and 
outpatient appointment in NHS hospitals in England.  All episodes containing an 
International Classification of Diseases Tenth Edition (ICD-10) code for mesothelioma 
(i.e. C45, C45.0, C45.1, C45.2, C45.7 or C45.9) during the study period were extracted.  
Patients whose first recorded episode with a mesothelioma code occurred prior 
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01/01/2005 were excluded, as were patients whose recorded address was outside 
England, as HES would not have information for the majority of their hospital 
attendances.  Episodes of pleural infection were identified within the cohort using ICD-
10 codes J86, J86.0 and J86.9.  Information on additional study variables were obtained 
from HES.  
 
The extracted mesothelioma cohort was linked to ONS mortality data for the period 
01/01/2005 to 28/03/2016, using individual, pseudonymised patient identifiers.  ONS 
contains information taken from death certificates for all deaths registered in England 
and Wales.   
 
3.2.3. Exposure variables 
The exposure variable was an episode of pleural infection occurring during the study 
period.  The date of pleural infection was recorded as the earliest date of the first 
episode in which pleural infection was recorded.  If a participant experienced more than 
one episode of pleural infection, the earliest episode was used. 
 
3.2.4. Outcome variables 
The primary outcome was survival, defined as date of diagnosis with mesothelioma to 
date of death.  Date of diagnosis was defined as the start date of the earliest episode 
where mesothelioma was recorded.  Date and cause of death were obtained from death 
certificates.  Patients with zero survival time and death certificate diagnoses of 
mesothelioma were excluded from the analysis.  
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3.2.5. Confounding/mediator variables 
Patient variables and treatment details were extracted from HES, using ICD-10 and 
Office of Population Censuses and Surveys Classification of Interventions and 
Procedures (OPCS-4) codes.  Confounders were defined as variables that had a potential 
influential effect on the risk of pleural infection and on survival.  Confounders included 
sex, age at mesothelioma diagnosis, disease site (pleural; peritoneal; pericardial; other 
or unspecified), socio-economic status based on index of multiple deprivation (IMD) 
quintile (1=least deprived; 5=most deprived), rural/urban classification (urban area of 
population >10000; town or fringe; village; hamlet or isolated dwelling), comorbidities 
(defined as number of additional diagnostic codes at initial presentation), mode of initial 
attendance (outpatient appointment; inpatient admission; procedure or operation), 
year of diagnosis (before or after 01/01/2008), documented asbestos exposure, 
documented pleural plaques, and binary (yes/no) outcomes for whether the patient had 
undergone a biopsy, a thoracoscopy (where a fibreoptic camera in inserted into the 
pleural space, either under sedation and local anaesthesia or as a surgical operation) or 
a pleurodesis procedure (where a chemical irritant, usually talc, is introduced in to the 
pleural space either as a slurry via a chest drain or as poudrage during thoracoscopy).  
 
Mediators were classified as variables that were located on the causal pathway between 
pleural infection and survival.  They included number of pleural interventions, average 




3.2.6. Statistical analysis 
Datasets were merged and de-duplicated to create a single record for each patient.  
Descriptive statistics were used to describe patient characteristics, stratified by pleural 
infection.  Data for each variable was visually inspected.  Mean values with 95% 
confidence intervals were calculated for normally distributed continuous data, with 
medians and inter-quartile ranges (IQR) used for non-parametric variables.  Categorical 
and binary data were reported as proportions. Significance tests were performed using 
t-tests and Kruskal-Wallis tests for parametric and non-parametric data respectively.  χ2 
tests were used for binary, ordinal or categorical variables, with Fisher’s exact test 
employed if the expected frequency in any group was less than 10.  The only variable 
with missing data was socioeconomic status. A separate ‘missing’ category was created 
for this variable and included in all analyses. 
 
Pleural infection incidence rate was calculated per 1000-person years.  Because the 
incidence of pleural infection was likely to vary depending on time since diagnosis, 
separate incidence rates were calculated for the periods 0-30 days, 31-90 days and 90+ 
days post-mesothelioma diagnosis. 
 
Factors associated with pleural infection were investigated using time-to-event analysis 
using univariable and multivariable Cox proportional hazards models with time since 
mesothelioma diagnosis as the time axis.  All variables were included in the 
multivariable model, regardless of significance on univariable testing.  Potential 
interactions between pre-specified variables (comorbidities, age, IMD category, number 
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of pleural procedures, average number of hospital attendances per year and year of 
diagnosis) were tested using the Mantel Haenszel method.   
 
Median survival was reported for the whole group, and for patients who did and did not 
experience pleural infection at any time after their diagnosis with mesothelioma.  
Kaplan Meier curves were plotted to visually compare unadjusted survival in people 
with and without pleural infection.  Overall survival was also assessed in patients 
diagnosed before and after 2008, the year that pemetrexed and cisplatin chemotherapy 
became standard care in the UK.(187)   
 
Survival analyses were modelled using Cox proportional hazards models, having checked 
the validity of the proportional hazards assumption using Schoenfield residuals and 
visually with “log-log” plots for individual variables.  Because any potential hazard 
associated with pleural infection could only occur after the infection began, and due to 
clinical suspicion that the hazard may change following recovery from infection, pleural 
infection was handled as a time-varying covariable by splitting follow-up into pre-
infection, ≤30 days post-infection and >30 days post-infection.  Thoracic surgery and 
chemotherapy were also handled as time-varying covariables, with follow-up split at the 
time of first treatment.  Survival was censored on 28/03/2016.   
 
The primary survival model assessed all-cause mortality, with mesothelioma-specific 
mortality modelled as a secondary analysis, censoring participants who died of other 
causes on their day of death.  Initially the model was adjusted for confounders alone, 
then the analysis was repeated to include mediators, and the impact evaluated.  The 
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main analysis included all patients.  A priori sub-group analysis investigated patients 
with pleural mesothelioma, since pleural infection was likely to be most relevant to 
these patients.   
 
3.3. Results 
22,896 patient records were identified, of whom 22,149 met the inclusion criteria and 
contributed 24,453 patient-years in total (Figure 3.1).   In the final cohort of 22,149 
patients, 81.7% were male, mean age was 71.8 years (range 18-102), and the majority 
had pleural mesothelioma (51.5% pleural, 5.0% peritoneal, 0.4% pericardial, 43.1% 
other or not specified).  For 72.7% of patients, the first recorded diagnosis of 
mesothelioma occurred during an inpatient admission, whilst 23.5% were diagnosed at 
operation or procedure, and 3.8% during an outpatient appointment.  The median 
number of comorbid codes at presentation was 5 (IQR 3-7), with essential hypertension 
(n=6,428; 28.9%), pleural effusion (n=5,337; 24.0%), drug, alcohol or tobacco use 
(n=4,269; 19.2%) and ischaemic heart disease (n=3,789; 17.1%) the most frequent. 
 
3.3.1. Pleural infection 
Of 22,149 patients, 510 (2.3%) developed pleural infection during the study period.  The 
incidence rate of pleural infection was 21.1 per 1000 patient-years (95% CI 19.4-23.0).  
The incidence rate was higher in the first 30 days after diagnosis with mesothelioma 
(169 per 1000 patient-years, 95% CI 150.8-190.2), followed by the period between 31 
and 90 days after diagnosis (34.0 per 1000 patient-years, 95% CI 27.8-41.6).  Pleural 
infection occurred much less frequently once 90 days had passed since diagnosis (6.6 
cases per 1000 patient-years, 95% CI 5.6-7.9).   
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Figure 3.1 Identification of patients and eligibility screening for population-cohort study.   
HES – Hospital Episode Statistics 
 
Patient characteristics are shown in Table 3-1, stratified by pleural infection.  The pleural 
infection group had a higher proportion of men, were more likely to be diagnosed as 
inpatients and had more comorbidities at diagnosis.  Patients with pleural infection 
were more likely to have undergone pleural drainage or aspiration, thoracoscopy, 
thoracic surgery or pleurodesis and were less likely to receive chemotherapy.  Overall, 
patients with pleural infection underwent more pleural interventions and had a higher 
number of hospital episodes per year than patients without infection.  Predictably, 
pleural infection occurred more often in people with pleural mesothelioma. 
HES inpatient episodes with an 
ICD-10 code of mesothelioma 
N=122,473 
HES outpatient episodes with an 
ICD-10 code of mesothelioma 
N=17,741 
Individual patient records 
once episodes merged 
N=22,896 
Death certificate diagnosis, n=563 
Zero survival time (i.e. date of 
diagnosis=date of death), n=58 
Included in study 
N=22,149 
24,453.8 total patient years 
First episode prior to 01/01/05, 
n=60 
Living outside England, n=66 
Patients with recorded 
survival >0 days 
N=22,275 
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 Pleural infection 
N=510 
No pleural infection 
N=21,639 p 
Male, n (%) 454 (89.0) 17,638 (81.5) <0.001 
Age, mean (SD) 70.9 (9.84) 71.8 (9.93) 0.038 
IMD quintile, n (%)           



























Rural/urban location, n (%) 
Urban with ≥10,000 population 
Town and Fringe 
Village 
















Mode of initial attendance, n (%) 
Outpatient appointment 
Inpatient admission 













No. of comorbid codes, median 
(IQR) 6 (4-9) 5 (3-7) <0.001 
Documented asbestos exposure, n 
(%) 107 (21.0) 3,418 (15.8) 0.002 





















Total no of pleural procedures, 
median (IQR) 3 (1-4) 1 (0-2) <0.001 
Diagnosed after 2008, n (%) 311 (61.0) 13,171 (60.9) 0.959 
Site of disease, n (%)                Pleural 
Peritoneal 
Pericardial 













Average no. of hospital episodes 
per year, median (IQR) 3.5 (2-5.5) 3 (1.5-5) <0.001 
Treatment received, n (%) 















Infection/sepsis cause of death 3 (0.6) 118 (0.6) 0.912 
 
Table 3-1 Characteristics of 22,149 patients with mesothelioma, stratified by pleural infection.  P 
values derived from t-tests, Kruskal-Wallis tests, χ2 test and Fisher’s exact test.  
Abbreviations: IMD – index of multiple deprivation; IQR – interquartile range; SD – standard 
deviation.  
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 Unadjusted analysis Adjusted analysis* 
 HR 95% CI p HR 95% CI p 
Male gender 1.94 1.47 to 2.56 <0.001 1.67 1.27 to 2.24 <0.001 
Age at diagnosis                  ≤65 
66 to 70 
71 to75 








0.66 to 1.12 
0.71 to 1.19 
0.81 to 1.36 












0.61 to 1.05 
0.64 to 1.08 
0.71 to 1.22 





















0.59 to 1.02 
0.64 to 1.09 
- 
0.65 to 1.12 
0.62 to 1.06 
















0.59 to 1.02 
0.63 to 1.08 
- 
0.64 to 1.10 
0.58 to 1.01 









Urban ≥10,000 population 
Town and Fringe 
Village 








1.01 to 1.70 
0.79 to 1.49 













0.95 to 1.63 
0.67 to 1.30 















0.01 to 0.25 
- 










0.02 to 0.86 
- 





Diagnosed after 2008 0.97 0.81 to 1.16 0.762 0.83 0.69 to 1.00 0.055 
No. of comorbid codes 1.13 1.11 to 1.16 <0.001 1.13 1.10 to 1.16 <0.001 
Non-pleural mesothelioma 0.67 0.56 to 0.80 <0.001 0.81 0.67 to 0.97 0.025 
Documented asbestos 
exposure 1.40 1.13 to 1.73 0.002 0.91 0.73 to 1.14 0.410 












3.14 to 4.58 
1.52 to 2.15 
0.90 to 1.32 












1.28 to 2.02 
0.51 to 0.83 
0.62 to 0.94 






Total no. of pleural 
procedures 1.50 1.44 to 1.56 <0.001 1.51 1.41 to 1.61 <0.001 
No. of hospital episodes per 










0.33 to 0.59 
0.09 to 1.39 










0.43 to 0.82 
0.10 to 1.69 





Table 3-2 Factors associated with pleural infection in 22,149 patients with mesothelioma, from 
unadjusted and adjusted Cox proportional hazards models.  All listed variables were included in 
the multivariable model.  
Abbreviations: CI – confidence interval; HR – Hazard ratio for pleural infection; IMD – Index of 
multiple deprivation.  
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3.3.2. Factors associated with pleural infection 
Factors associated with pleural infection are shown in Table 3-2.   In the multivariable 
model, characteristics associated with an increased risk of pleural infection included 
male gender (HR 1.67, 95% CI 1.27-2.24, p<0.001), number of co-morbidities (HR 1.13, 
95% CI 1.10-1.16, p<0.001) and having undergone pleural drainage (HR 1.61, 95% CI 
1.28-2.02, p<0.001) or thoracic surgery (HR 2.23, 95% CI 1.64-3.02, p<0.001).  Pleural 
infection was seen less frequently in patients diagnosed as outpatients (HR 0.12, 95% CI 
0.02-0.86, p=0.035), patients with non-pleural mesothelioma (HR 0.81, 95% CI 0.67-0.97, 
p=0.025), patients who underwent thoracoscopy (HR 0.65, 95% CI 0.51-0.83, p<0.001), 
percutaneous biopsy (HR 0.76, 95% CI 0.62-0.94, p=0.009) or pleurodesis (HR 0.44, 95% 
CI 0.35-0.55, p<0.001), and patients who had received chemotherapy (HR 0.60, 95% CI 
0.43-0.82, p=0.001). Pleural infection was associated with a higher number of pleural 
procedures (HR 1.51, 95% CI 1.41-1.61, p<0.001). 
 
There was evidence of interaction between several variables relating to pleural infection 
(Appendix 3).  However, sensitivity analyses controlling for the interacting variable did 
not alter the observed association any of the variables tested.  
 
3.3.3. Survival 
20,363 deaths occurred over 24,453 patient-years.  Participants censored on 




Overall median survival was 6.9 months (IQR 2.3-16.3), increasing to 7.8 months (IQR 
2.6-17.1) in patients diagnosed after 2008 (n= 13,482).  Median survival was 6.2 months 
in patients who experienced pleural infection (IQR 2.6-14.9) compared with 7.0 months 
(IQR 2.3-16.4) in those who did not (unadjusted HR 1.11, 95% CI 1.02-1.22, p=0.021).  
Kaplan Meier curves, separated by pleural infection, are shown in Figure 3.2.  
 
 
Table 3-2 Kaplan Meier curves demonstrating survival (unadjusted) in patients who did and did 
not experience pleural infection 
 
3.3.4. Primary outcome 
The risk of dying from any cause was higher after pleural infection, both in the 
immediate (30 day) post-infection period (adjusted HR 1.81, 95% CI 1.47-2.23, p<0.001) 
and in the longer term (30+ days) post-infection (adjusted HR 1.80, 95% CI 1.63-1.99, 
p<0.001).  Full results of the unadjusted and adjusted survival models are shown in 
Table 3-3.  
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 Unadjusted analysis Adjusted analysis 
 HR 95% CI p HR 95% CI p 
Pleural infection 
Pre-infection/no infection 
First 30 days post-infection 







1.40 to 2.12 











1.47 to 2.23 





Male gender 1.24 1.20 to 1.29 <0.001 1.26 1.21 to 1.30 <0.001 











1.14 to 1.24 
1.32 to 1.44 
1.64 to 1.79 












1.12 to 1.22 
1.28 to 1.39 
1.53 to 1.67 






IMD quintile   














0.90 to 0.98 
0.89 to 0.97 
- 
0.94 to 1.02 
0.99 to 1.08 
















0.91 to 0.99 
0.91 to 0.99 
- 
0.93 to 1.02 
0.98 to 1.07 









Urban ≥10,000 population 
Town and Fringe 
Village 








1.01 to 1.10 
0.94 to 1.04 








1.03                         




0.98 to 1.08  
0.96 to 1.07 
















2.08 to 2.46 











1.06 to 1.28 





Diagnosed after 2008 0.86 0.84 to 0.89 <0.001 0.87 0.85 to 0.90 <0.001 
No. of comorbid codes 1.02 1.02 to 1.03 <0.001 0.99 0.98 to 0.99 <0.001 
Non-pleural mesothelioma 1.06 1.03 to 1.09 <0.001 0.95 0.92 to 0.98 <0.001 
Asbestos exposure 1.05 1.01 to 1.09 0.017 1.07 1.03 to 1.12 <0.001 












0.87 to 0.92 
0.63 to 0.67 
0.90 to 0.96 












1.16 to 1.26 
0.84 to 0.92 
1.03 to 1.11 






Total no. of pleural 
procedures 0.87 0.86 to 0.87 <0.001 0.87 0.85 to 0.88 <0.001 
Average no. of hospital 










0.81 to 0.86 
0.55 to 0.74 










0.93 to 0.99 
0.83 to 1.12 





Table 3-3 Factors associated with all-cause mortality in 22,149 patients with mesothelioma, from 
adjusted and unadjusted survival models.  All variables were included in the multivariable model.  
Abbreviations: CI – confidence interval; HR – Hazard ratio for mortality; IMD – index of multiple 
deprivation  
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In the multivariable model, factors associated with increased all-cause mortality were 
age, male gender, being diagnosed as an inpatient, undergoing percutaneous biopsy, 
undergoing a drainage procedure, documented asbestos exposure or pleural plaques, 
and having undergone thoracic surgery.  Non-pleural mesothelioma, being diagnosed 
after 2008, being less deprived, undergoing thoracoscopy or pleurodesis, fewer pleural 
procedures and receiving chemotherapy were all associated with reduced mortality. 
 
3.3.5. Secondary analyses 
18,587 (91.3%) deaths were due to mesothelioma.  Mesothelioma-specific mortality 
outcomes were similar to those for all-cause mortality (Appendix 3).  Additionally, the 
survival model did not change substantially when adjusted for confounders alone 
compared with confounders and mediators. Finally, sub-group analysis of pleural 
mesothelioma patients yielded comparable results to the main analysis (Appendix 3). 
 
3.4. Summary of findings 
This large, population-level cohort study contradicted the hypothesis that pleural 
infection was associated with longer survival in mesothelioma.  The data showed that 
pleural infection was associated with higher mortality, both in the immediate post-
infection period and in the longer-term.   
 
The data available from HES were limited, however, and information on certain 
prognostic factors, e.g. patients’ performance status and tumour histological type, was 
not available.  This may have caused confounding to affect the observed result.  
Additionally, the microbiological organisms causing pleural infection were not recorded.  
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As previously stated, it is recognised that different bacterial species have widely 
differing physiological effects, and it was unfortunate that this could not be explored 
further with these data in regards to survival in mesothelioma.   These limitations are 
discussed in greater length in Chapter 6. 
 
The findings of this study must be interpreted within the limitations of an observational 
study.  Causality cannot be determined and, if the association between pleural infection 
and increased mortality in mesothelioma is genuine, the direction of the relationship is 
not known.  It may be that dying patients were more likely to develop pleural infection, 
rather than infection contributing to earlier death.     
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4. Chapter 4 – The TILT trial  
Some of the work in this chapter has been published:   
Bibby AC, Torgerson DJ, Leach S, Lewis-White H & Maskell NA.  Commentary: 
considerations for using the 'Trials within Cohorts' design in a clinical trial of an 
investigational medicinal product.  Trials. 2018;19(1):18.  
 
4.1. Background 
4.1.1. Intra-pleural immunotherapy in mesothelioma 
As discussed in Chapter 1, the treatment options for MPM are limited. The disease is 
currently incurable, with median survival less than 1 year from diagnosis.(1, 30, 36, 38, 
188) Pemetrexed and cisplatin combination chemotherapy extended survival by 2.8 
months compared with single-agent cisplatin, however chemotherapy is not suitable for 
everyone.(2, 4, 38).  The addition of bevacizumab, a targeted antagonist of vascular 
endothelial growth factor (VEGF), to chemotherapy conferred a further 3 months 
survival benefit compared with placebo.(6)  Unfortunately, access to bevacizumab is 
limited, as it is not yet licensed for use in MPM in the UK or the US.   
 
New therapeutic options are urgently required for MPM, and immunotherapy is an 
appealing choice.  MPM is an immune-evasive tumour that is able to suppress protective 
populations of CD8+ effector T cells and antigen presenting cells (APC) in the pleura, 
whilst also upregulating CD25+ regulatory T cells (Tregs).(11, 12, 67-69). The ability to 
overcome this local immunosuppression and maintain normal immune cell responses in 
the pleura has been shown to be associated with longer survival.(13, 69, 70, 189).   
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Some of the immunosuppression associated with MPM occurs as a result of exploitation 
of the immune checkpoint pathway.  Approximately 40% of MPM tumours express the 
programmed death 1 ligand (PD-L1) and, consequently, are able to down-regulate 
effector T cell activity and inactivate protective anti-tumour immune responses.(190, 
191)  The use of immune checkpoint inhibitors (ICI) to interrupt the interaction between 
the programmed death 1 (PD-1) receptor and PD-L1, and preserve anti-cancer immune 
activity has been investigated in MPM.(15, 17, 49, 50, 192).  However, to date, there is 
no published RCT evidence supporting the efficacy of ICI to extend survival with MPM, 
although several negative trials have been published.(51, 75) Recently, the combination 
of ipilimumab and nivolumab as a first-line therapy was associated with longer overall 
survival in comparison to standard chemotherapy, but the full trial report has yet to be 
published.(80) 
 
Like most pharmaceutical agents, ICI and chemotherapy carry a risk of toxicity, which 
can have serious consequences.(4, 17)  Many patients with MPM are reluctant to 
receive systemic anticancer treatment due to concern about side effects and reluctance 
to compromise their QoL.(48)  A treatment approach that could reduce the risk of side 
effects would be welcomed by this patient population. 
 
Topical administration of therapeutic agents is one potential way of reducing side 
effects.  In MPM, indwelling pleural catheters (IPC) present an opportunity to deliver 
medications directly into the pleural cavity.  This could maximise the concentration of 
the drug in the immediate tumour environment and may limit systemic absorption, 
leading to fewer side effects.(18, 19)  It is not known whether ICI can be administered 
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safely via an IPC, but alternative immunotherapy agents, i.e. bacterial products, have 
been administered intra-pleurally for several decades, with few complications.  As 
shown by the systematic review, summarised in Chapter 2, it is unclear from the current 
literature whether bacterial products have any effect on survival in people with pleural 
malignancy, whether due to MPM or other malignancies.(176)   
 
Clinical equipoise exists, therefore, as to whether bacterial products could be re-
purposed for use as anti-cancer agents in MPM.  It is an area of interest for clinicians, 
patients and mesothelioma stakeholders, and was highlighted as such by the James Lind 
Alliance in a 2015 priority setting partnership exercise.(162)  The question “Is there a 
role for intrapleural immunostimulants (a drug designed to stimulate an anti-cancer 
immune response, such as corynebacterium parvum extract)?” was designated the 
eighth most important question in mesothelioma research.   
 
The Trial of Intrapleural bacteriaL immunoTherapy (TILT) was designed to address this 
question, focussing on two bacterial products: OK432 and BCG.  These bacterial 
products were chosen based on in vitro and in vivo evidence demonstrating pro-
inflammatory activity and associated cytotoxic effects.(98, 100, 110, 114)  As described 
in Chapter 1, it was felt that the trial within a cohort (TwiC) methodology would be well 
suited to undertaking this trial in the MPM population.  Since the TwiC design had not 
been used in patients with MPM previously, a feasibility trial was planned.   
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4.1.2. The TwiC design 
The TwiC design (also known as the cohort multiple randomised controlled trial or 
cmRCT methodology) is a highly pragmatic approach to randomised clinical trials.(136)  
Patients who are already participating in a longitudinal, observational cohort study are 
screened to determine whether they are eligible to participate in the trial.  Eligible 
participants are selected at random to be offered the trial intervention, with non-
selected eligible participants acting as controls from within the cohort (Figure 4.1).  A 
key tenet of the TwiC design is that after randomisation takes place, people selected to 
be offered the trial intervention are told about the trial, provided with information 
about the intervention and asked to consent to receive it (i.e. the intervention arm is 
open label), whilst control patients in the cohort are not informed about the trial or the 
intervention and are not required to give any additional consent (i.e. they are blinded). 
 
The TwiC design has several potential benefits, including efficient recruitment, reduced 
cross-over between arms and lower risk of attrition from the control group.  
Additionally, there is potential to undertake multiple trials within the same cohort, thus 
enhancing efficiency and reducing some of the delays and costs associated with setting 
up and recruiting to clinical trials.(136, 157, 193)  TwiCs also replicate real-life clinical 
care more faithfully than standard RCTs. In clinical practice, patients are told about 
interventions if and when they are going to receive them, and not if they are not.  The 
exact same practice occurs in a TwiC.  In contrast, in a standard RCT, all patients are 
informed about the intervention, despite the fact that approximately half will never 
receive it.  Furthermore, in a blinded RCT, participants may never know whether they 
received the intervention or not.   
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TwiCs are highly pragmatic, therefore, and can provide useful information on the 
effectiveness of interventions.(136, 149, 157)  The counterpoint to this is that TwiCs are 
less suited to explanatory studies or early phase trials where safety and efficacy are 
being assessed.  These types of trials tend to require strict protocols, with most 
variables tightly controlled, so that the true effect of the intervention can be evaluated 
under perfectly regulated conditions.(149)  Because the safety profile of intra-pleural 
bacterial products was well established and their biological effect had been 
demonstrated in vitro and in vivo, a pragmatic methodology was preferred for this 
research.  Additionally, if patients were unwilling to take chemotherapy due to concern 
about side effects, they may make the same decision about intrapleural bacterial 
immunotherapy. In such a scenario, a pragmatic, effectiveness study would provide a 
better evaluation of the potential impact of this treatment in the real-world MPM 
setting. Finally, given the current dearth of effective treatment options for MPM and the 
recruitment challenges that have faced historic clinical trials in MPM, the potential 
efficiency associated with recruiting from within an existing cohort was appealing. 
 
4.1.2.1. Designing a CTIMP TwiC 
Since its initial description in 2010, the TwiC design has been used around the globe, in 
areas as diverse as public health, oncology, rheumatology and complimentary 
medicine.(194-199) However, at the time TILT was designed, the methodology had 
never been applied to a clinical trial of an investigational medicinal product (CTIMP).  
For safety reasons, CTIMPs are subject to more stringent regulations and governance 
than other research trials.(200-205)  
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In order for TILT, or indeed any CTIMP using the TwiC design, to comply with these 
regulations, certain methodological considerations had to be appraised during the 
design phase of TILT.(206)  Ultimately, it was necessary to make certain specifications 
within the trial protocol, clarifying the distinction between cohort participation and trial 
participation (see Section 4.1.2.4.).   
 
4.1.2.2. Trials suitable for the TwiC design 
The TwiC methodology is highly pragmatic and can provide valuable information about 
the real-life utility and effectiveness of interventions.  The design is less suitable for 
explanatory trials aiming to evaluate whether an intervention has an effect under ideal 
(and therefore tightly controlled) conditions, particularly early-phase clinical trials.(136)  
In the context of CTIMPs, therefore, the TwiC approach is more appropriate for trials in 
the later phases of clinical evaluation. 
 
Specific factors that make the TwiC design unsuitable for early-phase clinical trials 
include the necessary use of standard care as the comparator arm.  Not only are 
placebo-controlled trials not possible, but trials that entail additional interventions or 
investigations in the control arm, outside the remit of usual care, are also incompatible 
with the TwiC design.  This is because the additional procedures would be considered 
research activities and control participants should provide consent to undergo such 
activities.  However, the blinding of control participants is an inherent element of the 
TwiC design and obtaining additional consent from controls for trial-specific procedures 
would undermine this.  In contrast, participants who receive the intervention in a TwiC 
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do so in an open-label fashion.  This enables a “patient-centred” consent process in 
which every participant is informed about, and gives consent for, the precise activities 
and interventions that they will undergo.  However, in combination, these factors make 
the TwiCs design unsuitable for early-phase CTIMPs, evaluating drug safety and efficacy.   
 
4.1.2.3. Clinical trials regulations 
Clinical research involving pharmaceutical products is guided by the International 
Committee for Harmonisation of Technical Requirements for Pharmaceuticals for 
Human Use (ICH) Statement on Good Clinical Practice (GCP).(202)  This document 
provides an international standard for ethical and scientific quality in research involving 
human participants, based on the principles set out in the Declaration of Helsinki.  In the 
European Union (EU), this guidance has been transcribed into law in the form of 
European Directive 2001/20/EC, also known as the EU Clinical Trials Directive.  Similar 
legislation has been produced by the Food & Drug Administration (FDA) in the US,(203) 
and other regulatory authorities in other countries.  It is a legal requirement that all 
CTIMPs conducted in these countries adhere to the relevant regulations. 
 
The primary purpose of clinical trials legislation is to protect the safety, well-being and 
rights of trial participants.  A fundamental component of this is informed consent, 
whereby research participants are given information about all research procedures, 
including any potential risks associated with those activities.  Only once they have had 
time to consider this information will the participant be in a position to make an 
autonomous, informed decision regarding participation in the research.   
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In randomised trials with participants who have capacity, the process of randomisation 
is a research activity and should only occur once the participant has consented to take 
part in the trial.   Although both pre-randomisation and randomisation without consent 
designs have been used historically, notably as part of the Zelen design, they were 
generally considered unethical, with significant potential to damage the doctor-
participant relationship.(137, 138, 143) 
 
Initially concerns were voiced that the TwiC design entailed pre-randomisation, 
however, proposal of a ‘staged consent’ model resolved this issue.(142, 146)  With the 
staged consent process, all cohort participants provided initial consent at the time of 
enrolling, which included specific agreement to: 
• allow their cohort data to be used to screen their eligibility for clinical trials; 
• undergo random selection for future trials for which they were eligible; and 
• permit use of their data as comparison data for clinical trials, even in the event 
of non-selection for that trial. 
With all participants having consented to the above points, people randomly allocated 
to the trial intervention arm were asked to provide second consent, essentially agreeing 
to receive the trial intervention.(146)  Control patients were not required to provide any 
additional consent as they were not subject to any additional research processes.  Thus, 
all participants provided consent for every research activity they experienced. 
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4.1.2.4. Separating cohort and trial activities 
Applying the staged consent process to TILT enabled explicit separation of research 
processes into either cohort-related or trial-related activities.  Based on the model 
described above, screening for TwiCs, random selection and provision of control data 
were designated cohort activities, covered by the cohort consent form.  IMP 
administration was a trial activity, covered by the trial consent form.  Using this 
approach, trial participants were specified as those who had signed the trial consent 
form, whilst everyone else, including control patients, were participating in the cohort 
only (albeit a comparative cohort with randomisation element). 
 
This approach was essential to maintain legality in applying the TwiC methodology to a 
CTIMP. According to article 4.8.10(c) of ICH GCP, participants in trials involving 
investigational medicinal products (IMP) must be informed about the IMP and the 
probability of being assigned to it.(202)  Without staged consent, TwiCs fail to meet this 
requirement, as control participants are neither informed about the IMP nor the 
probability of being selected to receive it.  However, by specifying that control patients 
are cohort participants only, and that the trial population consists exclusively of 
participants who have signed the second consent form (i.e people who were selected to 
receive the intervention and agreed), adherence to ICH GCP requirements was ensured.   
 
This approach removed ambiguity, ensured legality and is likely to have facilitated the 
Medicines and Healthcare Products Regulatory Agency (MHRA) and Health Research 
Authority (HRA) approval processes.  However, it created complexity in other areas of 




Separating research activities into cohort-related or trial-related required careful 
allocation of costs to ensure that funders were satisfied with how grant monies were 
utilised.  For TILT, even though control participants were not, strictly speaking, 
participating in the trial, the intensity of their follow-up was increased to match the trial 
assessment schedule.  Since this data was crucial to the analysis of trial outcomes, it 
seemed appropriate to include the costs in the funding application for the trial, with a 
clear explanation that they would cover the cost of controls in the cohort.  Future CTIMP 
TwiCs will need to have adequate funding in place to cover both the research costs of 
trial participants and any additional processes for controls in the cohort. 
 
Another UK-specific financial consideration related to study support resources from the 
National Institute for Health Research (NIHR) Clinical Research Network (CRN).  
Commensurate with the complexity of the research, a higher level of support is available 
for randomised trials than for observational studies.  By designating controls as cohort 
participants rather than trial participants, we limited the level of study support that 
participating NHS hospitals could receive for these participants. This factor was 
highlighted when approaching centres to participate in the trial and was not considered 
problematic. However, if a full-scale trial is planned, the financial impact will be greater 
and may reduce some sites’ enthusiasm to participate. 
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4.1.2.6. Study assessment schedule  
CTIMP schedules tend to consist of more frequent data collection visits than most 
observational studies.(149)  However, to obtain meaningful comparison data in a TwiC, 
follow-up of cohort-based controls needs to match the trial assessment schedule. 
Since it would be impossible to design a cohort with a visit schedule that matched all 
potential future TwiCs, the protocol for the cohort study in which TILT was embedded 
(called ASSESS-meso) was designed with a flexible follow up regimen that could be 
altered based on clinical or research requirements.  Thus, the assessment schedule of 
cohort participants could be adapted if they were identified as TwiC controls without 
violating the cohort protocol, without subjecting participants to extra assessment visits 
that may be considered ‘trial-related’, and without requiring further consent.   
 
Even with flexible cohort follow up, if the trial assessment schedule was too demanding, 
there was a risk that altering controls’ follow-up to match it may induce curiosity or 
anxiety, leading to inadvertent or explicit unblinding of controls.  In addition, it could be 
considered unethical to place excessive research demands on the control population, 
particularly for MPM patients who had incurable cancer and a limited lifespan.  For this 
reason, the TILT assessment schedule was designed to be as undemanding as possible, 




4.2.1. The cohort - ASSESS-meso 
4.2.1.1. Study design & aim 
ASSESS-meso was a prospective, multicentre, pragmatic cohort study of patients with 
mesothelioma.  The aim was to collect longitudinal data on the natural history of 
mesothelioma, to identify different phenotypic sub-groups of the disease and to provide 
a resource for future TwiCs.   
 
Specific objectives included the collection of longitudinal data across multiple domains 
including clinical, biochemical, biometric and psychological parameters.  The collection 
and analysis of biological samples, including blood and pleural fluid, was intended to 
allow investigation of potential biomarkers and exploration of clinical and biochemical 
factors that influence outcome.  Finally, longitudinal data collected in the cohort 
provided control group data for TwiCs conducted within the cohort. 
 
4.2.1.2. Study design 
ASSESS-meso was a prospective, observational cohort study with a pragmatic and 
flexible assessment schedule. 
 
4.2.1.3. Participants 
To be eligible to participate in ASSESS-meso, patients were required to meet all of the 
following criteria: 
1. Histological, cytological or clinico-pathological diagnosis of MPM, confirmed at 
multidisciplinary team (MDT) meeting. 
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2. Willing and able to comply with study follow up assessments.  
3. Has capacity, as defined by the 2005 Mental Capacity Act. 
 
Additionally, to be eligible, none of the following criteria could apply: 
1. Aged less than18 years old. 
2. Unable to give written informed consent. 
3. Declined ongoing hospital follow up. 
 
4.2.1.4. Setting 
ASSESS-meso was initially set up in two tertiary referral pleural centres in the UK 
(Southmead Hospital, Bristol and the Churchill Hospital, Oxford).  After six months an 
additional hospital was set up as a study centre (Musgrove Park Hospital, Taunton), and 
thereafter five further sites were opened to recruitment (Hywel Dda Health Board, West 
Wales; Royal United Hospital, Bath; Derriford Hospital, Plymouth; Leicester Royal 
Infirmary; Manchester University Foundation Trust).  
 
4.2.1.5. Recruitment and consent 
Potential participants were identified at local mesothelioma and lung cancer MDT 
meetings.   Patients who met the eligibility criteria were approached by a member of 
the research team at their subsequent clinic appointment and invited to discuss the 
study with a member of the research team.  Potential participants were provided with 
the study participant information sheet (PIS) and given sufficient time to read it.   
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Patients were given the opportunity to ask questions before being invited to give 
written, informed consent to take part in the study.   Participants who wished to have 
longer to consider the study or who were unable to enrol in the study at their initial 
appointment were offered the opportunity to return at a later date.  There was no 
formal time limit between receiving a diagnosis of MPM and enrolling in the cohort, 
although it was recommended that enrolment occurred within six weeks of diagnosis to 
prevent survivorship bias. 
 
The ASSESS-meso consent form included a section relating to TwiCs.  Participants were 
asked to provide consent to be screened for future trials, to be randomly selected to 
join those trials and to provide comparative data for those trials even if not selected to 
join them.  Participants who did not want to be considered for future trials were 
welcome to enrol in ASSESS-meso but were not eligible to be screened for TwiCs. 
 
4.2.1.6. Study assessments 
Participants were followed up from enrolment until death or withdrawal from the study. 
Baseline assessment was completed at enrolment, with follow up assessments 
undertaken when participants attended appointments as part of standard clinical care, 
with a minimum frequency of 3 monthly.  More frequent follow up assessment was 
permitted if indicated for clinical reasons or if participants were providing data for a 
TwiC. 
 
At each study assessment, data was collected relating to clinical status, radiological 
imaging, blood tests and patient-reported outcome measures (PROMs).  Baseline clinical 
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data included information on patient co-morbidities and current medications, asbestos 
exposure history, diagnostic investigations and tumour characteristics.  If a pleural 
effusion was present, an intervention history was obtained.  Follow up clinical data 
focussed on treatment received, interactions with healthcare service, changes to 
medications and additional interventions that had occurred since the previous visit. 
 
Radiological assessment at baseline included chest radiography (CXR), thoracic 
ultrasound (TUS) and computed tomography scan (CT) of the thorax, performed within 4 
weeks of enrolment.  Tumour stage, based on the International Association for the 
Study of Lung Cancer (IASLC) eighth edition,(207) was recorded, as were the presence of 
pleural plaques, non-expandable lung (NEL) or other thoracic abnormality.  Follow up 
radiological imaging was undertaken at the discretion of the clinician, with the 
anticipation that most participants would have a CT scan every 6 months.  Follow up CT 
scans were assessed for tumour stage and radiological response, evaluated based on the 
modified response evaluation criteria in solid tumours (mRECIST).(208) 
 
Baseline blood tests included full blood count (FBC), urea and electrolytes (U&E), liver 
function tests (LFT), C reactive protein (CRP), lactate dehydrogenase (LDH), total protein, 
random glucose and serum mesothelin.  Blood tests taken at follow up visits included 
FBC, U&E, LFT, CRP and mesothelin. 
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Cessation of follow up 











Screening for TwiCs 
Confirmed diagnosis of mesothelioma 
AND 
Able to comply with study requirements 
AND 
Has provided written, informed consent 
Follow up assessments: 
 
Clinical review  
Pleural fluid assessment (if present) 
Imaging  
Blood tests  
PROMs 
Screening for TwiCs 
Telephone assessment 
Offered to participants who are unable to 
attend assessments in person 
 
Clinical review  
PROMs 
Pleural fluid drainage review (if present) 
Willing & able to continue face to face follow up? 
Willing & able to continue telephone follow up? 
Figure 4.1 ASSESS-meso study schema 
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At every assessment, participants were invited to complete a set of PROMs, which 
included 10cms visual analogue scales (VAS) for breathlessness, chest pain and sweating 
and a brief QoL questionnaire (EuroQol 5D health questionnaire, EQ-5D-5L).  At each 
assessment, cohort participants were screened for eligibility to participate in TILT. 
 
Participants who were unable to attend regular study follow up appointments, either as 
a result of frailty or geographical distance from a study centre, were offered telephone 
follow up.  Assessments included a brief clinical review with PROMs sent for completion 
via post or email.  For participants undergoing telephone follow up, the most recent 
blood test and imaging data were imported from other centres, where available.  Figure 
4.1 Shows the study schema.  Copies of the study case report forms (CRF) are provided 
in Appendix 4. 
 
4.2.1.7. Study registration and regulatory approvals 
ASSESS-meso was registered on ISRCTN (61861764).  Research Ethics Committee 
Approval was obtained on 03/02/2017 (ref 17/SW/0019) and Health Research Authority 
approval on 16/2/2017 (IRAS ID 220360). 
 
4.2.2. The trial – TILT 
4.2.2.1. Trial design & aim 
TILT was a multicentre, single-blind, three-arm, randomised feasibility trial of intra-
pleural OK432 vs intra-pleural BCG vs usual care in people with MPM, based on the TwiC 
methodology.   
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The aim of TILT was to assess the feasibility and acceptability of a full-scale trial using 
the same design.  Specifically, the feasibility and acceptability of the TwiC methodology 
was explored. The study aimed to answer the question “Is it feasible to undertake a 
TwiC of intra-pleural OK432 and BCG in MPM and is it acceptable to participants and 
relatives?”  
 
If feasibility was demonstrated, the intention was to progress to a full-scale TwiC of 
intra-pleural OK432 and/or BCG in MPM.  The results of TILT would inform the design of 
the subsequent full-scale trial. 
 
4.2.2.2. Participants 
To participate in TILT patients were required to meet all of the following inclusion 
criteria: 
• Histological or cytological diagnosis of MPM. 
• Enrolled in ASSESS-meso, with consent to be randomly selected for future trials. 
• IPC in situ that has drained more than 50ml of fluid on previous 3 drainages. 
OR has a pleural effusion suitable for IPC insertion and willing and able to 
undergo IPC insertion. 
• No chemotherapy in preceding 4 weeks and none planned for trial period or 
within 4 weeks of trial completion. 
• Performance status (PS) ≤2, or 3 and felt clinically suitable for trial. 
• Predicted survival ≥12 weeks from enrolment. 
• Able to give written informed consent & willing to meet trial requirements. 
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Additionally, to be eligible, participants must have none of the following exclusion 
criteria: 
• No IPC in situ with a contra-indication to IPC insertion.  
• Clinico-radiological diagnosis of MPM. 
• Trapped lung with <50% pleural apposition on x-ray. 
• Moderately heavy or heavily loculated pleural effusion. 
• Known immunodeficiency or immuno-suppressive medication. 
• Intercurrent infection (pleural or elsewhere) or clinical signs of sepsis. 
• Known sensitivity or allergy to OK432, BCG or penicillin. 
• Previous treatment with immunotherapy. 
• Currently enrolled in any other interventional clinical trial. 
• Brain metastases or central nervous system involvement of MPM. 
• Pregnancy or lactation, current or planned during the study period. 
• Age <18. 
 
4.2.2.3. Setting 
The trial took place at three hospital sites in the South of England: Southmead Hospital, 
Bristol; the Churchill Hospital, Oxford; and Musgrove Park Hospital, Taunton.  
 
4.2.2.4. Interventions 
Participants were randomly allocated to receive either: 
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• Intra-pleural OK432; 
• Intra-pleural BCG or; 
• Usual care with continued follow up in ASSESS-meso. 
 
OK432 is a heat-treated, penicillin-killed, freeze-dried streptococcal preparation derived 
from Streptococcus pyogenes group A2 (Picibanil, Chugai Pharmaceutical Ltd, Tokyo, 
Japan).  It is composed of dried streptococcal cells containing penicillin G potassium at a 
dose of 26,900 units/mg of dried cocci. A dose of 1 Klinische Einheit (KE) is equivalent to 
0.1 mg of dried streptococci.  OK432 was supplied as a dry white powder in vials of 5KE.  
For the trial, OK432 was reconstituted in 50ml of sterile 0.9% saline immediately prior to 
instillation into the pleural cavity.  The original dose of OK432 in TILT was 10 KE.  
However, after the first three participants had been enrolled to the trial an urgent safety 
measure (USM) was passed advising a reduced dose of 5KE be used in participants who 
were older, had poorer performance status or a greater number of co-morbidities.   
 
BCG is a live attenuated, low-virulence strain of Mycobacterium bovis prepared from a 
culture of Bacillus Calmette-Guérin (OncoTice, Merck Sharp & Dohme Ltd, The 
Netherlands).  It comprises a freeze-dried preparation of bacilli, with each 12.5mg vial 
containing 2-8 x 108 colony forming units (CFU).  BCG was supplied as a dry powder, 
which was reconstituted in 50ml of sterile 0.9% saline prior to administration.  The initial 
trial dose of BCG was 0.4-1.6 x 107 CFU (1ml of reconstituted solution), however, after 
the USM was passed, a reduced dose of 0.2-0.8 x 107 CFU (0.5ml of reconstituted 
solution) was advised for patients at high risk of adverse events or who would find it 
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difficult to manage an adverse event. For example, elderly patients, patients with 
performance status of 2-3, patients with multiple medical co-morbidities, especially 
cardiac or renal, and patients who lived alone or had high care needs.  
The IMP was delivered as a single dose, via an indwelling pleural catheter, within 14 
days of randomisation.  For the intervention visit, participants attended hospital and 
underwent medical assessment to ensure they remained suitable to receive the IMP.  
Effusions were drained to dryness to ensure IPC patency and a CXR was performed to 
exclude NEL.  If patients remained eligible, 3mg/kg of 1% lignocaine (to a maximum of 
250mg) was instilled via the IPC, followed by the IMP and a flush of 20mls of normal 
saline.  The IPC was disconnected and the IMP left within the pleural cavity for 1 hour.  
After 1 hour, the IPC was drained.  The participant was observed in hospital for another 
hour before returning home. 
 
4.2.2.5. Outcomes 
The primary outcome was feasibility.  The study was determined to be feasible if the 
following criteria were met: 
• Recruitment rate of ≥66% to time and target. 
• Attrition rate of <10% after randomisation, where attrition was defined as 
participants who declined to receive an IMP if randomised to receive it or who 
declined or failed to complete follow up in the cohort if allocated to control. 
• Data completeness rates >90%. 
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Certain features of the TwiC design were evaluated for feasibility.  Specifically, data 
were collected on: 
• The proportion of participants offered OK432 or BCG who declined to receive it. 
• The number of participants in the control arm who were unblinded. 
• The characteristics and outcomes of people who consented to join the cohort 
but declined to be considered for future trials. 
• The acceptability of TILT to participants and family members, evaluated during 
qualitative interviews after completion of the trial. 
 
Secondary outcomes included adverse events, exploratory efficacy data and PROMs.   
 
Adverse event (AE) data were collected at each assessment visit and evaluated for 
severity, expectedness and relationship to IMP.  Severity was graded according to the 
Common Terminology Criteria for Adverse Events v5.0, whereby: 
• Grade 1 was mild, causing no symptoms or mild symptoms, with no intervention 
required,   
• Grade 2 was moderate, causing some limitation to activities of daily living, 
requiring minimal, local or non-invasive intervention, 
• Grade 3 was severe or medically significant but not immediately life-threatening, 
causing disabling symptoms that limit self-care, requiring hospitalisation or 
prolongation of hospitalisation indicated, 
• Grade 4 was life-threatening requiring urgent intervention, and 
• Grade 5 was death related to AE. 
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Serious adverse events (SAEs), defined as any untoward medical occurrence that 
resulted in death, real and immediate threat to life, hospitalisation, prolongation of 
hospital stay, persistent or significant disability or incapacity or other health event which 
in the opinion of the clinician was serious (i.e. grade 3 or higher) were reported to the 
Sponsor within 24 hours.  Adverse event data was reviewed by the Data Monitoring 
Committee (DMC) who had the capacity to close the trial early if significant safety 
concerns arose. 
 
Expected AE were stated a priori and included death, admission to hospital or 
prolongation of inpatient hospital stay admission for a condition related to the 
underlying malignancy.  Relationship to IMP was determined based on the temporal 
relationship between the AE and IMP administration, the likelihood of the AE being due 
to an alternative cause and the established effects and side effects of the IMP.   
 
Exploratory efficacy measurements included survival, radiological tumour response 
rates, serial mesothelin values, pleural fluid drainage volumes and pleurodesis rates. 
Survival was calculated as date of diagnosis with MPM to date of death, as recorded on 
the death certificate.  Surviving participants were censored on 02/06/2020.  Radiological 
response rates were assessed by an independent thoracic radiologist who was blinded 
to trial allocation. To evaluate radiological response, tumour thickness was measured 
perpendicular to the chest wall or mediastinum at two positions on three different 
transverse CT slices, with responses defined according to the mRECIST criteria, whereby: 
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• complete response (CR) was disappearance of all target lesions with no evidence 
of disease elsewhere, 
• partial response (PR) was a reduction in total tumour measurement of at least 
30% from baseline, 
• progressive disease (PD) was an increase in tumour thickness of 20% or more, 
and 
•  stable disease (SD) was as any change in tumour size that did not meet the 
above criteria.(208)   
 
Serum mesothelin levels were measured at each study visit using ChemiLuminescent 
Enzyme Immunoassay technology (Lumipulse G; Fujirebio, Belgium).  Pleural fluid 
drainage volumes were recorded at the time of drainage by community nursing staff 
who were not involved in the trial and were unaware of the patients’ participation 
status.  Pleurodesis was defined as “pleural fluid drainage volumes of less than 50mls on 
3 consecutive drainages, with no significant residual fluid on thoracic imaging, or 
removal of IPC due to cessation of drainage with no further requirement for pleural 
intervention, whichever was recorded first”. 
 
Breathlessness, chest pain and sweats were completed by the patients at each visit 
using a 10cms VAS. QoL was evaluated using the EQ-5D-5L questionnaire, completed by 
participants at every study visit. 
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4.2.2.6. Sample size 
In line with NIHR guidance on feasibility trials, the aim of the TILT trial was not to 
evaluate the clinical effectiveness of intra-pleural immunotherapy, but rather to assess 
whether a full-scale trial would be possible.  According to that document, for feasibility 
trials “the sample size should be adequate to estimate the critical [feasibility] 
parameters to the necessary degree of precision.”(209)   
 
It was decided that the “critical feasibility parameter” for TILT was post-randomisation 
attrition, as this was the element of the TwiC design that was previously untested in this 
population.  Specifically, it was felt that attrition rates of 20% or greater would render a 
full-scale trial unfeasible.  For this reason, a target attrition rate of 10% with 95% CI of 
±10% was used in the sample size calculation. 
  
The following calculation was used to determine sample size: 
95% CI = 1.96 ×  �
𝑝𝑝 ×  (1 − 𝑝𝑝)
𝑛𝑛
  
Where p was the predicted attrition rate and n was the sample size.  The initial target 
sample size was 45 participants, which was sufficient to detect a 10% attrition rate with 
95% CI of ±9%. 
 
The target sample size was reduced before the study began, due to delays in obtaining 
OK432.  The revised sample size was 30 participants, which would have detected a 10% 
attrition rate with 95% CI of ±11%, which was deemed acceptable. 
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A further reduction to the target sample size occurred 18 months into the trial.  This was 
in response to slower than anticipated recruitment but (at that point) zero attrition.  The 
new estimated attrition rate was 5%, which could be detected with a sample size of 12 
people with 95% CI of ±12%. 
 
4.2.2.7. Randomisation 
Potential participants were screened for eligibility for TILT by a member of the trial team 
at every ASSESS-meso study visit, including initial enrolment.  Randomisation occurred 
at the first visit that they met the TILT eligibility criteria (designated Day 0 of TILT). 
Participants were blinded to randomisation occurring, in line with the TwiC 
methodology, having already consented to randomisation at ASSESS-meso enrolment. 
 
Randomisation was undertaken by a member of the trial team, using a centralised, 
concealed randomisation module embedded within the online study database.  
Randomisation occurred on a 1:1:1 basis, using a permuted block randomisation 
sequence, with blocks of varying and random sizes.  Randomisation was minimised by 
performance status (assessed on the day of randomisation, after drainage of fluid and 
graded as 0 or ≥1) and tumour sub-type (classified as epithelioid/cytological diagnosis 
versus non-epithelioid).  The randomisation sequence was generated by an independent 
database administrator using STATA (StataCorp LP) version 15 and was not visible to the 
trial team.   
 
The clinical trial team were unblinded to the outcome of randomisation.  Participants 
randomised to receive an IMP were informed of their allocation and provided with a PIS 
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about the trial. Participants allocated to control remained blinded to both the fact of 
randomisation and the outcome, and continued follow up in ASSESS-meso. 
 
4.2.2.8. Schedule of assessments 
The date of randomisation was designated Day 0.  Participants allocated to OK423 or 
BCG were provided with the PIS and given up to 5 days to consider it.  If they agreed to 
receive the IMP, they were scheduled in for an intervention visit within 14 days of 
randomisation.  Control participants were not required to attend for an intervention 
visit.  All participants underwent three subsequent trial assessment visits at week 3, 
week 6 and week 12. The TILT trial schema is shown in Figure 4.2. 
 
Having completed the 12-week trial period, participants returned to follow up under the 
ASSESS-meso schedule.  Data collection for ASSESS-meso continued until death, loss to 
follow up or withdrawal from ASSESS-meso. 
 
1.1.1.1. Statistical methods 
Descriptive statistics were used to summarise recruitment, attrition and data 
completeness rates.  Participant characteristics were tabulated according to allocation 


























During cohort visits 
 










































Figure 4.2 TILT trial schema 
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Secondary outcomes were summarised for each arm, based on allocation at 
randomisation.  Because of the small number of participants, people randomised to 
receive either OK432 or BCG were combined to form one IMP group. Survival data were 
analysed using the Kaplan-Meier method, with unadjusted and adjusted Cox 
proportional hazards modelling. Survival rates were compared with national survival 
data and survival rates from previous MPM clinical trials.  Pleurodesis rates and 
radiological response rates were compared between groups using Fisher’s Exact test.  
Outcomes with repeat measurements, e.g. PROMS and blood tests, were analysed at 
each trial visit using two-way analysis of variance (ANOVA) modelling with multiple 
regression, based on ITT allocation.  
 
Statistical analysis was undertaken using Stata (StataCorp LP) version 15. 
 
1.1.1.2. Trial registration and approvals 
The trial was registered on the European Clinical Trials Registry (EudraCT number 2016-
004727-23) and the ISRCTN Register (10432197).  Research Ethic Committee approval 
was granted on 02/05/2017 (ref 17/SW/0080), MHRA approval on 07/06/2017 
(18524/0228/001-0002) and HRA approval on 19/06/2017 (IRAS ID 215394). 
 
1.1.2. Challenges during trial set-up 
4.2.3.1.  Procurement of OK432 
OK423 has been used as an intra-pleural pleurodesis agent in South East Asia for three 
decades.  However, it does not have Marketing Authorisation (MA) from the European 





Authorisation (CTA) for OK432 to be used in TILT. This authorisation covered the storage 
and administration of OK432 at trial sites. 
 
However, to legally import an unlicensed drug into the UK (or indeed the EU), a 
declaration is required from a Qualified Person (QP), stating the drug has been 
manufactured to the standards set out in Good Manufacturing Practice (GMP).  The QP 
is also required to provide a batch release certificate, confirming that the imported drug 
batch corresponds with the Marketing Authorisation of its country of origin and the CTA 
of the trial it is being imported for.   
 
The original company approached to import OK432 were unable to perform QP release 
as the manufacturing company in China was unwilling to provide an official Certificate of 
Analysis and declined to undergo a formal laboratory inspection.  Without these 
documents the QP was unable to complete their declaration.  
 
Having explained this quandary to the MHRA, I worked closely with their import 
inspectors to clarify the essential information that was required for OK432 importation 
in the absence of an official Certificate of Analysis and formal laboratory inspection.  An 
alternative import company was identified who were able to meet the modified MHRA 
requirements for QP release.  Fortuitously, the QP for this company had prior 
experience working with the manufacturers of OK432 and had inspected their 
laboratories a year earlier for a previous client.  This provided reassurance for all parties 






Unfortunately, this process was time-consuming, and OK432 did not arrive in the 
respective pharmacies of the trial centres until 18 months after the initial HRA and 
MHRA approvals were granted.  To lessen the impact of the delay, the design of TILT 
was amended from a two-arm trial (OK432 vs standard care) to a three-arm study 
(OK432 vs BCG vs standard care).  The BCG and standard care arm opened as soon as 
the amendment was approved, and recruitment to these two arms occurred for 12 
months before OK432 was obtained.  Once OK432 was available, the third arm was 
opened, and the randomisation module altered to allow allocation to OK432. 
 
4.2.3.1.  Storage of OK432 
According to the product information for OK432, it should be stored at temperatures 
below 10°C, but avoiding freezing.  During importation from China, cold chain logistics 
were required to ensure these temperatures were maintained.  Unfortunately, within 
two weeks of the product arriving in the UK, and after only one participant had received 
it, one trial site experienced a temperature excursion of the clinical trials fridge.  Over 
three occasions, the temperature dropped below 0°C, to -6°C at the lowest point.  
Stability data was obtained from the manufacturer, following which the decision was 
made to destroy the affected stock.  
 
By coincidence, this event coincided with a Trial Steering Committee meeting at which 
an urgent safety measure (USM) was declared based on adverse reactions in the two 





dose regimen for both IMPs to attenuate the risk of side effects.  Based on the reduced 
dose regimen and the recruitment estimates of each trial site, surplus OK432 stock was 
able to be transferred from an alternative site to the affected site, and the trial 
continued without delay. 
 
4.2.2.9. Recruitment 
Although the TwiC methodology was employed in the hope it would expedite 
recruitment by providing an existing cohort of research-active patients who could be 
screened for eligibility, there were certain elements of the design that created 
challenges to recruitment.   
 
Two of the three trial sites involved in TILT were tertiary referral centres, with multiple 
active research studies underway.  It is common for patients to be referred to these 
centres specifically for consideration of clinical trials.  This practice is encouraged and 
trials are often publicised at clinical and academic meetings around the UK, inviting 
clinicians to refer willing patients to the relevant centre.  However, this was not possible 
for TILT.  To refer a patient to a tertiary centre, local clinicians must first discuss the trial 
with their patients and enquire whether they are willing to travel to the trial centre for 
further discussion and assessment.  However, this would have undermined the 
fundamental premise of a TwiC, which requires control patients to be blind to the 






Another consideration regarding participants referred from other centres was that 
whilst patients may be willing to travel a significant distance to be screened for a trial, 
they may be disinclined to repeat the journey if they are not selected for that trial.  
Consequently, if they were allocated to be a cohort-based control in a TwiC, they may 
decline ongoing follow-up at the trial centre, causing differential attrition.  For these 
reasons, recruitment to TILT was limited to the catchment area of each study centre, 
although it was recognised that this may have had an impact on recruitment.  
1.2. Results 
1.2.1. Participant characteristics  
1.2.1.1. ASSESS-meso 
At the time of writing (20/06/2020), 107 participants had enrolled in ASSESS-meso 
across eight study centres.  Collectively, participants had completed 433 study 
assessment visits, ranging from 1 to 12 visits per individual.  Forty-four participants 
(41.1%) had died, with a median survival time of 8.7 months from diagnosis (IQR 4.8-
13.8).  Data upload was complete for 91 participants, whose characteristics are shown in 
Table 4-1.  During the TILT recruitment period, 43 people were participating in ASSESS-
meso across the three recruiting sites. 
 
1.2.1.2. TILT 
Between 27/01/2018 and 31/11/2019, seven participants were successfully randomised 
for the TILT trial.  Three were allocated to receive BCG, one to receive OK432 and three 
were designated as controls.  All but one participant were male, all had epithelioid-type 





palliative cisplatin and pemetrexed chemotherapy.  Participant characteristics are 
shown in Table 4-2. 
 
1.1.1. Primary outcome – feasibility 
4.3.2.1. Recruitment, attrition & data completeness 
The pre-stated feasibility goal of recruitment rate >66% to time and target was not met. 
The planned sample size was 12, however, only seven participants were randomised 
during the 22-month trial recruitment period, yielding an overall recruitment rate of 
58.3% of target.  Furthermore, of seven participants randomised, two withdrew from 
the trial after randomisation; one who had been allocated to receive BCG and one who 
had been designated as control.  This created an attrition rate of 28.6%, which breached 
the pre-specified feasibility criteria of <10%.   
 
Data completeness was high. The main CRF, AM07 “Clinical Assessment”, was 
completed in full for all participants for all study visits.  A small number of data points 
were missing from CRFs AM08 “Blood tests” (38 missing values), AM09 “Imaging” (10 
missing values) and AM11 “Symptom scores” (12 missing values).  This resulted in a total 
of 60 missing values over 8750 data points, yielding a data completeness rate of 99.3%. 
This comfortably exceeded the feasibility criteria of >90% data completeness.  However, 
it was noted that most of the missing data related to control participants, particularly at 
Visits two and three.  It is possible that the TwiC methodological quirk that meant 
control patients were not explicitly participating in a trial caused confusion with regard 





 All participants 
Total 91 
Male 77 (84.6) 
Age, median (range) 74 (33-93) 
































Duration of symptoms                        < 1 month 
1-3 months 








































Brims prognostic score          1 (best prognosis) 
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Table 4-1 - Baseline characteristics of participants enrolled in ASSESS-meso, as recorded on 
27/02/2020.  Abbreviations: CT – computed tomography; US – ultrasound; VATS – video-assisted 





 All participants OK432 BCG Control 
Total 7 1 3 3 
Male 6 (85.7) -  3 (100) 3 (100) 
Age, median (range) 73 (60-83) 64 71 (60-73) 80 (73-83) 
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< 1 month 
1-3 months 
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Review of screening logs provided further information about the recruitment difficulties.  
Forty-three participants were undergoing follow-up in ASSESS-meso at the recruiting 
centres during the TILT enrolment period.  Of these, two people had chosen not to 
N=43 
Participants undergoing follow up in 
ASSESS-meso during TILT recruitment 
window at the 3 study sites. 
N=41 
Participants eligible for screening, screened 
on 52 separate occasions. 
N=2 
Did not consent to participate in TwiCs 
on enrolment to ASSESS-meso. 
N=7  
Participants eligible for TILT following 
screening.  
N=34 
Ineligible for TILT for one or more 
reasons. Screen failures were due to: 
• No IPC in situ: 39 
• Contraindication to IPC insertion: 12 
• Enrolled in another interventional 
trial: 5 
• Non-expandable lung or loculated 
effusion: 5 
• Recent or current chemotherapy: 4 
• Unable to meet the trial 
requirements: 3 
• Performance status >3 or predicted 
prognosis <12 weeks: 2 
• Recent thoracic surgery: 1 





























Declined to participate  
(1 person allocated to BCG and 1 person 





participate in TwiCs when they joined the cohort.  The remaining 41 patients were 
screened for TILT eligibility on 52 occasions (eight patients were screened on two 
occasions and three patients were screened on three occasions, due to the dynamic 
nature of certain eligibility criteria over time, e.g. participants may have had an IPC 
inserted several months after diagnosis or may have completed chemotherapy and 
become eligible).  The seven participants randomised for TILT were the only people to 
meet the eligibility criteria at any point (see Fig. 4.3). 
 
The most frequent reason that patients were not eligible for TILT was the absence of a 
functioning IPC (cause of 39 screen failures), which often co-existed with a known 
contra-indication to IPC insertion (present at 12 screen failures). The presence of non-
expandable lung with <50% pleural apposition on x-ray and/or a moderate or heavily 
loculated effusion was the cause of five screen failures.  Five participants were enrolled 
in an alternative interventional trial at the time of screening (MARS2, ATOMIC-meso and 
CONFIRM) and were therefore ineligible for TILT, whilst four participants were ineligible 
due to recent or concurrent chemotherapy treatment.  Nineteen patients had more 
than one reason for ineligibility.   
 
In addition to screening existing ASSESS-meso participants, the research team also 
reviewed the eligibility of patients discussed at the regional mesothelioma MDT, hosted 
by North Bristol NHS Trust.  A further 59 patients were discussed in this forum, the 
majority of whom were being treated at other hospitals in the region.  Fifteen of these 





these, six did not wish to travel to the study site, four enrolled in an alternative trial and 
four deteriorated and/or died before they could be reviewed at the trial centre. One 
person attended North Bristol and was randomised. 
 
The majority of patients deemed ineligible following MDT discussion had no pleural 
effusion, no IPC or had undergone pleurodesis (n=33).  Of the remaining, three patients 
had underlying NEL, two were receiving chemotherapy and one received 
immunotherapy in the private sector. Three patients deteriorated before they could be 
enrolled in ASSESS-meso and two declined further hospital follow up.  
 
4.3.2.2. Feasibility of the TwiC design 
Certain features of the TwiC methodology rendered it unfeasible for use in 
mesothelioma populations. Specifically, a large proportion of participants declined to 
participate in the trial after randomisation (2/7; 28.6%) and all patients in the control 
arm had been unblinded to the existence of the trial prior to randomisation (3/7; 100%).  
Other aspects of the design, however, were feasible.  For example, most people who 
enrolled in ASSESS-meso were willing to be screened and randomised for TwiCs (87/91; 
95.6%). Similarly, the TwiC methodology was considered acceptable by TILT participants 
and their family members when it was described to them during qualitative interviews 
on completion of the trial (described in full in Chapter 5).  The remainder of this section 






4.3.2.2.1. Attrition after randomisation  
Two patients declined to participate in TILT after randomisation; one who was allocated 
to receive BCG and one who was allocated to control.  Qualitative interviews with these 
participants and their family members provided insight into this decision and more 
information is provided in Chapter 5.  Broadly speaking, however, patients wished to 
prioritise quality of life and were concerned that participating in the trial may have 
compromised this.  The patient allocated to BCG was reluctant to receive a trial 
medication that carried a risk of side effects, whilst the patient allocated to control did 
not wish to return to hospital as frequently as the trial schedule required. Importantly, 
both patients had agreed to be considered for randomised trials on enrolment in 
ASSESS-meso and both remained keen to be considered for future TwiCs, even after 
choosing not to participate in TILT.   
 
Clearly patients need to know the specific requirements of a trial before they can decide 
whether they wish to participate.  With a standard RCT, this happens at the outset, as 
participants are provided with a trial PIS prior to enrolment.  However, with the TwiC 
methodology, eligible participants are randomised prior to receiving any information 
about the trial, creating the possibility of post-randomisation attrition.  Since it is 
impossible to provide information about every potential TwiC on enrolment to the 
cohort (and the volume of information received by patients would be unmanageable), it 
is likely that there will always be a proportion of people who choose not to participate in 
any given TwiC after they have been randomly selected to participate.  Post-
randomisation attrition could render the trial underpowered or introduce bias if 





4.3.2.2.2. Blinding of controls 
A key element of the TwiC design is that control participants remain unaware of the 
existence of the trial, therefore, as part of the feasibility evaluation, participants in TILT 
were asked whether they were aware of the trial prior to randomisation.  All seven 
participants stated that they had prior knowledge of TILT, with some control patients 
explicitly asking members of the trial team “Am I participating in TILT?” during research 
visits.  It was, therefore, impossible to maintain blinding of the control arm and this 
meant that many of the potential benefits of the TwiC design were lost. 
 
The mechanism through which participants had been unblinded to TILT were explored 
during qualitative interviews.  Interestingly, three participants had been involved in PPI 
groups at which TILT was discussed, months before the trial design was finalised.  Two 
participants had become aware of TILT after hearing other patients discussing it at local 
mesothelioma support groups.  Two participants had been told about TILT by clinicians 
at non-trial centres who knew about the trial but were unaware of the specific 
requirement for blinding.  One of these patients was the gentleman who withdrew after 
being allocated to the control arm.  He had been referred to the trial centre to be 
considered for TILT and did not wish to return once he knew he was not receiving the 
intervention. This would not have occurred if a standard, double-blind RCT design had 
been used. 
 
Attempts to blind patients to the existence of a trial also contributed to the recruitment 
difficulties. The trial was deliberately not publicised on resources such as the Cancer 





nor was it promoted at national respiratory research events such as the UK Pleural 
Society Annual Research Update Day.  Inevitably this reduced the number of potential 
participants referred to trial sites from other centres.   
 
Attempts to maintain blinding also meant that potentially eligible participants identified 
at the regional mesothelioma MDT were not informed about TILT when they were 
invited to attend the study centre.  It is unknown whether the seven patients who chose 
not to travel to Bristol would have attended had they been told about TILT or provided 
with a PIS, however it must be a consideration when reviewing the recruitment 
challenges faced by the trial. 
 
4.3.2.2.3. Willingness to be considered for TwiCs 
The majority of participants who enrolled in ASSESS-meso were willing to be screened 
and randomised for future TwiCs.  Only four out of 91 (4.4%) participants did not wish to 
be considered for future trials.  The characteristics of these participants are shown in 
Table 4-3.  Patient numbers were too small to perform statistical comparisons, however 
there were no overt differences between patients who chose not to be considered for 
future TwiCs and the overall ASSESS-meso study population.  Interestingly, all four 
patients who declined TwiCs were enrolled at the same study site, raising the possibility 






Participants who did 
not wish to be 
considered for TwiCs 
All ASSESS-meso 
participants 
Total 4 91 
Male 3 (75) 77 (84.6) 
Age, median (range) 79 (64-93) 74 (33-93) 
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4.3.2.2.4. Acceptability of the TwiC design 
The TwiC design was explained to trial participants and their family members during 
qualitative interviews, performed once they had completed trial follow up (see Chapter 
5).  The TwiC design was acceptable to participants and their relatives and, specifically, 
no-one expressing concerns about controls being “deceived”.  Participants’ and 
relatives’ views varied as to whether the TwiC methodology was preferable to a blinded, 
placebo-controlled trial, but overall it was considered an acceptable approach to clinical 
trials in MPM. 
 
The qualitative interviews were performed alongside TILT, i.e. each participant was 
interviewed soon after their final trial visit.  Contemporaneous analysis of the qualitative 
data enabled modifications to be made to the trial protocol to improve overall 
acceptability.  Specific changes were made after the first participant received BCG.  This 
participant reported feeling abandoned when he experienced an adverse reaction after 
the IMP administration: 
 
“I think [that] was the start of the point where we felt really alone, really 
alone.” Participant 32-6T, 71-year-old male. 
 
On his suggestion, daily telephone check-ups were initiated in the week after IMP 
administration. An extra safety visit was introduced at day 3 to ensure that participants 
were closely monitored and felt supported.  Finally, because that participant’s reaction 
had occurred over a weekend, it was recommended to all trial sites that the IMP be 





normal working hours and to reduce the risk of an adverse reaction occurring out of 
hours. These changes were well-received, as described by a subsequent participant: 
 
“I thought the more I see you, the better I am going to be, was my sort of 
idea.” Participant 104-1T, 61-year-old male.  
 
Specifically, the additional visits were not considered to be overly burdensome. 
 
“Interviewer:  [What about] the frequency of the trial visits? Were they a 
problem at all? 
Participant:  No, not a problem at all. Well, as I am retired, I don’t find it a 
problem… I didn’t find it any problem coming down here at 
any time of day because I have got nothing else to do.” 
Participant 104-1T, 61-year-old male. 
 
1.1.2. Secondary outcomes 
4.3.3.1. Adverse events 
4.3.3.1.1. Non-haematological adverse events 
A total of eight non-haematological adverse events occurred during the trial, affecting 
five participants.  There were three SAE, affecting one person in each arm of the trial.  
There were no grade four or five AE and no deaths related to AE (see Table 4-4).  
 
The most common AE was a systemic inflammatory response syndrome, consisting of 





IMP administration.  This affected all three participants who received OK432 or BCG and 
resulted in admission to hospital for the first two patients.  In both cases, symptoms 
settled with analgesia and antipyretics and the patients were discharged within three 
days.  One patient (who received BCG) experienced a recurrence of low-grade fever and 
fatigue some days after being discharged from hospital.  These symptoms persisted for 
several weeks but eventually resolved following treatment with an oral steroids. 
 
In response to this, the data monitoring committee passed a USM recommending the 
use of a lower dose of BCG and OK432.  The USM also recommended three days of anti-
inflammatory and anti-pyretic medication to be given after IMP administration and 
introduced an additional safety visit at 72 hours post-IMP administration, as suggested 
by participant 32-6T.  The next participant to receive BCG was treated in accordance 
with the USM and experienced a milder inflammatory response that did not require 
admission to hospital. 
 
 OK432 BCG Control 

















Serious adverse event 1 1 1 
Specific events: 
Systemic inflammatory response 
Pleural infection 
Chest wall pain 





















One patient experienced pleural infection related to their IPC.  This patient was in the 
control arm of the trial.  They were initially managed as an outpatient with oral 
antibiotics, however this failed to control the infection, so the patient was admitted to 
hospital for intravenous antibiotics and free drainage of the pleural space.  This 
treatment was successful. 
 
4.3.3.1.2. Haematological adverse events 
Participants randomised to receive an IMP experienced a peak in CRP at visit one (the 
first visit after IMP administration) whilst control participants did not (mean CRP 200 for 
IMP group; 95% CI 74.4-325.6 vs mean CRP of 14 for controls; 95% CI -22.0-50.0; p0.032 
- Fig 4.4).  Two-way ANOVA demonstrated a strong relationship between serum CRP and 
receipt of IMP (F(1, 15)=9.95; p=0.007) as well as serum CRP and trial visit (F(3, 15)=4.81; 
p=0.015).  There was a meaningful interaction between receipt of IMP and trial visit on 
serum CRP (F(3, 15)=7.22; p=0.003), with the greatest effect of IMP seen at visit one 
(correlation coefficient 207.17; 95% CI 107.5-306.9; p<0.001).  
 
Serum platelets also rose at Visit one in people randomised to receive OK432 or BCG, 
whilst remaining relatively static in control participants (mean platelets for IMP group 
588.3; 95% CI 323.0-853.7 vs mean platelets for controls 240.5; 95% CI 178.1-302.9; 
p=0.043 - Fig 4.5). Two-way ANOVA confirmed an association between IMP allocation 
and trial visit on serum platelets (F(1, 15)=6.31; p=0.024), however this relationship was 







Figure 4.4 Mean CRP and 95% confidence intervals of patients randomised to receive OK432 or 




Figure 4.5 Mean platelet values and 95% confidence intervals of participants randomised to 







Figure 4.6 Mean alanine aminotransferase and 95% confidence intervals for patients randomised 
to receive OK432 or BCG compared with controls at each study visit 
 
 
Figure 4.7 Mean albumin levels with 95% confidence intervals for patients randomised to receive 
an IMP compared with controls at each study visit. 
 
Alanine aminotransferase and albumin were abnormal in control participants at visit 
two compared to people in the IMP group (Figs 4.6 and 4.7 respectively). However, on 





at that timepoint, so the observed difference between groups was solely due to that 
person.  He had been treated for pleural infection one week previously, which was the 
likely cause of his raised ALT and reduced albumin. 
 
 
Figure 4.8 Mean results for (a) haemoglobin, (b) white cell count, (c) neutrophils, (d) neutrophil 
lymphocyte ratio, (e) estimated GFR, (f) bilirubin (g) alkaline phosphatase (h) mesothelin) with 
95% confidence intervals for patients randomised to receive an IMP compared with controls at 































There was no difference in haemoglobin, white blood cell count, neutrophil count, 
neutrophil lymphocyte ratio, glomerular filtration rate (GFR), bilirubin, alkaline 
phosphatase or mesothelin between participants randomised to receive an IMP and 
those in the control arm over the trial visits (Fig 4.8). 
 
4.3.3.2. Pleural fluid drainage volumes and pleurodesis rates  
The absolute volume of fluid drained from participants’ IPCs at each community 
drainage ranged from 0mls to 1500mls. The average amount of fluid drained each time 
was 436.7mls (median 353.6, IQR 1-741.7).  Participants randomised to receive OK432 
or BCG experienced a steady decline in the average volume of pleural fluid drained since 
the previous trial visit, whilst control participants’ drainage volumes were stable over 
the trial period (Fig 4.9).   
 
On linear regression, there was a trend towards a negative association between trial 
visit and IPC drainage volume in people randomised to receive an IMP (unadjusted 
correlation coefficient for visit two -949.8; 95% CI -2020 to 120.9; p=0.077 and for visit 
three -1096.9; 95% CI -2340.1 to 146.2; p=0.078), however this association was not 
present on ANOVA modelling (F(3,11)=2.04; p=0.167). 
 
Six out of seven participants (85.7%) achieved pleurodesis and all six had their IPCs 
removed as a result. Median time from randomisation to pleurodesis was 42 days (IQR 





pleurodesis than control participants and there was no difference in time to pleurodesis 
between the groups (HR 0.35; 95% CI 0.06-2.13; p=0.255). 
 
 
Figure 4.9 Average IPC drainage volumes (mean & 95% confidence intervals) at each trial visit for 
participants randomised to receive OK432 or BCG and controls. 
 
4.3.3.3. Radiological response rates & survival  
No partial or complete radiological responses were seen on CT scans at the end of TILT 
compared with baseline CT imaging.  Three participants (42.9%) had progressive disease 
and four had stable disease (57.1%).  There was no difference in radiological outcomes 
in people randomised to receive an IMP and those allocated to control (Table 4.5, 
p=0.486).  
 
Survival status was reviewed on 02/06/2020; four patients were alive and three had 
died, with a minimum follow up of 8.9 months for living patients (range 8.9-45.0, 





survival rate of 71.4% (5/7).  There was no difference in median survival between 
participants randomised to receive OK432 or BCG (18.1 months; IQR 12.1-23.3) and 
control participants (29.0 months; IQR 5.2-45.0) with an unadjusted HR of 2.1 (95% CI 
0.2-24.5; p=0.563) and an adjusted HR of 1.7 (95% CI 0.1-31.0; p=0.731).   
 




Complete/ partial response - - 
Stable disease 3 (75%) 1 (33%) 
Disease progression 1 (35%) 2 (66.7%) 
 
Table 4-5 Radiological responses on end of trial CT scans compared to baseline CT 
 
Survival for all participants compared favourably with national figures, even allowing for 
the fact that all TILT participants had epithelioid histology.  The 2018 National Lung 
Cancer Audit for Mesothelioma (reporting data from 2014 to 2016) quoted a median 
survival of 13.1 months (IQR 6.5-23.3) for people with epithelioid MPM.(210)  Recent 
open-label, phase II trials of immunotherapy in similar cohorts of MPM patients 
reported median survival of 16·6 months (95% CI 13·1–20·1) in patients treated with 
durvalumab and tremelimumab (NIBIT-meso-1), and 15·9 months (95% CI 10·7–not 
reached) in people given ipilimumab and nivolumab (MAPS2).(17, 82)  The similarity 
between these trials and TILT survival outcomes is more likely to be a reflection of 







4.3.3.4. Patient-reported outcome measures 
Overall patients rated their symptoms as relatively low severity and reported reasonably 
good QoL.  Breathlessness was the most troublesome symptom, with a median VAS 
score of 18.3 (range 0-36, IQR 8.3-25), where zero represented no breathlessness at all 
and 100 was the worst breathlessness imaginable.  Chest pain (median 4.7, range 0-
11.2, IQR 1.5-11.2) and sweats (median 2.2, range 0-14.5, IQR 0.3-7.9) were reportedly 
less severe.  Median QoL score was 80 (range 66.7-90, IQR 76.9-81.7), where 0 was the 
worst health imaginable and 100 the best.  
 
 
Figure 4.10 Patient reported symptom scores (mean and 95% confidence intervals) for 
breathlessness in people randomised to receive OK432 or BCG compared with controls at each 
study visit 
 
There was no difference between the trial arms in patient-reported symptom scores for 
breathlessness (Fig 4.10), chest pain (Fig 4.11), sweats (Fig 4.12) or QoL (Fig 4.13) at 





absolute values for maximum change and relative values, adjusted for baseline scores 
(two-way ANOVA analyses, all p values > 0.05). 
 
 
Figure 4.11 Patient reported symptom scores (mean and 95% confidence intervals) for chest pain 
for people randomised to receive OK432 or BCG compared with controls at each study visit 
 
 
Figure 4.12 Patient reported symptom scores (mean and 95% confidence intervals) for sweats in 






Figure 4.13 Patient reported symptom scores (mean and 95% confidence intervals) for quality of 
life in people randomised to receive OK432 or BCG compared with controls at each study visit 
 
Daily VAS scores were only collected on participants who received an IMP.  Two 
participants experienced a rise in breathlessness following IMP administration, whilst 
one was minimally breathless throughout. Breathlessness resolved within 10 days for 
one participant, whilst for the other it became more severe and persisted for the 21-day 
monitoring period (Fig 4.14).  A similar pattern was seen for chest pain (Fig 4.15).  
Sweats occurred later, approximately five to seven days after the IMP was administered 







Figure 4.14 Daily VAS scores for breathlessness in people who received an IMP for the 21 days 




Figure 4.15 Daily VAS scores for chest pain in people who received an IMP for the 21 days 







Figure 4.16 Daily VAS scores for sweats in people who received an IMP for the 21 days following 
IMP administration 
 
1.2. Summary of findings 
TILT was the first trial to apply the TwiC methodology to a CTIMP.  We demonstrated 
that it was possible to adhere to the necessary clinical trial regulations and maintain 
ethical standards of informed consent and transparency using this design, and thus 
obtain the requisite approvals from the Research Ethics Committee, the HRA and the 
MHRA.  Additionally, the trial design and processes were acceptable to participants and 
their relatives, with no participants or relatives expressing concerns about deception 






Although it was feasible to design and conduct a CTIMP TwiC, it was not feasible to use 
the TwiC methodology to conduct a trial of intra-pleural immunotherapy in people with 
MPM.  TILT failed to recruit to time and target, partly due to fewer eligible patients than 
predicted and partly due to specific elements of the TwiC design.  Additionally, post-
randomisation attrition was an issue, and this could cause bias if a similar phenomenon 
occurred in a full-scale trial.  Finally, it was not possible to maintain blinding of control 
participants to the existence of the trial.  This undermined one of the key features of the 
TwiC methodology and negated the intended benefit of reducing disappointment in 
control participants. In light of these findings, any future full-scale trial of intra-pleural 
immunotherapy in MPM should not be based on the TwiC design.  Potential 
modifications to the method that could avoid the problems experienced in TILT, whilst 







2. Chapter 5 - Qualitative study 
2.1. Background 
MPM carries a significant physical, psychological and social burden. In her qualitative 
interviews with people with MPM, Dr Helen Clayson identified certain specific physical 
issues arising as a result of the occupational nature of the disease.(174) Many patients 
described experiencing a rapid deterioration in health and fitness, which was 
challenging for them to accept, as people who had previously relied on their strength for 
work and, often, their sense of self.(174)   
 
Psychologically, Lebovitz et al described the anticipatory anxiety reported by people 
with MPM who had seen friends and colleagues die of the disease and had spent many 
years awaiting their own diagnosis.(211) This was described as the “Damocles 
Syndrome” by Barak and colleagues, who interviewed current and prior asbestos 
workers and found anticipatory anxiety was commonplace.(212)  Expectation of a future 
diagnosis meant that when the diagnosis of MPM was confirmed it was often met with 
“stoical fatalism” and a sense of inevitability.(211, 212)  Despite this, interviews also 
highlighted that many people experienced depression on receiving the diagnosis, as well 
as anger.(213, 214) Some patients struggled to process these emotions whilst 
simultaneously dealing with the burden of medical interventions.(213-215)  
 
Socially, people with MPM described feeling isolated and mourned the loss of their jobs 
and ability to “contribute”.(214) The legal ramifications of MPM as a prescribed disease, 
for which compensation was payable, were also challenging. Many people with MPM 





damages or benefits, as doing so challenged their sense of independence and self-
sufficiency.(174)  
 
Although the experience of MPM is well researched, it is not clear how patients view 
taking part in MPM research. Considering the physical, psychological and social 
challenges of living with this condition, it would be understandable if people with MPM 
were reluctant to participate in trials. Trial participation inevitably places greater 
physical demands on people as they are required to attend appointments more 
frequently.  Additionally, trial medication may cause side effects.  This may require 
people to have to rely on others to look after them during this period – something which 
may not sit comfortably with the stoical and self-reliant nature of many people with 
MPM. 
 
The limited prognosis associated with MPM could also create challenges for trial 
participation.  Numerous studies have acknowledged the difficulty of recruiting people 
with incurable or palliative conditions to trials.(216-218)  However, the same studies 
found that patients were often interested in research and could have benefited from 
participation.(218)  Qualitative methods can be useful in clinical trial settings to help 
understand participants’ experiences and to identify potential recruitment barriers.(170, 
219)   
 
Inviting people with terminal diagnoses to participate in clinical trials can introduce 





certainty associated with having an incurable disease and the uncertainty inherent in a 
trial.(220)  Clearly, the fact of having an incurable cancer such as MPM is associated with 
great distress. However, for many people, especially those who have been living with 
anticipatory anxiety for several years, there may be some relief in the certainty of a 
confirmed diagnosis.  Participation in research introduces uncertainty related to the 
potential therapeutic effects of the intervention and the possible risks and negative 
consequences of treatment.  The possibility that the trial intervention may extend 
survival or even induce remission further undermines the pre-existing prognostic 
certainty.(220)  This uncertainty can generate stress and anxiety and, if experienced for 
prolonged periods of time, may undermine people’s sense of identity and disrupt their 
self-perception.(221)  
 
Is the discomfort of uncertainty, albeit associated with the potential for an improved 
prognosis, worth abandoning the security of an inevitably dire situation for? The 
qualitative interviews aimed to gain insight into this question and other elements of 
clinical trial participation in people with MPM. 
 
2.2. Qualitative research methodology  
Qualitive research methods arose from the fields of social and behavioural sciences, as a 
method of “study[ing] things in their natural settings, attempting to make sense of, or to 
interpret, phenomena in terms of the meanings people bring to them.”(222)  This 
“interpretive, naturalistic approach to the world” can provide rich and informative data 





as well described, by quantitative research methods.  Qualitative approaches can also be 
used to complement and add meaning to the numeric and statistical outcomes of 
quantitative methods.(223) 
 
Ormston, Spencer, Barnard and Snape described the key elements that make up 
qualitative research.(166) 
• The research aims and objectives should be focussed on generating a detailed, 
interpreted insight of participants’ worlds by hearing their personal histories, 
experiences and perspectives, and learning about the conclusions they draw 
from their social and environmental circumstances. 
• Data should be generated using adaptable and responsive methods that reflect 
the social context of the research and, in being non-standardised, can be 
modified to allow exploration of new and emerging issues with each participant. 
• Qualitative research should yield rich and complex data that can be analysed in a 
way that retains subtlety and complexity, respecting each participant’s 
individuality, as well as identifying recurrent, overarching themes. 
• By retaining an open attitude to themes and theories as they evolve during 
analysis and interpretation, the research output will be a detailed description of 
the topic under study, embedded in participants’ perspectives. 
• The investigator’s role in the research process should be explicitly acknowledged, 
using a reflexive approach.  In some cases, this requires researchers to report 







2.3.1. Study design 
Qualitative methods were judged to be the optimal research approach for this study, as 
they would provide a detailed picture of participants’ and their relatives’ experiences of 
living with MPM and participating in the TILT trial.   
 
One to one interviews and focus groups were considered as potential methods of 
collecting qualitative data.  Both have advantages and disadvantages, with interviews 
offering the opportunity to discuss individual experiences and personal matters to a 
deep level, whilst focus groups tend to yield a wider range of experiences but with less 
depth of discussion.(224)  One to one interviews were chosen for participants following 
discussion with the PPI group who provided their views about potential data collection 
methods. Men with MPM stated, universally, that they would be reticent to share their 
experiences in a group setting.  In contrast, focus groups were originally planned for 
relatives as it was thought that group sessions would encourage free discussion, with 
the opportunity for people to share or contrast their experiences, generating richer 
data.(225)  Additionally, it was felt that the reduced intensity of a group setting may 
encourage relatives to speak more openly, particularly about any perceived negatives or 
criticisms of the trial, a feeling that was supported by relatives in the PPI groups.  
Unfortunately, the small number of people recruited to TILT and the geographical and 
temporal distances between them rendered focus groups unfeasible, and so one to one 







The aim of the qualitative interviews was to explore the experiences of participants and 
their relatives of living with MPM and participating the TILT trial and to assess the 
acceptability of research processes.  The qualitative research aimed to answer the 
question “Was TILT acceptable to participants and their relatives?” 
 
2.3.3. Participant eligibility 
Because the aim of the qualitative study was to explore experiences of trial 
participation, all TILT participants were eligible.  Participants’ relatives were also invited 
to participate because previous qualitative research has highlighted that people with 
MPM often display stoicism in response to their condition,(174) and because PPI groups 
suggested that relatives and carers would have had different experiences and 
perspectives on the trial.  On the suggestion of PPI members, friends, carers and other 
acquaintances were also included as potential participants, provided the TILT participant 
agreed to their involvement.   
 
An eligibility criterion for TILT was that people should have a predicted life expectancy 
of at least 12 weeks, therefore it was not expected that many participants would die 
before qualitative interviews could take place.  However, previous clinical trials in this 
patient population have shown that clinicians are poor at predicting survival, and 
therefore it was acknowledged that some participants may not survive long enough to 
take part in the qualitative study.(40)  Bereaved relatives’ perspectives on research were 





terminal stages of their life placed an unacceptable additional burden on their loved 
one’s limited energy or consumed too much of their remaining time together.  
Contrastingly it may have provided a sense of purpose during a person’s final days and 
the opportunity to leave a ‘legacy’ through participating in research. A critical 
interpretive synthesis of 239 quantitative and qualitative research studies examining 
research participation at the end of life commented on these possibilities, and 
ultimately concluded that the majority of participants’ experiences in end of life 
research were positive, as long as the research approach was sensitive to their 
needs.(226)  I were keen to understand the experience of research at the end of life in 
people with MPM, hence the option to interview bereaved relatives was included in the 
study protocol.  
 
2.3.4. Participant sampling 
Sampling for qualitative interviews can take several forms, and different strategies may 
be used in combination.  Methods include convenience sampling, purposive sampling, 
theoretical sampling and snowball sampling.(227)  Convenience sampling, in which 
participants are identified opportunistically, is often driven by timing or resource 
limitations.  It can be helpful in recruiting difficult to reach groups and may be 
associated with low research costs, but often results in low credibility data with limited 
transferability.  In contrast, purposive sampling involves deliberate selection of certain 
individuals to participate, based on specific characteristics or experiences. Purposive 
sampling can be employed to ensure a broad selection of participants is enrolled, to give 





researcher needs to identify the characteristics of interest, based on their own 
experience of the research area and supporting information from the existing literature. 
Another approach, theoretical sampling, is a dynamic strategy in which participants are 
selected to test emerging theories that have arisen from analysis of data from previous 
participants.  It has similarities to purposive sampling as there is a purposeful element to 
it, however, it is undertaken alongside data analysis and is directly informed by findings 
in the data.  Finally, snowball sampling is a technique of expanding the study population 
by asking an existing participant to suggest other people who would be willing to 
participate.  This approach can be used to augment populations sampled via other 
methods and is useful for recruiting from close-knit or hard to reach communities.(227) 
 
In this study, purposive sampling was planned, with the aim of enrolling participants 
who had experienced each aspect of the trial, i.e. control participants, participants who 
received BCG or OK432 and people who declined any element of the trial.  Due to the 
small numbers recruited to TILT, this amounted to approaching all TILT participants and 
inviting them to take part in the qualitative study.  Recruitment of relatives was similarly 
purposive, with additional snowballing to extend sampling to the wider community of 
family and friends. 
 
2.3.5. Sample size 
Sample size in qualitative studies is often determined by saturation, the point at which 
no new concepts or themes are detected in the data.(228)  However, predicting the 





the study is researching a novel or unfamiliar area. Certain factors are associated with 
reaching thematic saturation after fewer interviews, for example if a homogeneous 
group is interviewed about a similar experience or with a narrow objective.(229)   
 
The concept of saturation arose out of Grounded Theory, based on a constant 
comparison approach to analysing qualitative data.(230)  With constant comparison, 
each new observation or interview is analysed and compared with the pre-existing 
analysis to assess for similarities and differences.  Using this approach, the point of 
theme saturation is relatively easy to identify as no novel data or themes are found in 
successive interviews.  However, saturation can be less easy to identify using other 
qualitative analysis methods and, as a result, saturation is often claimed by researchers 
without a clear explanation of how it was assessed or understood outside of the 
Grounded Theory approach.  
 
An alternative model for determining sample size is the concept of information 
power.(231)  Proposed by Kirsti Malterud and colleagues in 2015, information power 
describes the amount of information relative to the study that a particular sample holds.  
Information power is influenced by the aim of the study (i.e. whether a narrow or broad 
subject is under investigation), the specificity of participants (i.e. whether they share 
certain characteristics or experiences), the quality of the dialogue, whether the analysis 
is case-based or cross-case and whether new theories are being generated. Good quality 





based using an existing theoretical model will have high information power and require 
the fewest participants. 
 
The sample size for the TILT qualitative study was initially based on achieving theme 
saturation, however, this approach was reviewed following publication of Malterud’s 
concept of information power.  Fortunately, there were similarities between the two 
approaches in that both suggested a relatively modest number of participants would be 
acceptable. Specifically, the TILT population was relatively homogeneous/ specific 
(predominantly White British men, aged between 60 and 80, with a background in 
industrial occupations) and they were interviewed about a narrow and shared 
experience (living with MPM and participating in TILT).  Correspondingly, their relatives 
were all White British women of retirement age, who had lived through the similar 
experience of caring for men with MPM during the trial.  Interviews were analysed 
across cases, but the intention was not to develop new theories.  Therefore, information 
power was expected to be high and a small number of interviews (i.e. the majority of 
the seven TILT participants and a similar number of relatives) would be sufficient to 
achieve the study aim.   
 
2.3.6. Participant invitation 
Participants were invited to take part in the qualitative study in person, following 
completion of their final TILT trial assessment visit.  If they were interested, they were 





they had attended with the participant or, if they had not, via a letter with the PIS 
enclosed, given to the TILT participant to take home. 
 
Bereaved relatives were sent a letter 6 weeks after the TILT participant’s death, which 
offered condolence and thanked them for their relative’s participation in the trial.  The 
letter included a brief description of the qualitative study, a PIS and an opt-in form (with 
stamped addressed envelope) to be returned to the study team if the person was willing 
to be contacted to discuss the study further (Appendix 5).  The letter stated that if the 
study team did not receive a reply, no further attempts to contact the person would be 
made.  The letter was reviewed and approved by the trial PPI group, to minimise the risk 
of causing distress.  If a bereaved relative returned the expression of interest form, they 
were contacted by telephone by a member of the trial team. 
 
Potential participants were given sufficient time to read the PIS, usually at least 72 
hours.  After this period, a member of the trial team contacted them by telephone to 
discuss the research and answer any questions they may have.  At the end of the 
conversation, people were asked whether they were willing to participate.  If they 
agreed, a time and date was agreed and participants were asked where they wished the 
interview to take place. I anticipated that participants would feel more comfortable in 
their own homes and would be more likely to talk openly in that setting.  Additionally, 
since I was going to perform the interviews, as a hospital doctor who had had previous 
clinical interactions with participants in the hospital setting, I felt that the interview 





with the trial PPI group confirmed this, with the majority stating that they would prefer 
to have an interview in their own home.  Alternative options were provided, however, 
including the home of a friend or relative, a neutral space e.g. village hall or library, their 
local hospital or a non-clinical space at a local university.   
 
2.3.7. Interview process 
I (Anna Bibby, AB) conducted the interviews myself. I am a White British female in my 
late 30s with qualifications of MBChB, BSc, MRCP, DTM&H. At the time of the study, I 
was employed part-time as a clinical academic and part-time as a consultant respiratory 
physician, on a background of 15 years clinical experience in the NHS.  I was the 
Principal Investigator for TILT and, as part of my PhD programme, had received formal 
training in qualitative research methods, qualitative analysis and NViVo software via 
taught courses at the University of Bristol.  I also received support and guidance in 
qualitative methods and social theory from Prof Rachael Gooberman-Hill (RGH), a 
Professor of Health and Anthropology at the University of Bristol. All participants had 
met me on at least one prior occasion, usually in the course of their clinical care.  All 
were aware of my role as PI for TILT.   
 
Where possible, interviews were held with just the participant and me present, however 
in three interviews participants requested their relative(s) be in attendance and this was 
permitted.  Participants provided written informed consent for the interview, including 
consent to be audio-recorded, for the audio-recording to be stored electronically and 





all participants, so all interviews were conducted in English, without translators. 
Interviews lasted between 24 minutes and 92 minutes. Field notes were not made.   
 
Interviews followed a semi-structured approach using a pre-specified interview topic 
guide (Appendix 6), with scope for additional questions or discussion based on individual 
participants’ responses.  Participants were asked about their prior experience of clinical 
research, their reasons for participating (or not) in TILT and their views on TILT-related 
trial processes. Participants who had received an IMP were asked about their experience 
of IMP administration and effects. Participants who declined to participate in any 
element of TILT were asked about their reasons. The TwiC design was explained to 
participants and their opinions were solicited as to whether they felt the design was 
acceptable, fair and transparent.  The topic guide evolved iteratively with successive 
interviews, with additional questions about participants’ attitudes to other treatments 
e.g. chemotherapy added later.  
 
The topic guide originally included exploration of participants’ individual diagnostic 
pathways, as well as their feelings and responses on receiving the diagnosis of MPM.  
However, before the first interview took place, the research team became aware of an 
existing qualitative study that was investigating a similar topic.  The RADIO-meso study 
(Receiving A DIagnosis Of mesothelioma), funded by Mesothelioma UK, consisted of 
interviews, focus groups and an electronic consultation exercise with patients, relatives 
and healthcare professionals.(232) Based on the qualitative findings, a set of 





experience of being diagnosed with MPM.(233) To avoid duplication of this work, the 
topic guide was changed and questions relating to diagnosis were removed.  
 
2.3.8. Data analysis 
Interviews were digitally audio-recorded, with recordings subsequently transcribed 
verbatim and anonymised.  Pseudonyms were generated for each participant and are 
used throughout this thesis. Transcripts were reviewed and checked for accuracy, then 
re-read and recordings listened to, to increase familiarity with the data.  Transcripts 
were uploaded to QSR NVivo v12 qualitative analysis software.  
 
Thematic analysis was selected as the method of analysis for this study.  Thematic 
analysis is “a method for identifying, analysing and reporting patterns in data... in rich 
detail”, whilst also enabling interpretation of certain elements of the topic.(228) Of the 
many diverse analytic approaches used in qualitative research, thematic analysis has 
been suggested as a foundation method and one of the first that researchers should 
learn.(228)  This was one reason for selecting it for this study. 
 
Unlike several other qualitative analysis methods, thematic analysis is not tied to a 
specific theoretical or epistemological position.  This lends it flexibility and it can be as 
equally applied to a realist/ experiential paradigm as it can to more theoretical 
approaches.(234)  Unfortunately its independence from formal anthropological or 
sociological theories, as well as its flexibility, have led to accusations that thematic 





required to perform thematic analysis are rigorous as long as certain analytical decisions 
are made upfront.(228)  If these decisions are explicitly stated, there will be nothing 
ambiguous or vague about the analysis. These key decisions are: 
• Whether the aim is to provide a broad description of the whole dataset or a 
detailed depiction of one specific element. 
• Whether the analysis will be approached in an inductive or deductive manner. 
• Whether themes will be identified at a semantic or latent level. 
• Whether the research is being undertaken from a realist or constructionist 
perspective. 
 
For this study, a rich account of the entire dataset was desired, with a specific focus on 
the acceptability of the TwiC design.  An inductive approach was chosen, whereby 
themes were directly informed by the data, with no preconceived ideas about what 
themes were present before analysis began.  The alternative, deductive coding, entails 
the researcher approaching the data with list of pre-determined themes and identifying 
codes within the text that correspond only to the themes of interest.  Both methods 
have their merits, with inductive coding seen as a useful approach for generating 
hypotheses, whilst the deductive method can be more hypothesis testing.(236)  An 
inductive approach was deemed preferable for this study as the lack of prior qualitative 
research on the subject meant that there were no existing hypotheses or established 
themes to apply deductively to the data.  Inductive coding allowed the data to 
determine the themes and ensured that the data was comprehensively represented, 






The next two decisions related to the level at which meaning was ascribed to themes 
and the relationship with underlying socio-cultural context. For example, a semantic 
theme is based on explicit information, interpreted at a surface level, whilst latent 
themes explore deeper to identify associated beliefs or philosophies underpinning the 
surface statement.(228, 237) Latent themes almost always require a degree of 
theorising and are usually (but not always) associated with a constructionist approach. 
 
Constructionism is based on the theory that all experiences and meaning are socially 
created and are not, therefore, inherent to a particular individual.(228)  Qualitative 
analysis undertaken with a constructionist approach is focused on understanding the 
socio-cultural context that informs an individual’s interpretation of an experience.  The 
alternative is a realist interpretation, which assumes a direct and usually unidirectional 
relationship between language and meaning, i.e. a participant’s statement is an 
authentic representation of their experience or meaning, and it is that meaning (or 
experience) that is of interest for the research.  
 
In this study, I wished to understand the reality of trial participation at an individual 
level, rather than aiming to appreciate the deeper socio-cultural motivations informing 
participants’ experiences or to formulate a theory of trial participation in people with 






Whilst learning about inductive approaches to qualitative research, I read about Glaser 
and Strauss’ Grounded Theory.(230)  This is a specific inductive method, where 
researchers attempt to enter into the research field with an entirely open mind to allow 
theory to be developed inductively from the data.  I considered whether Grounded 
Theory was appropriate for this study, however, given the research team’s history of 
clinical and academic work in the field of MPM, I ultimately felt it was unsuitable, as a 
truly naïve approach was not possible.  Instead I elected to use a general inductive 
approach, as described by David Thomas in 2003.(238)  This approach afforded a degree 
of flexibility by acknowledging that the analysis would be shaped by both the overall aim 
of the research (determined deductively) and the interpretation of the raw data 
(analysed inductively).  Thus, it was anticipated that the qualitative study would produce 
several novel, inductively-generated themes, embedded within two overarching 
concepts determined by the study objectives, i.e. the experience of living with MPM and 
the experience of participating in the trial. 
 
Qualitative data can be organised for analysis using the Framework Method, in which 
themes are indexed using a structured matrix.(239) This can be used for deductive 
coding, where the matrix is pre-populated with specific themes and topics of interest, or 
completed inductively with themes identified during, rather than prior to, analysis.  
During coding, the matrix is filled in with sections of transcript representing each theme, 
hence the framework is applied to the data.  Whilst this is a neat way to structure codes, 
a potential pitfall of the framework approach is that it organises data in a manner that is 





researchers to apply quantitative descriptions to the data, e.g. “Eight out of ten 
participants commented on X theme”.(239)  This would be an incorrect interpretation of 
the approach that would miss almost all of the richness that is integral to qualitative 
analysis and the data it based on.  For this thesis, the flexibility offered by Braun and 
Clarke’s method of thematic analysis and the opportunity it provided to produce a 
detailed and complex account of what was expected to be a rich dataset was more 
appealing. Deciding key elements of the analysis at the outset (i.e. inductive 
interpretation based on a semantic and realist approach, aiming to provide a broad 
description of the whole dataset) ensured that the thematic analysis would be rigorous 
and would yield insightful and trustworthy results. 
 
For these reasons, thematic analysis was performed in accordance with the six-step 
process described by Braun and Clarke, consisting of:  
1. data familiarisation,  
2. creation of initial codes, 
3. searching for themes,  
4. review of themes,  
5. definition and description of themes, and  
6. publication of data.(228)  
Having conducted all the interviews and transcribed several, I was immersed in the data 
from the outset.  Transcripts were inductively coded to develop an initial code list.  
Interviews were coded sequentially, with the code list reviewed prior to each successive 





lists were compared and refined, based on discussion between RGH and me. I then 
coded the rest of the data and grouped coded segments into categories and themes. 
Themes were mapped graphically to identify connections between themes and to 
develop a descriptive account of the whole dataset. 
 
2.3.9. Ethical considerations 
Participation in the qualitative study was voluntary and participants were given as much 
time as they required to consider their decision to participate.  Participants were 
assured, in writing in the PIS and in person at the start of the interview, that they could 
withdraw at any point without affecting their future clinical care.  All participants 
provided written informed consent prior to participating, including consent for the 
interview to be digitally audio-recorded and stored, and for the use of anonymised 
quotations in the final report.  Participants were informed that the content of the 
interview was confidential and would be anonymised during transcription.  All data was 
stored in accordance with the Data Protection Act. 
 
It was recognised that participants would either be personally living with or caring for 
someone with terminal cancer and that reflecting on this experience could potentially 
cause distress.  This was explicitly recognised in the PIS and participants were offered a 
list of people they could contact after the interview if they wanted additional support.  A 
standard operating procedure was produced for responding to distress in qualitative 
interviews and any participants who did become distressed were offered the contact 






The research team acknowledged that there were specific ethical issues around 
approaching bereaved relatives to participate in the qualitative study.  However, I felt it 
was important that these people had the opportunity to share their experiences of 
caring for someone who was participating in research during the end of their life, as 
these experiences may have differed quite significantly from other participants’.  
Similarly, I did not want to deprive deceased participants of the chance to have their 
stories heard.  Equally, however, I did not want bereaved relatives to feel pressurised to 
take part nor did I wish to intrude upon their grief.  I discussed the subject extensively 
with members of the PPI group and with attendees at several local mesothelioma 
support groups (both of which included people whose partners had died from MPM).  
Following these conversations, we decided that it was appropriate to approach 
bereaved relatives on a single occasion, via letter, with an opt-in offer to participate in 
the qualitative study.  A specific PIS was written for bereaved relatives.  Both the 
invitation letter and the PIS were reviewed on two occasions by the PPI group to 
minimise the chance of causing distress.  All documents were reviewed and approved by 
the Research Ethics Committee before the study began (ref 17/SW/0080).   
 
2.3.10. Reflexivity 
When designing any research study, it is important to identify potential factors that may 
influence the findings and strive to minimise them wherever possible.  However, clinical 
research cannot and does not occur in a vacuum, especially in qualitative research 





presentation. Despite all attempts to remain neutral, it is, in reality, impossible for 
researchers to separate themselves completely from their existing knowledge or views 
on a topic.  It is important, therefore, to appreciate the potential impact the researcher 
may have had on the findings of this study.  A biography has been provided in Section 
5.3.7 to enable the reader to make their own assessment of how my characteristics and 
background may have influenced the research process and to what degree. Further 
discussion follows in this section.   
 
The overall aim of the thesis was inescapably linked to my clinical experience in the field 
of MPM and recognition of the lack of treatment options available.  My familiarity with 
the field may have facilitated some aspects of the qualitative study as participants did 
not need to explain medical terms or processes to me. My knowledge of MPM and 
clinical experience in this field also enabled me to establish a good dialogue about all 
aspects of this condition. Finally, having worked with people with advanced cancer and 
their relatives for several years, I am skilled in communicating about difficult topics such 
as incurable conditions and end of life matters. 
 
However, my background as clinician may have been disadvantageous in other ways.  
Specifically, it has been suggested that healthcare professionals should not interview 
their own patients, as there is a chance that participants will try and please them by 
saying what they think the clinician wants to hear.(240) However, in situations where 
this cannot be avoided (such as this thesis), patients should be encouraged to speak 





possible, interviews were conducted in patients’ homes rather than on hospital 
premises to redress the dynamic of clinician and patient.  Specifically I wanted 
participants to feel relaxed and comfortable and in control, and thought this would be 
more likely in familiar surroundings rather than in a sterile, clinical setting, where the 
doctor is usually the person in a relative position of power.  To further reduce the 
doctor-patient dynamic, I wore professional but non-clinical clothing, with no hospital 
identification, stethoscope or other medical accessories.  Occasionally, participants 
asked a clinical question during the interview and, if possible, I politely told them that I 
would be happy to answer the question at the end but would prefer to continue to hear 
about their experiences first. 
 
The fact that I was PI for TILT may have influenced how participants related their 
experiences of trial participation.  However, it was clearly stated at the beginning of 
each interview that the aim of the process was to learn from their experiences and to 
improve research for future participants, so participants should not be afraid to express 
their views.  I tried to be humble and receptive, and to respond neutrally to all 
comments regarding the trial, whether positive or negative.  Suggestions for 
improvement to the trial were invited and openly explored.  This approach seemed to 
be successful, as participants appeared willing to speak freely about their experiences in 
the trial, including quite strong opinions and appropriate criticism of certain areas of the 







2.4.1. Participant characteristics 
Eleven interviews were performed with five of the seven (71.4%) TILT participants and 
seven of nine (77.8%) relatives approached, two of whom were interviewed together 
(Ida and Janet).  Ida was also present for her husband Harry’s interview, and Bob was 
present for his wife, Eleanor’s interview.  Aside from Ida and Bob, participants were 
interviewed on one occasion only. 
 
One TILT participant agreed to be interviewed but was sadly admitted to hospital and 
died before the interview took place.  Her husband (the only relative to be bereaved 
during the study) did not respond to the qualitative interview invitation.  The other TILT 
participant who declined the qualitative study was approaching the end of his life and 
felt too unwell to be interviewed.  His daughter-in-law was interviewed.   
 
Participant characteristics are shown in Table 5.1.  Interviewees had participated in both 
the active intervention arm and the control arm of TILT.  Unfortunately, the sole TILT 
participant to receive OK432, and coincidentally the only female participant in the trial, 
was one of the people who did not complete a qualitative interview. Therefore, the 
qualitative interviews reflected the experiences of men who received BCG or were 
controls.  Interviews were completed with the TILT participant who declined to receive 
BCG having been offered it, and with the relative of the control participant who declined 







Study ID Pseudonym Role Sex Age Study site Interview location 
32-6T Alan TILT participant (BCG) M 71 Bristol Patient's home 
33-9C Bob TILT participant (Control) M 84 Oxford Patient's home 
32-6T-W Caroline Wife of Alan F 71 Bristol Patient's home 
104-1T Dave TILT participant (BCG) M 61 Taunton 
Community 
Hospital 
33-9C-W Eleanor Wife of Bob F 81 Oxford Patient's home 
32-24C Frank TILT participant (Control) M 81 Bristol Patient's home 
32-24C-W Georgina Wife of Frank F 79 Bristol Patient's home 
32-27T Harry TILT participant (Declined BCG) M 74 Bristol Patient's home 
32-27-W Ida Wife of Harry F 72 Bristol Patient's home 
32-27-D Janet Daughter of Harry F 48 Bristol Patient's home 
32-38C-D Kate Daughter-in-law of control participant  F 43 Bristol 
Community 
Hospital 
Table 5-1 Characteristics of participants in the qualitative study 
 
2.4.2. Themes 
In keeping with the overall aim of the study, the majority of interview content related to 
two overarching topics: the experience of MPM and the experience of research 
participation.  Within these topics, seven themes were identified:  
i. physicality, 
ii. quality of life, 
iii. uncertainty and risk,  





v. motivations for participating in research, 
vi. downsides of research participation, and 
vii. specific TwiC features. 
 
The first three themes were common to both overarching research topics, indicating a 
commonality of experience that spanned having MPM and participating in research.   In 
contrast, theme iv appeared to relate only to the experience of having MPM, whilst 
themes v, vi and vii were predominantly grounded in the experience of the trial.  The 
quality of life theme (theme iii) was linked with participants’ motivations for 
participating in the trial (theme v), whilst the theme about uncertainty and risk (theme 
iii) informed some of the reported downsides of trial participation (theme vi).  Each 
theme consisted of three or four sub-themes, which are listed in Table 5.2.  The 
relationship between the seven themes, their sub-themes and the overarching research 
topics is illustrated in Figure 5.1. 
 
The same themes arose from interviews with trial participants and interviews with their 
relatives. Interestingly, however, perspectives often differed between the two groups.  
Figure 5.2 shows examples of themes that were shared between participants and 
relatives where the experience of the theme varied and others where they accorded.   
 
The remainder of this chapter consists of a description of each theme, with an account 





research topics are outlined and areas where participants’ and relatives’ positions 
diverged are highlighted.  All names are pseudonyms. 
 
Table 5-2 Themes describing the experience of MPM and participating in a clinical trial 
Major theme Subtheme 
Physicality 
Impact of symptoms 
Stoicism and valuing strength 
Relatives as advocates 
Experiencing side effects 
Quality of life 
Quality not quantity 
Decision-making: chemotherapy 
Decision-making: clinical trials 
Uncertainty and risk 
Gathering information and seeking certainty 
Appreciating equipoise 
Perception of risk 
Commitment to decisions 
Anxiety and the future 
A terminal diagnosis 
Impact on relatives 
Grieving for lost opportunities 
Keeping positive vs giving up 




Understanding the science 
Relatives’ reluctance 




Completing trial paperwork 
Specific TwiC features 
Lack of placebo 
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 TILT participants 
 
 Relatives 
Symptoms - stoical      Symptoms - vocal & advocating 
Quality of life  
Chemotherapy decision-making 
Desire for certainty 
The future – pragmatic & accepting         The future – anxious & fearful 
Trial participation – enthusiastic         Trial participation - reluctant 
Trial downsides - organisation 
  Trial downsides – timing too short          Trial downsides – timing OK 
  Commitment to decision – no regret            Commitment to decision - regret 






2.4.2.1.1. Impact of symptoms 
Almost all participants commented on the physical aspects of MPM, frequently 
mentioning symptoms of breathlessness and fatigue.  Symptoms often impacted on 
people’s day-to-day activities and, for some participants, elicited strong emotions, 
including frustration and anger.  
 
“I’ve only got to walk up the top of the garden and I can feel it and I’m 
struggling to breathe.” Harry, 74 M, person with MPM. 
 
“Just the sheer physical effort of talking to somebody, and you know how he 
loves to talk, and that really cost him. If he did anything physical, he’d spend 
three or four days recovering from the smallest thing, and for [husband] he 
just hated it, every second of it.”  Caroline, 71 F, wife of person with MPM. 
 
2.4.2.1.2. Stoicism & valuing physical strength 
Despite being limited by their symptoms, men with MPM often underplayed their 
physical problems.   
 
“I know I’ve got it … but I don’t feel bad. I’m okay, I like to walk, my body still 






“Larry done a lot of, ‘Oh, I am fine, I am great, I am OK,’” Kate, 43 F, 
daughter-in-law of person with MPM. 
 
One possible reason why patients underplayed their symptoms was that men with MPM 
appeared to place a high value on physical health and strength, often emphasising their 
previous high levels of fitness.   
 
“I have always been fit and healthy.” Dave, 61 M, person with MPM. 
 
“I remember he came out on the bottom floor and said, ‘Would you like to 
come up to my office by lift or do you want to walk up?’ and I said I would 
walk up, so I walked up five flights of stairs.” Frank, 81 M, person with MPM. 
 
“I can remember on the Wednesday a friend came round wanting the 
concrete mixer, and I was humping and carrying, and I felt absolutely 
wonderful, I felt fine. And that’s the last time I felt really, you know, a 
mountain isn’t a problem.” Alan, 71 M, person with MPM. 
 
In response to this, several people with MPM acknowledged that their physical strength 
was deteriorating, and that they were having to realign their expectations with their 
ability.  For most, this was difficult to come to terms with, and they often expressed 






“It really has been a hard lesson and a shock for me to have to realise that 
I’m going to have to give up my golf and table tennis.” Frank, 81 M, person 
with MPM 
 
“OK I didn’t really appreciate [Nurse] saying, “You were a fit 70-year-old, 
now you’re an unfit 70-year-old”. It happened, what, over four months? I 
certainly wasn’t ready for that. OK, she’s probably right, but I wasn’t very 
happy with that.” Alan, 71 M, person with MPM. 
 
2.4.2.1.3. Relatives as advocates 
Relatives found it hard to watch their loved ones struggle with symptoms. They 
described feeling powerless to help, able only to watch as their husband’s struggled or 
visibly deteriorated.   
 
“Interviewer:  Had you seen him finding things harder?  
Ida:   I have, yeah, especially ‘cause he loved his garden and veg.  
It’s pitiful to see him absolutely gasping for breath, isn’t it? 
Janet:   And hard for you when you can’t make it better. 
Ida:   Can’t help him, no, that’s right, yeah.  You can’t fix it, you 
can’t make it easier, you just have to watch. 
Janet:   Yeah.” 






“I’m watching my husband going downhill.” Caroline, 71 F, wife of person 
with MPM. 
 
In response to this, several relatives had assumed the role of advocate, speaking out 
when their loved ones would not and campaigning to ensure their partners received the 
best care.  Sometime these efforts were hindered by their relatives’ stoicism, causing 
frustration. One person was particularly concerned that her relative was missing out on 
community palliative care input because he was not forthcoming about his symptoms. 
 
“I was told you can’t have a nurse specialist because [Larry]’s gone, ‘Oh, I am 
fine, I am fine,’ and I go, ‘You actually have to tell her you are breathless! You 
need this, I am not doing it all’.” Kate, 43 F, daughter-in-law of person with 
MPM. 
 
2.4.2.1.4. Side effects 
Most participants who received the investigational medicinal product experienced side 
effects from the trial drug. They described how this felt. 
 
“By 9 o’clock I was running a temperature, I had flu symptoms. So I went to 
bed.  Didn’t think anything more of it, because I was expecting to get, well I 
was prepared.  It was a little bit quicker than I was expecting to get flu-like 
symptoms, I thought you said, ‘Within the next day or so’… So yes, we, I went 





couldn’t breathe, I couldn’t do anything else… My chest was very restricted, I 
was basically panting.” Alan, 71 M, person with MPM. 
 
 “Yeah, you know, you said, you might feel a bit unwell and all this. I felt bad. 
You know, I… for a couple of days I was just in bed and didn’t bother getting 
up. I thought, I have got no mojo, not that I didn’t have any strength, I just 
didn’t have any mojo and I think that I wasn’t expecting.” Dave, 61 M, person 
with MPM. 
 
Despite being warned about potential side effects, it seemed that participants had not 
expected to feel the way they did, as quickly as they did. However, for one participant, 
the side effects were manageable because he recognised that they were caused by the 
trial medication, and thought that they meant the drug was working: 
 
“Because I had felt… well, not so well, but okay previous to it. I thought well 
that must be the effect of the drug… this might be doing some good.”  Dave, 
61 M, person with MPM. 
 
Again, the partners of men with MPM expressed how upsetting and frightening it was to 







“It was that chain of events that happened, and I felt so helpless, [husband] 
thought he was going to die and to be honest I think the ambulance people 
did too.” Caroline, 71 F, wife of person with MPM. 
 
The same person described advocating on her husband’s behalf when he was admitted 
to hospital.  She was fiercely protective of him and fought to ensure her husband 
received the best possible care once he arrived in hospital.   
 
“I just couldn’t, couldn’t get my head… What nurse puts a man who is going 
grey with blue lips, in a chair to wait for a bed? Can they not just put him on 
a trolley if nothing else? He’s sat there and he’s swaying. Can you not find 
him something more comfortable? I know I was rude that day, I fully 
appreciate it but it wasn’t a good experience, and yes it was me that took up 
the cudgels, but again [husband] was too poorly to want to do anything 
about it.” Caroline, 71 F, wife of person with MPM. 
 
Clearly the side effects of the trial drug had significant physical and emotional impact on 
participants who received it, as well as their relatives.  Interestingly, participants in the 
control arm of the trial also had an appreciation of potential side effects, with several 
people expressing relief that they or their husband had not received the trial drug. 
 
“I’d hate to think what it would have been like if I had had the bacteria.” 






“So, I was glad in a way that he did have the placebo because who knows 
what would have kicked off.” Georgina, 79 F, wife of person with MPM. 
 
2.4.2.1.5. Synopsis 
The importance placed by people with MPM on good health and physical strength, and 
the negative impact of symptoms and medication side effects, revealed the particular 
values and priorities held by this patient group.  These values informed their overall 
quality of life and shaped some of the decisions they made regarding treatment and 
research participation, as identified in the second major theme. 
 
2.4.2.2. Quality of life 
2.4.2.2.1. Quality not quantity 
Quality of life was important to participants and their relatives, especially in light of the 
limited life expectancy associated with MPM. 
 
“I think, for us at the moment, quality of life is the first priority. For the years 
that we have got left, and hopefully there will be quite a few, that we 
appreciate the quality of life.” Eleanor, 81 F, wife of person with MPM. 
 
Participants were able to balance the overall amount of time they had remaining with 
the importance of feeling well in that time.  For most, living longer was not desirable 






“If I have got some extra time that’s brilliant, but I couldn’t face it like this.” 
Frank, 81 M, person with MPM. 
 
At the time of interviewing, most participants were content with their existing quality of 
life and hoped their circumstances would remain similar in the future.  However, this 
aspiration was overshadowed by an awareness that the prognosis was uncertain and 
that their condition was liable to change at some point. 
 
“Long may the situation reign that I’ve got, but I can't bank on it, can I?” 
Bob, 84 M, person with MPM. 
 
“Janet:   [We’re] just happy to keep going. 
Ida:   Yeah, as long as he’s like this, like he is, yeah. 
Janet:   With the new drain. 
Harry:   Yeah, I’m happy to carry on like this, if I could stay like it.” 
Janet 48 F, and Ida, 72 F, daughter and wife of Harry, 74 M, person with MPM. 
 
2.4.2.2.2. Decision-making: chemotherapy 
The desire to preserve quality of life influenced participants’ decisions about 
chemotherapy.  Most participants believed that the limited benefits of chemotherapy 





specific survival benefit associated with chemotherapy and were not willing to sacrifice 
their overall wellbeing for two to three months of longer life. 
 
“No, he said as well, ‘If it was only going to give me two months extra, I 
wouldn’t have treatment, because the impact of having the treatment would 
affect the quality of life I was having, potentially.’” Kate, 43 F, daughter-in-
law of person with MPM. 
 
“We’d seen the results of chemo and it didn’t work, it was absolutely hell to 
go through, so there didn’t seem any point; if you’re not going to get more 
than a couple of months out of it, what is the point? That was the decision 
that was reached.” Caroline, 71 F, wife of person with MPM. 
 
“We had this long discussion about should he have the chemo or not and we 
were both of the opinion that he shouldn’t have it… He looked at it from a 
much more practical side, went into all the statistics and found out how short 
a time it would prolong his life and thought, ‘Well, on balance it’s not worth 
it’.” Georgina, 79 F, wife of person with MPM. 
 
One participant was particularly eloquent in summarising what he perceived to be the 






“I don’t see much point in bashing yourself with a hammer just to feel better 
when it stops.” Alan, 71 M, person with MPM. 
 
Relatives were supportive of their husbands’ decision not to receive chemotherapy.  In 
some cases, relatives recognised that their family members were too unwell to tolerate 
chemotherapy and appeared relieved that it had not been offered to them.  As with the 
previous theme, relatives were protective of their family members and keen to ensure 
that everything was done in their best interests. 
 
I had already said to him the day before we went in, ‘He won’t be offered any 
chemo’, he wouldn’t have sustained it, you know, because you get obviously 
very unwell with chemotherapy, you have to have a reserve, he didn’t have 
any reserve.” Kate, 43 F, daughter-in-law of person with MPM. 
 
“At the time he was looking ill, so it was like I could understand why the 
chemo wouldn’t be suitable for him.” Janet, 48 F, daughter of person with 
MPM. 
 
2.4.2.2.3. Decision-making: clinical trials 
A similar pattern emerged when participants described the decision whether to 
participate in clinical trials.  People with MPM were well-informed and able to evaluate 
the potential benefits of receiving a trial medication against the possible impact of side 





“[Doctor] sent me a recent paper, which he was very positive about. But 
when I looked at it, it talked about dramatic improvements, doubling of life 
expectancy from six months to twelve months type of thing, so I thought, 
mmm, umm, and with some really serious side effects, and so I decided that 
wasn’t for me because quality of life is important.” Frank, 81 M, person with 
MPM. 
 
Concern about side effects from trial medication was the predominant factor in one 
participant declining to receive BCG in TILT. 
 
“That first [trial], what I, what I backed out of… I thought, well, with all my 
ailments another one ain’t gonna be very nice, so that’s the reason why.” 
Harry, 74 M, person with MPM. 
 
His wife had harboured similar concerns about TILT and expressed a sense of relief when 
her husband chose not to participate in the trial. 
 
“I knew that [husband] would probably say he would help in any way, but 
when you mentioned this… that putting bugs into him? And he’ll be feeling 
like he’s got the flu for a while and I thought, ‘Oh, I don’t know, he’s getting 
better, he don’t need any of that’. That did play on my mind. But he said he’s 
not gonna, he wouldn’t do that... I was, yeah, I was relieved.” Ida, 72 F, wife 







People with MPM tended to make rational and pragmatic decisions, with quality of life 
at the forefront of their decision-making.  Participants sought out information to enable 
them to balance potential benefits e.g. of treatment, against the perceived detriment to 
their quality of life.  Whilst this approach helped people make informed decisions, it 
required objective data, creating a desire for certainty that could not always be fulfilled, 
as described in the next theme. 
 
2.4.2.3. Uncertainty 
2.4.2.3.1. Gathering information & seeking certainty 
People with MPM were knowledgeable and actively sought out information to help 
them make decisions and plan for the future. They often showed a preference for 
factual, numerical data.  
 
“A statistic I used to have at the back of my head for meso is that – I’ll just 
get this right – five per cent of people live for five years and that’s the sort of 
figure, that’s the statistic I want.” Frank, 81 M, person with MPM. 
 
“I mean reading various leaflets and [wife] going on the internet and kids 
doing various stuff, [son] particularly. [They’re] quite convinced that I’ve only 






The search for information was often driven by family members, who consulted a wide 
range of sources. Many people accessed the internet, others approached acquaintances 
with scientific backgrounds or their GP.  One person discussed things with another MPM 
patient when deciding whether to have an IPC inserted. 
 
“Then the missus was on Google.” Dave, 61 M, person with MPM. 
 
“We, well [wife], wanted some additional information, so we went to see our 
local GP.”  Alan, 71 M, person with MPM. 
 
So, then we talked about it, and [son] went through to his friends in [Drug 
Company], came back and said, ‘There really isn’t much they can do, but 
there are several treatments that have possibilities. But Mum, you have to 
understand, it’s not going to stop it.’” Caroline, 71 F, wife of person with 
MPM. 
 
“Before I had the IPC, there were a couple of questions that I wanted to ask 
and I asked [Nurse], ‘Once it’s settled down, can you lie on it?  And she said, ‘I 
don’t know. But I know a man who does.’ So she gave me [patient]’s name, 
and [he] phoned me about 4 or 5 hours later and explained the situation. 






In gathering information, participants wanted certainty and found uncertainty difficult 
to handle.  Participants wanted information to be unequivocal and expressed frustration 
if the information they were given was ambiguous or not specific to them.   
 
“You know, one person says, ‘It is not going to really do you a lot of good’. 
Another person says, ‘Well, we don’t know, it might do’. So, what do I do? I 
would rather somebody say, ‘It is of no use to you whatsoever and don’t 
bother’ or, ‘Go for it’. But don’t wishy-washy in between either a yes or a no.” 
Dave, 61 M, person with MPM. 
 
“[Doctor] said the other day, ‘I can’t give you an answer to that’. ‘Why not?’ I 
said, ‘You keep telling me that there are certain key things that are similar to 
all meso patients, therefore you should be able to give me an answer to that 
question’. ‘Yes, but it’s always different in different people…’ ‘That I fully 
accept, but why can’t you tell us what is common to all meso patients, apart 
from the fact that they’re not going to get better?’ ‘Well, because…’ ‘No, 
don’t prevaricate, I don’t want that and [husband] doesn’t need that’. 
Caroline, 71 F, wife of person with MPM. 
 
2.4.2.3.2. Appreciating equipoise 
Participants expressed confidence in their clinicians’ knowledge (“I am looking at you as 





this was a perception that clinicians should be omniscient, even to the extent of being 
able to predict the future.  
 
Alan  “I didn’t have the anaphylactic shock, so what was it that I 
had? And nobody seemed to know. It was a reaction. It was 
a severe reaction, but I remember [Doctor] saying we didn’t 
think it was going to be so severe. 
Interviewer No 
Alan  But that’s what he’s there for.” 
      Alan, 71 M, person with MPM. 
 
This had implications on participants’ understanding of trial equipoise.  During some 
interviews, participants revealed that they had assumed clinicians had prior knowledge 
about the efficacy and overall effects of the trial drug, not realising that this lack of 
knowledge was the very reason the trial was being performed.  
 
“I felt at that time you wouldn’t have offered him something that would have 
fundamentally made him a lot worse.” Caroline, 71 F, wife of person with 
MPM. 
 
“I accept you don’t know how I am going to react to something [but] It 
would also be nice to say, ‘OK, you’ll probably take 3-6 months to get over 






2.4.2.3.3. Perception of risk 
The sense that clinicians had a greater knowledge of the trial drug than they were 
sharing impacted on participants’ perceptions of the risks involved in the trial.  All 
participants who received a trial drug were provided with comprehensive verbal and 
written descriptions of the potential adverse effects, including numeric estimates of the 
likelihood of each side effect and depictions of possible severity.  Despite this, both 
participants who experienced a reaction professed surprise that it had occurred. 
 
“Yeah. I didn’t realise at the time, after you gave me the drug, how bad I was 
going to feel.” Dave, 61 M, person with MPM. 
 
“There seemed to be a great deal of lacking of knowledge as to what was 
happening.  Yes, the leaflet said, you know, ‘You may feel terrible’ and then 
went on, ‘If it was this, then steroids’ and various other things you can get, 
but… err, had anyone told me I could feel so rough?”  Alan, 71 M, person 
with MPM. 
 
The desire for certainty arose again in this context.  The participants and relatives of 
those who experienced a reaction had expected to be warned about the specific 
symptoms they ultimately experienced. Alongside this personal prediction, they 
described wanting assurances about how long the side effects would last and a 






“If you ever said well this is going to put you in bed for a couple of days or it 
possibly could put you in bed for a couple of days…then I would have gone, 
‘Yeah, okay I can live with that’.” Dave, 61 M, person with MPM. 
 
“I think if perhaps we’d been made more aware of what those negatives 
could be. Maybe not [husband], but if you’d actually said to me, ‘This is what 
he’s going to experience’” Caroline, 71 F, wife of person with MPM. 
 
“I don’t think I’d have a problem if you told me I was going to feel really, 
really rough and that’s one of the side effects. Um, hopefully you’d get over it 
within a month or 6 weeks. I think, but I’m not sure, that I would probably 
have said, ‘OK.’ I’m going to feel really, really rough but at least at the end of 
it… I would know that I was going to be over it. If I was going to get over it, 
you don’t mind.” Alan, 71 M, person with MPM. 
 
The information provided in the PIS did not prepare people sufficiently for the reality of 
experiencing an adverse event.  People did not seem able to relate to theoretical risks 
described on paper.  Some participants did not read the paperwork, whilst others read 
it, but did not believe it would happen to them. 
 
“No, I am interested but… yeah, I don’t know. A lot of it, if it involved reading 





not… word of mouth and I am fine, but I just can’t be bothered with all this 
[paperwork].” Dave, 61 M, person with MPM. 
 
“Having read leaflets that you get with your pills and the rest of it, and 
having read about the side effects you might get, I must admit I do get two 
thirds of the way through and I think, ‘Really?’.  I was certainly ill-prepared 
for having the reaction I did.” Alan, 71 M, person with MPM. 
 
One relative provided another perspective on risk perception, suggesting that for her 
husband, the altruism that motivated him to participate in the trial was greater than 
could be deterred by the risk of complications. 
 
“I think he was aware of [the risks]. Yeah. But I think the desire to be part of 
some research and perhaps doing some good was stronger than his fear of 
having some side effects at that stage.” Georgina, 79 F, wife of person with 
MPM. 
 
2.4.2.3.4. Commitment to decision 
Despite feeling poorly prepared for the reactions they experienced, participants did not 
regret their decision to participate in the trial and were confident that they would make 







“Interviewer:  Do you think if we had been clearer… and said, ‘Look, for 
some people this has happened, to some people this has 
happened’, given you the worst case scenarios, would it 
have changed anything? 
Dave:  It wouldn’t have changed it. No. It wouldn’t have changed 
what I did… It wouldn’t have changed anything.” 
             Dave, 61 M, person with MPM. 
 
This commitment to a decision once it had been made reflected participants’ propensity 
for absolute thinking and preference for certainty. It seemed that once the decision had 
been made, it became the “correct” decision for them, regardless of the consequences.   
 
“Interviewer:  So, you mentioned that you didn’t know you were going to 
be the first [participant]. Would that have changed your 
mind? 
Alan:  Probably not. I’d already made my decision. Right, wrong,    wh      
Interviewer: Would anything have changed your mind? 
Alan:  I don’t know. Something catastrophic like, ‘For God’s sake    don                     
Interviewer: You might reconsider? 
Alan  But I don’t think so, no. 
Interviewer: You’d pretty much decided? 
Alan  You know, I’d made the decision and I was sticking to it.” 






“Make a decision, stick with it, if it goes wrong, you made it.” Dave, 61 M, 
person with MPM. 
 
2.4.2.3.5. Synopsis 
People with MPM wanted to be knowledgeable about their condition and obtained 
information from a variety of sources.  They preferred absolutes, sought certainty and 
found ambiguity difficult to accept.  This impacted on the perception of trial equipoise 
and created challenges in communicating risks in a manner that could be assimilated 
and understood.  It seemed likely that the desire for certainty was driven by anxiety 
about an uncertain future and a desire to control unpredictable events in the context of 
a short life-expectancy.  
 
2.4.2.4. Anxiety and the future 
2.4.2.4.1. A terminal diagnosis 
The poor prognosis associated with MPM meant that the inevitable prospect of death 
weighed heavily on participants and their relatives.  For some, the prospect of a future 
fatal illness had been hanging over them for some time, due to losing colleagues from 
the disease. 
 
“The minute I hear MPM, I hear you have got 18 months to live… and there is 






“But I tend to feel when we go to [the MPM support group], every now and 
again somebody will say ‘Oh, where’s John?’ ‘Oh, he died’. They’re almost 
waiting for each other to die.” Eleanor, 81 F, wife of person with MPM. 
 
“I’ve heard a lot, a few people, gone [i.e. died] working with asbestos and I 
thought, well, I’m next.” Harry, 74 M, person with MPM. 
 
Many people described feeling anxious about the future, particularly in regard to the 
uncertainty ahead and how to prepare for it. 
 
“Sometimes I sit there and dwell and think, I wonder what the actual end is 
going to be like. You know, am I going to be in pain, am I going to be this, am 
I going to be that?” Dave, 61 M, person with MPM. 
 
“I think it’s this thing of the unknown, when you’re dealing with something 
that is so completely outside your comfort zone in any shape or form, even 
from just knowledge point of view. It’s hard to deal with that when you care 
about somebody, and you watch them deteriorating.” Caroline, 71 F, wife of 
person with MPM. 
 
As with the previous theme, participants often demonstrated a highly practical 
approach to death. Again, they seemed to want certainty and information delivered as 






One of the reasons I’m interested in knowing how much time I’ve got is how 
do I prepare? I mean, if it’s 18 months away I’m not going to start thinking 
about funerals et cetera.” Frank, 81 M, person with MPM. 
 
One relative described her father-in-law learning about the average life expectancy for 
MPM and treating it as an absolute fact, actively counting down the time he believed he 
had left:  
 
“I [know] a gentleman and he was given 6 months and he went home and 
put it on his calendar and then he lived his life right up to the date and then 
he was like [what now]?… And we talk about that, [Larry]- same thing! He 
said, ‘Well, oh, I have got a year… well I have got eight months left now.’” 
Kate, 43 F, daughter-in-law of person with MPM. 
 
The same gentleman’s pragmatic attitude towards his own death manifested as 
macabre humour: 
 
“He has got this Dupytren’s contracture (a flexion deformity of the hand) and 
he said, ‘Oh, that will be burnt off soon,’ and I was like, ‘Oh, what does that 







2.4.2.4.2. Impact on relatives 
Whilst many people with MPM were matter of fact about death, their relatives were 
more fearful about the future.   
 
“I kind of worry about the big things, like eroding ribs, bleeding out, 
aspiration.” Kate, 43 F, daughter-in-law of person with MPM. 
 
Relatives were also more likely to discuss their partner’s concerns, indicating that the 
pragmatic outlook presented by people with MPM was not always a true representation 
of what they were feeling. 
 
“Where do you go for help? That’s the thing I think [husband]’s scared about, 
and I’m scared about now.” Caroline, 71 F, wife of person with MPM. 
 
Fear for their family member’s health was ever present and several relatives described 
listening out for their relatives to check that they were still alive. The inescapable 
awareness of their relative’s mortality permeated every minute of their lives. 
 
“I used to lie awake and listen to him breathing.” Caroline, 71 F, wife of 
person with MPM. 
 
“I then started to notice that we could hear [Larry], which was great and I 
said, ‘That’s great, I can hear him coughing, that’s brilliant because I can 






Men with MPM were aware of the impact of their diagnosis on their wives and family 
members. They often articulated greater concern for their relatives than they did for 
themselves, although were not always able to discuss their anxieties with their families. 
 
“Just, um, I’m a bit worried about [wife]. Just, she won’t, she just does too 
much and there’s no way I can tell her to quiet. For example, she was 
insistent on coming to see me twice a day in hospital and that wasn’t good. 
Yeah, things like that.” Frank, 81 M, person with MPM. 
 
“I think [wife] is struggling a little bit. You know, she thought that, same as I 
did, you know, we were going to retire and live till a ripe old age of 150. But 
as I don’t talk about it then I don’t really know how she feels.” Dave, 61 M, 
person with MPM. 
 
One man was particularly concerned about how his wife would manage with the 
practical tasks around the home after he died.  He described a sense of responsibility to 
help her develop these skills. 
 
“Yeah, it has been a big shock for [wife] because I did all the, um, how shall I 
put it? I did a lot of work in the house and with the shock of me having this 
relapse, it has been a big worry for [her] and I’ve been trying to work hard to 





tyre pressure on the tyres? How do you order oil for the central heating? I’ve 
been trying to work through it all.” Frank, 81 M, person with MPM. 
 
2.4.2.4.3. Grieving for lost opportunities 
The poor prognosis associated with MPM led several people to reflect on future plans 
that had been spoiled and opportunities that were now lost. 
 
“I was thinking, he is not going to be here next Christmas, like the Christmas 
next… (becomes tearful)”. Kate, 43 F, daughter-in-law of person with MPM. 
 
“He feels cheated now and I suppose I feel cheated too, because he’s just 
retired and there were so many things that we hoped to go on with. Yes, 
we’ve been married for 50 years and that was very nice, but we still hadn’t 
actually finished.” Caroline, 71 F, wife of person with MPM. 
 
However, others were more resigned to this loss and appeared more accepting of their 
altered circumstances. 
 
“Bob:  We haven’t done any longish holidays for two years now and 
   we probably won’t. 
Eleanor:  Well, we’ve been there and done that.” 






“Things are improving. I can walk up and down the drive. I’ve started driving 
the car just into [town] but I am realistic about it all and I wouldn’t say I was 
depressed, I’m disappointed, but I’ve got to be realistic.” Frank, 81 M, person 
with MPM. 
 
2.4.2.4.4. Staying positive vs giving up 
People had different strategies for coping with their altered futures, and many 
described trying to maintain a positive outlook on life despite the circumstances.  For 
some people, this entailed actively avoiding negative thoughts and not allowing MPM to 
dominate.  
 
“He’s always had such an amazing positive attitude. He’s always just refused 
to give in. He just keeps going and I think that’s been a great help really in 
getting him through all these different things.” Georgina, 79 F, wife of person 
with MPM. 
 
“We’re eating properly, we go walking, we keep active, we keep positive as 
far as we can and put it in the background.” Eleanor 81 F, wife of person with 
MPM. 
 
“I can’t just sit and think about it day in day out. Otherwise, I don’t know 
what I would do, go nuts, I think. I am not saying I put on a brave face, but it 





here it comes. I would rather, okay, that is symptom, I have got that. I will 
cope with that somehow and move onto the next one. Rather than sit and 
wait and think, is it coming? …I just put it to the back of my mind and don’t 
even give it another thought.” Dave, 61 M, person with MPM. 
 
 
Some people actively focused on positive experiences, using techniques such as 
mindfulness to focus on pleasant moments during their day. 
 
“I try to make the most of every situation. Instead of saying, ‘Oh God, this is 
terrible having to come down here every day,’ I’d try to see things and there 
was all sorts of nice things in the hospital. The chapel and see, the quiet 
rooms I found very nice as well… I came down one night and was feeling a bit 
down and, it would be half past eight at night, I got out of the lift and there 
was a gospel choir singing. I just sat down and listened, and it was so 
uplifting.” Georgina, 79 F, wife of person with MPM. 
 
For several participants, maintaining a positive outlook involved looking on the bright 
side, invoking a sense of gratitude that their situation wasn’t worse. 
 
“I think he’s lucky, to be honest, there’s a lot of people worse than him, so 






“The [patient-reported outcome measures] were asking me to comment on 
situations where I wasn’t feeling particularly bad. Most of the answers to the 
questions were either high or in the affirmative and I tended to get the 
feeling that I was, perhaps, a very fortunate man. I think I am.” Bob, 84 M, 
person with MPM. 
 
Not everyone was able to maintain a positive outlook, however, and some relatives 
commented that their family member appeared to have “given up”.  Understandably, 
this was upsetting and, in a poignant statement with echoes of Dylan Thomas’s poem, 
one woman described her fear that her husband was failing to “rage against the dying of 
the light.”(241) 
 
“I wanted [husband] to fight it and he wasn’t, and that disturbed me more 
than anything because I’m just not used to that… I was disappointed in that, 
and I think to be honest that frightened me for what was to come, because 
he couldn’t control it, and because he couldn’t control it and wasn’t fighting 
it, I felt this is never going to happen, he’s never going to fight it, and he 
hasn’t really. He does what he can but he’s not fighting it in the same way. 
It’s almost as though he’s put up a hand and said, ‘Okay, this is what’s going 
to happen, I’ll let it happen now’.” Caroline, 71 F, wife of person with MPM. 
 
“[He said], ‘Yes, I have gotten weak.’ I said, ‘So, why haven’t you gone out as 





a bit late now, I am too weak.’ I said, ‘Maybe you could go to the door and 
then come back again? Oh, forget it.’ He said, ‘Well, I am going to die 




People with MPM were acutely aware of their limited life expectancy, as were their 
relatives. Death was often thought about and discussed openly.  Men with MPM 
appeared to adopt a pragmatic approach to their own mortality, whilst relatives were 
more likely to articulate anxiety about the future and grief for lost opportunities.  Some 
people cultivated a positive mentality, which appeared to be a helpful coping strategy.  
People who were unable to stay positive, however, were perceived to have “given up”, 
something which caused great distress to their relatives. 
 
2.4.2.5. Motivations for participating in research 
2.4.2.5.1. Altruism 
People with MPM were often motivated to participate in research by altruistic 
sentiments and a desire to be helpful. 
 
“The main motivator was being helpful. I can't do much, but I can help and 
do that.” Bob, 84 M, person with MPM. 
 






There was recognition that research was necessary to progress science and medicine, 
especially in view of the limited options and poor prognosis associated with MPM.  
 
“If it’s not right for me, hopefully it’ll be right for someone else. And if you 
don’t have people with that attitude, you’re never going to progress. We’ll 
still be giving lead poisoning and whatever it is to find a cure. Bleeding, 
leeches and all… Without research we’re still in the dark ages.” Alan, 71 M, 
person with MPM. 
 
“There’s got to be trials because otherwise you’re never going to find 
anything that’s going to help this dreadful disease.” Caroline, 71 F, wife of 
person with MPM. 
 
“We’ve always been happy to help. Anything which will improve a situation… 
because I think it’s your moral duty, isn’t it, to offer what you can when you 
can.” Eleanor 81 F, wife of person with MPM. 
 
2.4.2.5.2. Reciprocity 
Some people were mindful of the potential ways that trial participation might benefit 






“My visits to the hospital, I know I’ll get something out of it, you’re gonna tell 
me something or teach me something or do something to make me feel 
better.” Harry, 74 M, person with MPM. 
 
“Of course, also, once you’ve decided you’re going to do it, you’re this focus 
of all this attention and all these extra things that they are taking from you 
that are going to be used as part of the research, but also extra things are 
being done to look at what’s wrong with you, and that can't be bad.” Bob, 84 
M, person with MPM. 
 
Most people enjoyed the regular contact with the research team that came with trial 
participation. 
 
“No, I have always felt… every visit I have had, I have either seen [Nurse] or 
[Doctor] and they have always been chipper and upbeat, how are you and all 
that. Made you feel like, not something special but you know, that they want 
to talk to you.” Dave, 61 M, person with MPM. 
 
Participants also talked about the desire to repay the care they had received from 
clinicians. 
 
“I’ve been looked after extremely well, given the right sort of options and a 






“I was keen to show that I appreciate what your team had been doing for 
me.” Frank, 81 M, person with MPM. 
 
Several participants acknowledged the reciprocal nature of the relationship. 
 
“Well, it’s a two-way process, isn’t it? We want to keep [husband] around for 
as long as we can and you, on the other side, want to know as much as you 
can about the condition so that you can improve your side of it. It works both 
ways.” Eleanor 81 F, wife of person with MPM. 
 
“Yes, you get added value, you do. It was a mutually beneficial 
arrangement.” Bob, 84 M, person with MPM. 
 
For some people, the option of participating in a trial offered hope and gave people 
something to focus on. 
 
“I personally think you need something to work towards, even if it’s a small 
goal, you need that to work towards and I think that’s what the trials give 
people. It’s the combination of working towards it with the glimmer of hope 
at the end, that whilst you know you’re terminal, the terminally of it could be 






“Interviewer:  When you first heard about the trial, what were your 
thoughts? 
Kate:  Oh! Very hopeful because, it was hope… it was hope because 
we weren’t so sad… sad isn’t the right word. There was 
nothing, it’s like an abyss isn’t it?  
Interviewer: And this was something? 
Kate:  It was. And if you see a trial, there is still that point where 
you can… there is an unknown. Oh my god, this could be a 
miracle! You don’t know, do you! I was like, ‘This is exciting’, 
it’s hopeful.” 
    Kate, 43 F, daughter-in-law of person with MPM. 
 
2.4.2.5.3. Understanding the science 
In line with earlier themes, people with MPM were well-informed about research.  
Several participants demonstrated an astute understanding of the biology of bacterial 
immunotherapy, and the ability to comprehend the scientific rationale behind the trial 
increased its appeal. 
 
“I’m always interested in the most recent scientific data and if I think there’s 





“As a layman I quite like the idea of taking something that is used to living 
inside you, some bacteria or other, and modifying it to make it a killer for 
what you want it to kill. That seems to me like a really good idea, if you can 
make it work, and that’s the basis for which this thing was being sold, you 
could push this stuff down the catheter.” Bob, 84 M, person with MPM. 
 
“[You said] ‘There’s the TILT trial, there’s the immunology that [is] being 
looked at.’  And I said, ‘Well, I didnt know anything about immunology’, and I 
asked you to explain more about it, and I said, ‘Oh! It’s like small pox!’… And 
I said, ‘I think I would like that to be part of the road that I would like to go 
down’. That seemed to make sense. I can get my head around smallpox. It, 
well it started of course with cow-pox.  Immunising you against small-pox by 
giving you cow-pox. So I could understand that… It seemed to sort of relate, 
one to the other.” Alan, 71 M, person with MPM. 
 
Participants were also motivated to increase their own knowledge and understanding by 
participating in the trial, often reading up on the subject before deciding to take part. 
 
“Well, I knew [husband] would follow it to the nth degree… He’ll leave no 
stone unturned. He’s looked at all the research papers and everything. He’s 
done all the research and I’m happy just to sort of back him up. I’m 
interested, very interested, but he does all the research.” Georgina, 79 F, wife 





2.4.2.5.4. Relatives’ reluctance 
Relatives were generally supportive of their family member’s decision to participate in 
research. 
 
“He’s very up for going for things, and he wanted to help, and I supported 
him in that, as did our family.” Caroline, 71 F, wife of person with MPM. 
 
“I’ll back him up. Whatever he wants to do I’ll back him up.” Georgina, 79 F, 
wife of person with MPM. 
 
“Everything we do is a joint decision.” Eleanor 81 F, wife of person with 
MPM. 
 
However, they also expressed a greater degree of reluctance regarding trial 
participation and were more likely to recognise the potential downsides of taking part.  
 
“I wasn’t keen for [husband] to be involved, to be honest... If he’d wanted, I 
would have gone along with it and supported him. It wouldn’t have thrown 
me. I’m a very strong person and it wouldn’t have thrown me at all, but I 
would rather he hadn’t done it because I know he doesn’t like being ill.” 
Georgina, 79 F, wife of person with MPM. 
 
“I’m more reticent because I’m aware of what comes afterwards in so many 






The daughter of one participant explained how she had to consider the impact of the 
trial on her mother, as well as her father.   
 
“But seeing him, well, I was worried that if he got, yeah, it’s flu and 
whatever, but it was, also, I had to think about my mum, ‘cause she’s the one 
looking after him and it’s taken its toll on her as well, so yeah.  Obviously, I’d 
support whatever decision he made, but he did need to think of my mum as 
well. She’s the one doing all the toing and froing” Janet 48 F, daughter of 
person with MPM. 
 
One relative expressed regret that her husband had participated in the trial: 
 
“Interviewer:  Do you wish [he] hadn’t done it? 
Caroline:  Sometimes, yes, sometimes.” 
Caroline, 71 F, wife of person with MPM. 
 
The same person said that she would be reluctant for her husband to participate in 
research again unless there was a very clear benefit to him.  For her, her husband’s well-
being took priority over any greater altruistic outcomes of research. 
 
“I’d like to know what good it would do him really, at the end of the day… 





is going to shorten his life even more, if I’m honest.” Caroline, 71 F, wife of 
person with MPM. 
 
2.4.2.5.5. Synopsis 
People with MPM were motivated to participate in research for multiple reasons, 
including altruism, a desire to further understanding of the disease and improve 
treatment options, and a wish to repay clinicians for their care.  As with their clinical 
care, participants had a good understanding of the science behind the research and this 
increased their interest.  Relatives, whilst supportive of their family members’ decisions, 
tended to be more guarded about research, with a greater appreciation of the potential 
downsides. 
 
2.4.2.6. Downsides of research participation 
The first participant to receive the trial medication experienced an adverse reaction, 
during which time he reported feeling very isolated.  In interview, he made several 
suggestions for improvement to the trial, the majority of which were implemented 
immediately via an amendment to the protocol (see Section 4.3.2.2.4.). 
 
Other participants were generally positive about their experience of participating in the 
trial. 
 
“I have no suggestions [for improvement], no, I think it was all good stuff” 






Participants’ views differed regarding parts of the trial that they perceived as negative or 
in need of improvement. This was likely a reflection of the different personalities and 
priorities of the participants involved. There were no specific elements of the trial that 




One participant felt that the time between consenting to receive the trial medication 
and it being administered was too short.  
 
“My only concern was there was a very short time between having the IPC 
put in and actually doing the trial. The IPC went in [on a Wednesday and a 
week later] on the Thursday…you put the BCG in. I thought that was too 
quick… with hindsight.” Alan, 71 M, person with MPM. 
 
However, his wife stated that she was comfortable with the amount of time they had 
been given to consider trial participation and with the scheduling of drug administration. 
She highlighted the urgency associated with administering treatment in MPM because 
of the short life expectancy. 
 
“Bearing in mind what we knew about the MPM there wasn’t really that 









The same person had concerns relating to organisational and logistical aspects of the 
trial.  Her experience with her husband during routine medical appointments made her 
anxious that the trial would be poorly organised. 
   
“I was worried about the chaotic way… when we come in for the meetings, 
when we come in for the consultations, invariably because so many people 
use that set of rooms, it’s always chaotic as to getting the bloods, and this, 
and that, even something as simple as weighing somebody. It didn’t instil me 
with confidence… I just thought if it’s always as chaotic as this, how are they 
going to do the TILT treatment with [husband]?” Caroline, 71 F, wife of 
person with MPM. 
 
Her concerns appeared well-founded as her husband was not satisfied with his 
experience of receiving the trial drug: 
 
“Your procedure was very inadequate.” Alan, 71 M, person with MPM. 
 
Specifically, he felt the process was disorganised and poorly planned, which instilled 






“You’d sort of get so far and then go, ‘Oh! We haven’t got a 3-way valve.’ So 
someone would go off, probably [Nurse], and come back with a 3-way valve. 
And then you’d say, ‘We’re going to need some more saline, we haven’t got 
enough’ and then she’d go off and come back, and that didn’t fill me with 
confidence.” Alan, 71 M, person with MPM. 
 
He suggested a run-through of the administration procedure would have improved the 
overall proficiency of the operation, something which was taken on board by the 
research team and will be implemented in future trials. 
 
“I felt that you would have done better if you’d have a dry run. You didn’t 
need me there. Get your team together, what are you going to do, make sure 
you’ve got all the equipment.” Alan, 71 M, person with MPM. 
 
It was possible that Alan’s experience of receiving the trial drug was affected by the 
subsequent adverse reaction that he suffered.  During her qualitative interview, his wife 
recognised the logistical difficulties inherent to any large organisations but emphasised 
that her priority was her husband. This highlighted, once again, the pattern of relatives 
adopting the role of protector on their husband’s behalf.  
 
“Yes, I’m less tolerant of what I perceive to be as inefficiency. Even though I 





monster machine that rolls along. I understand all the reasons, but I think 
when it’s down to the individual you care about, that tolerance evaporates 
very quickly.” Caroline, 71 F, wife of person with MPM. 
 
2.4.2.6.3. Communication 
Another concern raised by the same participant was that of communication. He stated 
that he would have liked more frequent contact with the research team. 
 
“But we would have expected, well we did expect to have got a phone call 
from someone else. Even if it was a quick, “Oh hi, I’m phoning on behalf of 
[Doctor]. How are you?” Alan, 71 M, person with MPM. 
 
However, others were satisfied with the amount of contact they had with researchers 
and with the amount of information they were provided.   
 
“You know what I mean, [Doctor] was always quite informative but not to 
the extent of saying this will happen or that will happen, but was always, you 
know, kept me in the picture.” Dave, 61 M, person with MPM. 
 
Participants did not report any issue with additional visits to the hospital to complete 






“Interviewer: You’ve had some visits for the TILT trial, you’ve been up to 
[hospital] a bit more often than you would have done if you 
hadn’t been in the trial… How did you find that? Was that 
troublesome at all? 
Bob:  Not really, we are retired and it takes time, but as I’ve 
already said, we’ve found a way to do it easily by using Park 
and Ride.”  
Bob, 84 M, person with MPM. 
 
“Interviewer: Coming to see us in the hospital, for some people that’s 
 quite a big deal and it’s quite stressful.  Would you say the 
same? 
Harry:   No, I wouldn’t, no… It’s the story of my life, in and out of 
hospital.” 
Harry, 74 M, person with MPM. 
 
2.4.2.6.4. Completing trial paperwork 
Participants were asked about their experience of completing trial paperwork, including 
filling in the PROMs on a daily basis for three weeks. Most participants stated they did 






“Yeah, you know, those little tick sheets take half a minute, don’t they? It is 
not like you are having to write a ten-page essay every day, no, it is nothing.” 
Dave, 61 M, person with MPM. 
 
One man did not particularly enjoy completing the PROMs as it drew attention to his 
lack of symptoms and made him feel like a charlatan. This echoed previous themes 
around the tendency of men with MPM to downplay their symptoms and look for the 
positives in their situation. 
 
“Answering all the questions isn’t one of my favourite occupations, because 
mainly the questions are asking me if I’ve got something wrong with this or 
this or this or this, and I haven’t. I am a fraud!” Bob, 84 M, person with MPM. 
 
2.4.2.6.5. Synopsis 
In general, participants were positive about their experience of participating in the trial, 
with few mentioning any downsides or areas for improvement.  One participant, who 
had a serious adverse reaction to the trial drug, described certain factors that worsened 
his experience, including a lack of communication with the trial team and a general 
sense of disorganisation.  His wife felt similarly on many of these matters but had insight 
into the fact that her outlook had been influenced by her concern for her husband. 
Overall participating in the trial was acceptable to participants and relatives, although 






2.4.2.7. Specific TwiC features 
The TwiC methodology was explained to participants during qualitative interviews and 
their thoughts elicited. Participants often commented spontaneously on the areas of the 
TwiC design that had been considered potentially beneficial for this population.  In 
general, the rationale for choosing the TwiC design was validated by these comments. 
 
2.4.2.7.1. Lack of placebo 
Most participants were aware that clinical trials often included a placebo arm.  Their 
views on the inclusion of a placebo in trials differed, with one person declaring that he 
would not wish to join a trial if there was a chance he would receive a placebo. 
 
“I don’t think I would have wanted to do a trial knowing that I would have 
been given a placebo.” Dave, 61 M, person with MPM. 
 
Other people were more amenable to the idea, recognising the existence and potential 
benefits of the placebo effect. 
 
“Years ago, I’d have said I’d like to know, and possibly I still would but I have 
seen the results of placebo as well, and that’s put off the evil moment for a 
long time because the body did something, or the mind did something, and I 
think, it’s something I don’t understand, but it is very powerful in some cases.  
So if you say, yeah sometimes a placebo if you don’t know it’s a placebo, 





that control of your head doing it works.” Caroline, 71 F, wife of person with 
MPM. 
 
Most people were pleased that the intervention arm of the trial was open-label. 
Knowing that they had been selected to receive the trial drug reduced uncertainty and 
made the decision over whether to participate easier. 
 
“What I did take from it from it… is that I was quite glad that, you know how 
trials are blinded, is that the right word? And therefore, you don’t know if 
you are getting the placebo or not. I was quite glad to find out that actually 
you talked because I think that, I don’t know, I think it would have made an 
impact. I think, again, that would have caused more conversations about if 
we should go for it or not.  If he had come back and said, ‘Oh yes, I can get on 
the trial but I don’t know what I am having,’ then I don’t know if the outcome 
would have been the same.” Kate, 43 F, daughter-in-law of person with 
MPM. 
 
2.4.2.7.2. Blinding of controls 
A key element of the TwiC design is blinding control participants to the existence of the 
trial. The justification for this is that it can reduce control patients’ disappointment at 
not receiving the trial medication, particularly in conditions where treatment options 





appeared to be the case in people with MPM as several participants admitted they had 
hoped to receive the trial drug. 
 
“I signed up to the trial, or tried to sign up to the trial, for a number of 
reasons. The first was, looking at the data I had the impression that there 
could be an enhancement [in survival].” Frank, 81 M, person with MPM. 
 
“Dave:  I know you have to do a comparison, but I would not have 
been happy with a, well, just given a cup of tea… 
Interviewer:  So, you were in it to get the drug? 
Dave:  Yeah.” 
Dave, 61 M, person with MPM. 
 
Unfortunately, it was not possible to maintain blinding of controls in TILT, and all 
participants were aware of the trial before randomisation.  On finding out they had not 
been selected to receive the trial drug, unblinded control participants expressed 
disappointment, although this was handled with the usual stoicism and acceptance. 
 
“He was so disappointed.” Georgina, 79 F, wife of person with MPM. 
 
“Yes, I was keen, but when the computer put me in the other side, even 
though I was keen I thought, ‘Fate has put me in the other half’, and that’s 






Another potential benefit of TwiCs is reducing contamination if control participants, in 
their eagerness to receive the trial treatment, obtain it independently from the trial. 
Again, this appeared relevant to the MPM population, as one unblinded control 
participant explicitly asked whether he could receive the trial medication outside the 
trial. 
 
“When [Doctor] looked at the computer and decided that I wasn’t going to 
be on the trial, I said, ‘Could I have the chemical added as a separate issue?’” 
Frank, 81 M, person with MPM. 
 
Another person believed he could request to be switched to the active trial arm if 
initially allocated to control. 
 
“I put my name forward for [TILT] but I didn’t get to be in the positive one, I 
was going to be a controlled one, although I’m sure they would have 
changed me.” Bob, 84 M, person with MPM. 
 
If it had been successful, blinding of controls could have reduced the disappointment 
experienced by controls and the risk of contamination from participants seeking the trial 
treatment elsewhere. However, ethicists have discussed the potential harm associated 
with withholding information from control participants and the possibility of it damaging 





expressed concern about the possibility of being blinded as a control.  Participants were 
happy to put their trust in doctors and be provided with information as determined by 
them.  They did not feel that blinding would result in controls feeling deceived or misled. 
 
“I think possibly, if you don’t know about it, you’re not losing out on 
anything.” Caroline, 71 F, wife of person with MPM. 
 
“I put my faith in anybody. You know, I rely on absolutely everything [Doctor] 
said. If she tells me it is black, it is black.” Dave, 61 M, person with MPM. 
 
2.4.2.7.3. Attrition 
A potential problem with the TwiC design is participant attrition after randomisation. 
This is particularly pertinent to people allocated to the intervention arm who only hear 
about the intervention once randomisation has occurred.  In TILT, one participant chose 
not to receive BCG after being allocated to receive it and another person declined to be 
followed up at the trial centre having been allocated to the control arm.   
 
The participant who declined to receive BCG did so based on concern about side effects.  
Having had an IPC inserted, his breathing was the best it had been for some years and 
did not want to jeopardise this.  His decision not to participate was not taken lightly, and 







“Harry:    When I got home, 
Ida:  Yeah, you did have second thoughts. 
Harry:  Yeah, I did… I told [Nurse] about the [trial] I backed out of…  
   Well, I felt a bit guilty actually.” 
           Harry, 74 M, person with MPM and Ida, 72 F, his wife. 
 
The same gentleman was more than willing to continue participating in the 
observational cohort study and said he would be prepared to consider other trials of 
investigational medicinal products in the future, depending on how he was feeling at the 
time. 
 
“If I can help in that way, then I will… I’d certainly try a new drug… Course I 
would, yeah, if I’m fit.” Harry, 74 M, person with MPM.  
 
However, it is important to note that despite Harry’s wiliness to participate in future 
trials, a future TwiC would once again involve him being randomised before being told 
anything about the trial.  Given his (very reasonable) wish to assess his physical 
condition at the time before deciding to join another trial, it’s possible that he may 
choose not to participate again.  For Harry, the decision to join a trial required 
contemporaneous assessment of his health and careful consideration of the risks and 
benefits of the trial intervention.  In a standard RCT, this process would occur at the 
outset, but with the TwiC model it occur after randomisation has taken place.  Harry was 





had already been selected to receive the intervention.  This may have placed a greater 
emotional burden on him as he felt that he was actively “backing out” of a trial, rather 
than simply not signing up in the first place (as would be the case with a standard RCT).  
 
The other participant who withdrew from TILT had been allocated to the control arm 
and was unblinded to this allocation.  He was not interviewed as he was nearing the end 
of his life when he was invited to join the qualitative study.  His daughter-in-law was 
interviewed and described his motivation for declining follow up at the trial centre. 
 
“[Larry] had already said he can’t see the point in this, because of going all 
the way down there and the impact on just going there… if it is not going to 
do anything.” Kate, 43 F, daughter-in-law of person with MPM. 
 
She explained that because he knew he had been allocated to the control arm, he did 
not feel it was worth the effort to travel to a different hospital.  She believed that he 
would have agreed to participate if he had been randomised to receive the trial drug. 
 
“I do think if you had given the facts and he was getting the drug, he would 
have had it because he would have been very, ‘I am going to try it and it’s a 
trial,’ so it’s not like, erm, I think he would have tried it, I think he would have 






Although she was less certain, she also believed he would have agreed to participate 
had the trial been a blinded placebo-controlled RCT. 
 
“If you do think you are offered something, are you going to miss out on it? 
Do you know what I mean? If you are offered [a trial] … even a placebo one, 
you are still offered that… and then you think, ‘Well if I don’t go for that, 
what am I going to get?’” Kate, 43 F, daughter-in-law of person with MPM. 
 
Kate was keen for her father-in-law to be considered for future trials, which was made 
possible with the TwiC methodology and Larry’s ongoing participation in ASSESS-meso 
at his local hospital.  She found this aspect of the TwiC design positive.  
 
“I was worried about, then, if he wasn’t on the list for TILT any more… would 
that mean that if any other trials came up he would fall through the net. And 
he went, ‘Oh no no no, he has explained to me that actually you would stay 
on a register,’ and I said, ‘Well that’s alright then.’” Kate, 43 F, daughter-in-
law of person with MPM. 
  
However, if future trials were based at hospitals other than their local one, blinding 
would have to be breached in order to invite Larry up to the trial centre to undergo 
randomisation. It seemed probable that if he were allocated to the control arm again, 






Certain elements of the TwiC methodology were implicated in both participants’ 
decision not to participate in the trial.  Although both people were keen to be 
considered for future trials – an opportunity that the TwiC design facilitated – if the 
same approach was used, the chances of further post-randomisation attrition seemed 
high.  Clearly post-randomisation attrition is an important consideration with the TwiC 
design, particularly if it is to be used for trials with people with high symptom burdens, 
limited life expectancy, or using an interventions with a high risk of side effects. 
 
2.4.2.7.4. Synopsis 
Participants were pleased that the trial was unblinded, as this reduced uncertainty and 
helped with decision-making around participation.  However, the failure to blind control 
participants led to some people feeling disappointed when they were not selected to 
receive the trial drug.  This could have increased the likelihood of contamination 
between the trial arms, had the trial medication been available elsewhere.  Other 
elements of the TwiC methodology may have contributed to the post-randomisation 
attrition of two participants.  Overall, the TwiC design was considered acceptable by trial 
participants and their relatives.  
 
2.5. Summary of findings 
The qualitative study described peoples’ experiences of having MPM and participating in 
the TILT trial, as well as that of their relatives.  The identified themes related to both 
trial participants and relatives, although perspectives often differed between the two 






Some sub-themes have been described previously, including the stoicism of MPM 
patients, the importance placed on physical strength and the tendency of relatives to 
take on the role of advocates and fight of their loved one’s behalf.(174) This study adds 
to the existing data by highlighting the importance placed on quality of life and the role 
this plays in decision-making.  Another important finding was MPM patients’ desire for 
certainty and difficulty accepting uncertainty. This had implications in the interpretation 
and understanding of risk, which in turn has important consequences for clinical and 
academic practice in MPM populations.   
 
With one notable exception, experiences of trial participation were positive.  The TwiC 
methodology was acceptable to everyone.  People with MPM were found to be highly 






6. Chapter 6 – Discussion 
6.1. Introduction 
The final chapter of this thesis is in four parts.  The key findings of the research are 
summarised with respect to the stated objectives of the thesis (section 6.2), before 
being interpreted in the context of the existing literature (section 6.3).  The strengths 
and weaknesses of each work-stream are discussed (section 6.4) and finally, the 
implications for future research are considered (section 6.5). 
 
6.2. Summary of key findings  
The overall aim of this thesis was to explore the role of intra-pleural bacterial 
immunotherapy in MPM and to determine whether a full-scale trial of intra-pleural BCG 
or OK432 was warranted, feasible and acceptable.  This was achieved via four specific 
objectives. 
 
The first part of the research, and the first two objectives of the thesis, investigated 
whether bacteria in the pleural space were associated with longer survival in pleural 
malignancy.  This question was addressed by reviewing the existing literature relating to 
intra-pleural bacterial products in MPE and by performing a population-level cohort 
analysis of survival in mesothelioma patients with spontaneous bacteria in the pleural 
space (pleural infection). 
 Key finding 1 – There was no strong evidence to support the hypothesis that 







 Key finding 2 – Pleural infection was associated with higher short- and long-term 
mortality in people with mesothelioma. 
 
The second stage of the research and the final two objectives of the thesis focussed on 
the feasibility and acceptability of a randomised trial of intra-pleural bacterial 
immunotherapy in MPM, and of using the TwiC methodology to conduct a CTIMP in this 
population.  Objective three addressed the feasibility element via a feasibility trial.  
 Key finding 3 – It was possible to design and execute a CTIMP using the TwiC 
methodology and to obtain the requisite approvals from the Research Ethics 
Committee, the HRA and the MHRA. 
 
 Key finding 4 – The TwiC methodology was not suitable for trials in people with 
MPM, as blinding of control participants was rarely possible, recruitment was 
negatively impacted by attempts to maintain blinding and significant attrition 
occurred post-randomisation.  
 
 Key finding 5 – Recruitment to the trial was challenging, due to fewer eligible 
patients with non-loculated effusions, expandable lung and functioning IPCs in 
situ than originally anticipated.  
 
 Key finding 6 – Intra-pleural bacterial agents were associated with a significant 






The fourth and final objective of the thesis was to evaluate the acceptability of the TILT 
trial and the TwiC design to participants and their relatives. Qualitative interviews were 
performed to explore this, which yielded several other important findings about the 
experience of living with MPM. 
 Key finding 7 – People with MPM were highly motivated by quality of life rather 
than longevity and this influenced their decision-making with regard to systemic 
anti-cancer treatment and clinical trial participation. 
 
 Key finding 8 – People with MPM valued certainty and were uncomfortable with 
uncertainty and unpredictability.  This had important consequences around risk 
communication, in both clinical and research settings. 
 
 Key finding 9 – Participants and their relatives were engaged and well-informed 
about MPM and about research. People chose to participate in TILT due to a 
combination of altruism, scientific interest and potential personal gain, and all 
participants found the TwiC methodology acceptable. 
 
 Key finding 10 – For people with MPM and their relatives, thoughts of the future 
were associated with anxiety and grief for lost opportunities.  Whilst people with 
MPM tended to be stoical, their relatives were less accepting and often took on 
the role of advocate for their family member.  The specific needs of both groups 





6.3. Interpretation of research findings 
6.3.1. Intra-pleural bacterial agents and pleural malignancy: key finding 1 
 
Key finding 1 – There was no strong evidence to support the hypothesis that intra-pleural 
bacterial agents are associated with longer survival in malignant pleural disease. 
 
The systematic review found mixed evidence relating to intra-pleural bacterial products 
in pleural malignancy.  Six studies reported a survival benefit associated with intra-
pleural bacterial products, whilst eight found no difference.  No specific bacterial 
product was more likely to be associated with a survival benefit and no particular 
underlying disease more likely to benefit.  
 
There are several possible interpretations for the findings of this review.  Firstly, the 
variety of products, doses and administration regimens used in the different studies may 
have obscured a genuine effect related to a single product or specific dose.  
Alternatively, there may be a consistent effect associated with all intra-pleural bacteria, 
but methodological issues with the studies meant they failed to demonstrate it.  Finally, 
it is possible that intra-pleural bacterial agents have no association with survival in 
pleural malignancy.   
 
With respect to the first point, it is accepted that different bacterial species and strains 
elicit differing degrees of immunological responses.  For example, gram positive and 
gram negative bacteria induce different patterns of cytokine release with varying, and 





bacterial strains or preparations can have widely varying clinical effects, as has been 
demonstrated with different BCG preparations in bladder cancer.(244)  It is plausible, 
therefore, that the lack of consistent effect noted for any single product could be a 
result of some studies, for example all of those with positive outcomes, using one strain 
whilst negative studies used an alternative, less immunogenic strain.  Additionally, doses 
and administration regimens varied, with few bacterial products having an established 
optimal dosage.  Apart from one RCT of OK432,(103) no formal dose-finding studies 
have been published for any of the bacterial products.  This could have resulted in the 
use of sub-therapeutic doses with consequent apparent inefficacy or supra-therapeutic 
dosing with associated toxicity causing higher mortality. 
 
An alternative explanation is that the studies failed to detect an effect that did exist.  
Small sample sizes and the fact that survival tended to be a secondary outcome measure 
meant that the majority of studies were under-powered to detect differences in 
mortality.  In fact, several of studies were pilot projects with no formal sample size 
calculation undertaken.  In the absence of meta-analysis, results from small individual 
studies should be interpreted with caution. 
 
Finally, it may be the case that bacterial products have no effect on survival, despite 
good evidence that they are effective pleurodesis agents.(83)  A similar effect was seen 
when chemotherapy drugs were administered intra-pleurally in malignant effusions – 
the drugs effectively caused pleurodesis but did not affect the underlying cancer or alter 





pleural cavity have limited absorption into the systemic circulation.  This has been 
shown to be the case with intra-pleural fibrinolytics in empyema.(19, 249, 250)  Since 
most MPE arise as a result of metastatic disease, with at least one tumour located 
anatomically distant from the pleura, a lack of systemic absorption following intra-
pleural administration will limit exposure of distal tumours to the agent, limiting 
efficacy.   
 
By this theory, intra-pleural drug administration would be an effective approach for 
localised pleural tumours i.e. MPM.  Delivering the drug directly into the pleural space 
would result in high concentrations of the therapeutic agent in the precise area where 
its activity is required, whilst simultaneously reducing the risk of side effects from 
systemic absorption.(18, 246)  The only study to investigate intra-pleural bacterial 
products in MPM was negative, although exclusion of 21 patients from the final analysis 
due to death, early progression of disease or loss to follow up put this study at critical 
risk of attrition bias.(182)  
 
6.3.2. Pleural infection and survival with mesothelioma: key finding 2 
 
Key finding 2 – Pleural infection was associated with higher short- and long-term 
mortality in people with mesothelioma. 
 
The cohort study demonstrated that patients with mesothelioma were more likely to die 





the longer term.  This finding was in direct contrast to previous findings that survival was 
longer in patients with MPM and an IPC in situ who developed pleural infection.(186)  
However, the initial study was small and retrospective and may have been affected by 
recall bias.  Alternatively, it may be that the presence of an IPC attenuated the risk 
associated with pleural infection by enabling regular pleural drainage and reduction in 
overall bacterial load, which was not the case for patients in the cohort study reported 
in this thesis. 
 
The cohort study replicated findings from a similar population-level study undertaken in 
Canadian patients with lung cancer.(251)  In that study, patients who underwent 
curative surgery and experienced an episode of post-operative pneumonia, empyema or 
mediastinitis had a higher mortality than those without post-operative infection 
(adjusted HR of 1.67, 95% CI 1.39–2.01).  This finding may simply reflect worse 
outcomes in patients who experienced post-operative complications, but the similarity 
of the hazard ratio to that seen in the mesothelioma cohort supports the possibility of a 
genuine association between pleural infection and higher mortality. 
 
Causality could not be determined from this observational study and for several 
variables the association with mortality may have represented a bi-directional or circular 
relationship.  For example, although it is acknowledged that patients who underwent 
multiple pleural interventions were at higher risk of pleural infection, once infection 
occurred, they automatically required more interventions to manage it.  As mentioned 





i.e. it may be that dying patients were more likely to develop pleural infection, rather 
than infection being implicated in shortening their life. 
 
In interpreting the results of the cohort study, it is important to recognise the distinction 
between statistical significance and clinical meaningfulness.  The large sample size 
meant that a high level of statistical power was achieved, with p values below the 5% 
significance level for several analyses.  However, p values provide no information on the 
size of an effect or its clinical relevance.  For example, whilst the variable ‘comorbidities’ 
was associated with a statistically significant reduction in mortality (p<0.001), a HR of 
0.99 is unlikely to represent a meaningful survival benefit.  Additionally, the idea of a 
threshold p value of 0.05, below which results can be accepted as “true” is controversial.  
It is preferable to interpret p-values in absolute terms, as a measure of the strength of 
an association and the results of this study are best interpreted using this 
approach.(252)  Importantly, the hazard associated with pleural infection in this study 
was both clinically meaningful and statistically strong. 
 
Several of the findings from the cohort study were in accordance with previous 
observational work regarding prognostic factors in mesothelioma.  Male gender and 
increasing age have been shown repeatedly to be associated with shorter survival,(1, 
253) whilst being diagnosed during an acute or emergency presentation rather than in 
outpatient clinic is a poor prognostic indicator in several cancer types.(254) Meanwhile 
socio-economic position is a predictor of outcome in many medical conditions, both 






It was anticipated that chemotherapy would be associated with enhanced survival, given 
its proven therapeutic role.(4, 5)  That said, the overall survival benefit associated with 
chemotherapy was relatively small.  This reflects the fact that for several years during 
the study period there was no standard of care chemotherapy for mesothelioma and 
ineffective agents were used, in the absence of any better options.  Following the 
introduction of pemetrexed and cisplatin doublet regimen in 2008, survival outcomes 
improved.  However, the mortality benefit seen in patients diagnosed after 2008 
remained modest, due to the limited efficacy and low response rates associated with 
current chemotherapy regimens.(4, 47)  
 
Regarding other treatment modalities, radiotherapy has no role in the radical treatment 
of mesothelioma, although it can be an effective measure for pain control.(1)  The 
cohort data corroborated this. Surgery is rarely performed for MPM in the UK and RCT 
evidence has suggested it is associated with worse outcomes.(257, 258) The British 
Thoracic Society advocates against surgery apart from in the clinical trial setting; a 
recommendation that these data support.(1)  
 
The longer survival associated with thoracoscopy and pleurodesis was likely to be the 
result of confounding.  Thoracoscopy and pleurodesis are undertaken for diagnostic and 
symptom management purposes and do not have any disease modifying ability.  The 
lower mortality associated with these interventions was likely to have resulted from 





be sufficiently fit, and this fitness determined their subsequent survival rather than the 
intervention.  The corollary of this is that patients in whom thoracoscopy was contra-
indicated (e.g. due to frailty) were more likely to be investigated via less-invasive 
pathways, i.e. percutaneous biopsies, and thus survival was worse in this group.  
Similarly, pleurodesis is generally undertaken in patients who are expected to live long 
enough for recurrent fluid to be a problem, whilst patients with shorter life expectancy 
are often treated with recurrent aspirations.  
 
6.3.3. Applying the TwiC design to a CTIMP: key finding 3 
 
Key finding 3 – It was possible to design and execute a CTIMP using the TwiC 
methodology, and to obtain the requisite approvals from the Research Ethics Committee, 
the HRA and the MHRA. 
 
Prior to TILT, the TwiC methodology had been used to undertake trials relating to a 
range of research areas in multiple countries across Europe and North America.(197-
199, 259) However, no CTIMP had ever been performed using the TwiC design.  Given 
the increased regulatory requirements for CTIMPs, and specifically declaration 4.8.10(c) 
of ICH GCP that states all participants in a CTIMP must be informed about the IMP and 
the probability of being assigned to it, careful consideration was required when 
designing TILT to ensure the trial was fully compliant and legal.(202, 206) This was 
achieved by clearly separating patients into trial participants (people who had been 





control participants in the cohort (people who had been randomised to control and had 
not signed the TILT consent form).   
 
The consequence of separating patients in this way was that all research activities 
needed to be clearly and precisely defined as either trial-related or cohort-related.  By 
determining this at the outset, the protocols for ASSESS-meso and TILT were clear and 
explicit about what activities related to which part of the research. Additionally, the 
consent forms for each study contained specific points relating to the activities that 
would be performed as part of that study.  For example the ASSESS-meso consent form 
asked participants to consent to undergo screening for future trials, to be randomly 
selected for trials and to allow their information to be used as comparison data for 
future trials, even if they had not been selected to participate.  This created an 
unambiguous record of the activities each participant had agreed to undergo and a clear 
documentation of whether they were participating in the cohort study, the trial, or both. 
I believe this clarity facilitated the process of obtaining the necessary regulatory 
approvals, specifically from the MHRA. 
 
Another approach that helped secure Research Ethics Committee approval was 
submitting the proposals for ASSESS-meso and TILT to the same committee and 
physically attending both meetings when the projects were discussed. The concept of 
TwiCs was discussed in depth at the initial meeting (when ASSESS-meso was under 
review) and the committee were able to resolve some minor concerns that they had 





was reviewed by the same committee 2 months later, they were familiar with the idea 
and approved it with no further concerns. 
 
I believe that TILT has set a precedent for future CTIMP TwiCs to follow.  Since TILT 
began, I have been approached by several research teams around the UK who were 
designing and planning CTIMP TwiCs of their own.  I have shared the TILT documents 
with these teams, and several of the trials are now up and running, having been granted 
the necessary approvals.  Most recently, a large UK-wide COVID-19 cohort has been 
established as a resource for future TwiCs (COVIDENCE-UK - 
https://www.qmul.ac.uk/covidence/about-the-covidence-uk-study/).  On the request of 
the PI of that study, I shared the TILT documents with the team and agreed for the exact 
same wording to be used in the COVIDENCE PIS and consent form. 
 
6.3.4. Performing TwiCs in the mesothelioma setting: key finding 4 
 
Key finding 4 – The TwiC methodology was not suitable for trials in people with MPM, as 
blinding of control participants was rarely possible, recruitment was negatively impacted 
by attempts to maintain blinding and significant attrition occurred post-randomisation. 
 
One of the fundamental elements of the TwiC methodology relates to control 
participants not being informed about the existence of the trial.  This mimics usual 
clinical care and aims to reduce the risk of disappointment if participants had been 





was not possible to blind control participants in TILT as all participants were aware of 
the trial prior to randomisation.  Universally, this was a result of individuals’ 
engagement with research processes and active enquiry about research opportunities. 
 
Qualitative interviews with participants revealed that they were highly motivated with 
regard to their healthcare and well informed about current and potential future 
treatment options.  Participants were actively supportive of research to advance 
mesothelioma care and would often seek out information about clinical trials in the 
hope of participating.  Clinicians have reported similar experiences working with MPM 
patients on a day-to-day basis.(260)  This created a quandary as, whilst high levels of 
patient activation are desirable, in TILT active patient engagement rendered blinding of 
controls impossible.  Since no clinician or researcher would ever advocate for reduced 
patient activation, it seems that this element of the TwiC methodology is not achievable 
in MPM populations.  
 
Additionally, attempts to maintain blinding of control participants (before researchers 
became aware that their efforts had failed) meant that the trial was not advertised on 
the clinical trial sections of websites such as Mesothelioma UK and Cancer Research UK.  
This limited recruitment from the wider MPM community.  Similarly, whilst patients 
from other centres were screened for eligibility at the regional mesothelioma MDT, they 
could not be explicitly invited to attend the trial site to discuss the trial, as to do so 






Although missing data was not a large problem in TILT, it appeared that data was more 
likely to be missing in control participants.  In particular, no control participants 
returned the daily VAS booklet.  Control participants were also more likely to have 
missed study follow-up visits.  This could be a result of people being less motivated to 
attend study visits or complete the booklet because they did not realise they were 
providing data for the trial (or because they did and knew they were not in the 
intervention arm, so were disincentivised to complete trial data collection).   
 
Alternatively, the fact that these people were officially only participating in the cohort 
study may have created confusion for research teams at recruiting sites.  Although the 
protocol clearly stated that the follow up schedule for control patients must be altered 
to match the TILT regimen, it is feasible that research teams (and patients themselves) 
were established in the routine of ASSESS-meso follow up visits and failed to amend the 
research schedule accordingly.  It is also possible that control patients were simply not 
recognised as providing comparison data for the trial.  Either way, the lower data 
completeness rates was likely to be a result of controls not being officially labelled as 
trial participants.  Since it was a necessary requirement in order to comply with clinical 
trials regulations that controls only participated in the cohort, the risk of lower quality 
data in the control arm must be acknowledged as a risk in CTIMP TwiCs. 
 
Other elements of the TwiC methodology contributed to the lack of TILT feasibility. 
Because participants were randomised before being given any information about the 





randomisation.  On qualitative interviewing, he revealed that he was concerned about 
the potential side effects outlined in the PIS, particularly because at the time of 
randomisation he felt better than he had for many years.  Like many TILT participants 
and patients with MPM, he wished to prioritise quality of life over potential 
longevity.(48) 
 
The magnitude and impact of post-randomisation attrition will vary depending on the 
nature of the trial intervention and the likelihood and severity of side effects.  It is 
possible that a non-pharmacological intervention would be more acceptable to people 
with MPM, and a TwiC of such an intervention would be less vulnerable to post-
randomisation attrition.  However, given that all medications have some form of side 
effects, and anti-cancer agents are notoriously problematic in this regard, it seems that 
a CTIMP TwiC in MPM patients will inevitably suffer from some degree of post-
randomisation attrition. 
 
Post-randomisation attrition could have several undesirable consequences if it occurred 
in a full-scale trial.  If many participants were to withdraw after randomisation, the 
study would be underpowered to detect the estimated effect based on the original 
sample size calculation.  One way of addressing this would be to include in a larger 
“correction factor” in the sample size estimate to allow for potential attrition. 
Alternatively, recruitment could be continued until the target number of participants 






Post-randomisation attrition also introduces potential bias. Traditionally, RCTs are 
analysed on an intention to treat (ITT) basis, based on allocation at randomisation.  
However, with a TwiC, attrition is likely to affect the intervention arm disproportionately 
because people randomised to the control arm are not asked to provide further consent 
after randomisation and, therefore, have fewer opportunities to decline participation.  
The TwiC design enables outcome data to be collected on people who decline the 
intervention (assuming they agree to continue follow up in the cohort), so ITT analysis 
can be performed and can include the data of all participants randomised. However, 
differential attrition affecting the intervention arm could attenuate or negate a positive 
treatment effect, depending on how many people were included in the final analysis 
despite not receiving the trial agent. 
 
An alternative is a per protocol (PP) analysis, where only the data of people who 
received the treatment to which they were allocated are used in the analysis.  However, 
there are likely to be inherent differences between people who decline to participate in 
trials and those who agree, so excluding non-participators from the intervention arm 
but not the control arm (as they have not had the chance to decline participation) will 
again result in mismatched trial groups.  Applying PP analysis to TwiC data is likely to 
result in an overestimate of the effect of the trial intervention, as “non-participators”, 
who are likely to have poorer outcomes generally, are still included in the control group 






Perhaps the most appropriate analysis plan to adjust for differential attrition in TwiCs is 
compliance-averaged causal effects (CACE) modelling, a form of instrumental variable 
analysis.  Instrumental variable analysis allows estimation of the effect of an exposure 
on a chosen outcome, accounting for potential unmeasured confounding by the use of 
an unbiased instrument that independently predicts the exposure.(261)  For example, in 
a clinical trial, allocation at randomisation (Z) is associated with exposure to the 
intervention (X) with no direct effect on outcome (Y) apart from via the exposure (Figure 
6-1).  The strength of the association between randomisation and intervention is 








To apply instrumental variable analysis to a TwiC, certain assumptions are required.  
Firstly, that a similar proportion of people in the control arm would have declined an 
intervention had they been offered one. Secondly, that theoretical non-compliers in the 
control arm would have similar characteristics to the known non-compliers in the 










Figure 6.1 Instrumental variable analysis to estimate the effect of an intervention (X) on an 
outcome (Y), using allocation to randomisation (Z) as the instrumental variable.  The relationship 
between allocation at randomisation and exposure to intervention is mediated by post-





outcome.  If these assumptions are valid, the proportion of people who would have 
declined participation in the control arm can be derived and their outcomes 
extrapolated from non-participators in the intervention arm.  In this way, outcomes can 
be calculated for theoretically compliant controls and compared to outcomes of the 
known compliers in the intervention arm to generate an estimation of the direct effect 
of the intervention on the outcome (Table 6-1).(158) 
 
a) Intervention arm Control arm 
 N Events Event rate N Events Event rate 
Compliers 900 90 0.1 ? ? ? 
Non-compliers 100 20 0.2 ? ? ? 
Total 1000 110 0.11 1000 150 0.15 
 
b) Intervention arm Control arm 
 N Events Event rate N Events Event rate 
Compliers 900 90 0.1 ? ? ? 
Non-compliers 100 20 0.2 100 20 0.2 
Total 1000 110 0.11 1000 150 0.15 
 
c) Intervention arm Control arm 
 N Events Event rate N Events Event rate 
Compliers 900 90 0.1 900 130 0.14 
Non-compliers 100 20 0.2 100 20 0.2 
Total 1000 110 0.11 1000 150 0.15 
 
Table 6-1 Worked example of CACE analysis a) Data collected during trial b) With extrapolated 





Instrumental variable analysis of TwiC data was compared with ITT and PP approaches in 
a simulation study, using differing levels of non-participation.(156)  The instrumental 
variable models were less biased than the other two methods at all levels of non-
compliance.  However, they suffered from lower power, as would be expected due to 
smaller participant numbers being used in the final analysis.  PP and ITT both 
underestimated the effect size, whilst overestimates were noted with the instrumental 
variable approaches.   
 
The different options for analysing TwiC data must be considered within the context of 
the overall research focus, specifically, whether a pragmatic or explanatory result is 
desired.  As a pragmatic research method that aims to yield effectiveness data relating 
to real-world outcomes, it could be reasoned that ITT analysis is the correct approach 
for TwiCs.  If a researcher wishes to know how many people would benefit from a 
certain treatment if it were widely prescribed in the general population, then an analysis 
that includes the outcomes of people who chose not to take the treatment, i.e. ITT, will 
provide that answer, with all the biases and confounding factors that would affect it in 
real life.  A methodological purist might argue that applying the CACE analysis to TwiC 
data is an inappropriate attempt to extract efficacy outcomes from a pragmatic trial, 
rather than the effectiveness outcomes it is intended to supply. 
 
In summary, certain elements of the TwiC design, such as blinding of controls and 
participants only being informed about the intervention after randomisation, were 





aspects of the trial meant that TILT did not replicate the TwiC methodology in its truest 
form and, consequently, many of the expected benefits were lost.  It is, therefore, not 
an ideal methodology to use for MPM trials. 
 
However, rather than dismiss the TwiC methodology entirely in MPM, a modified TwiC 
approach may be workable in this population.  Using an existing cohort to screen people 
for trial eligibility has obvious benefits in a rare disease that has patchy geographical 
distribution and patients who are willing to travel to be involved in research.  There is 
scope to broaden the coverage of ASSESS-meso across the UK and to embed trial 
screening questions into the regular study visits.  In this way, smaller, less research-
active sites would screen patients at every visit and be alerted if someone were 
potentially eligible for a clinical trial elsewhere.  They could then be offered the 
opportunity to travel to the trial centre to discuss the trial in greater detail.  Since many 
RCTs of oncological treatments in MPM have similar eligibility criteria, the screening 
questionnaire would not be particularly onerous or time-consuming. 
 
Equally, there is no reason not to embed a standard double-blind RCT design within an 
existing cohort.  This would remove several of the TwiC feasibility issues identified 
during TILT, as well as removing the methodological gymnastics required to ensure the 
TwiC complies with CTIMP regulatory requirements.  By embedding an RCT within a 
cohort, certain TwiC benefits could be maintained, for example data collection on 
people who withdraw from the trial and collection of long-term outcome measures, e.g. 






6.3.5. Recruitment and eligibility: key finding 5 
 
Key finding 5 – Recruitment to the trial was challenging, due to fewer eligible patients 
with non-loculated effusions, expandable lung and functioning IPCs in situ than initially 
anticipated.  
 
When TILT was initially designed, there were no data available to inform estimates of 
eligibility within the MPM population.  Specifically, nothing had been published relating 
to the proportion of people with MPM who were not actively receiving chemotherapy, 
nor on the number of MPM patients who had an IPC in situ in the absence of non-
expandable lung (NEL).  Hence, it was difficult to estimate the proportion of patients 
with MPM that would meet the eligibility criteria for TILT and recruitment rates were 
hard to predict at trial initiation. 
 
After the study opened to recruitment, two papers were published reporting relevant 
data.  The first described the number of MPM patients who were eligible for 
chemotherapy but chose not to receive it.  Of 139 patients offered first-line 
chemotherapy, 46 (33.1%) declined to receive it, opting for conservative care 
instead.(48)  These people would have been eligible for TILT upon making that decision, 






The second study, published after TILT opened to recruitment, reported the presence of 
pleural effusions, with and without NEL in a clinical cohort of patients with MPM.  As 
expected, pleural effusions were commonplace, occurring in 83% of people at diagnosis, 
but the prevalence of NEL was considerably higher than previously expected, occurring 
in 33% of people with effusions.(39)  Just 55% of people with newly-diagnosed MPM 
had a pleural effusion with expandable lung. 
 
A rough calculation based on these two papers revealed that just 18% of people with 
MPM were eligible for TILT at the point of diagnosis, based on the chemotherapy and 
NEL criteria alone.  This pool of potential participants would be reduced further 
following application of the remaining eligibility criteria, although to what extent cannot 
be predicted.  Whilst the pool of potentially eligible people may have been boosted by 
patients later in their disease course who had completed frontline chemotherapy, this 
relies on their performance status and predicted survival still meeting the necessary 
inclusion criteria. In reality, this cohort is unlikely to be particularly sizeable. 
 
If a full-scale trial of intra-pleural immunotherapy were planned, these influential 
eligibility criteria would have to be given due consideration.  A compelling safety 
argument can be made for avoiding chemotherapy whilst administering live bacteria to 
patients.  All chemotherapy agents are potent immunosuppressors and carry a high risk 
of neutropaenia and associated sepsis.(262)  Combining this with administration of live 
bacteria could expose patients to significant harm.  Hence, ongoing or recent receipt of 






Although agents can be delivered into the pleural space in the absence of an IPC, e.g. 
using pleural aspiration equipment, the inevitable inflammatory response caused by 
intra-pleural bacterial agents and the resultant increase in pleural fluid production 
means that some form of drainage is necessary in the days following administration.  
The options for managing this include inpatient admission for a temporary chest drain or 
outpatient management with an IPC.  The latter seems favourable in the palliative 
population and given the risks associated with inpatient hospital stays.  Therefore, an 
IPC is a pre-requisite for intra-pleural bacterial immunotherapy.  However, this does not 
necessarily mean that the patient must have a pleural effusion at enrolment.  Previous 
studies have inserted IPCs into patients with minimal or no effusion in order to deliver 
intra-pleural agents.(263-265)  However, this requires thoracic surgery, which not all 
patients will be suitable for.  For example, at least two TILT participants were not 
medically fit enough to undergo a general anaesthetic.  Therefore, widening the 
inclusion criteria to people without an effusion who could undergo surgical placement 
of an IPC is, again, unlikely to dramatically increase the number of eligible patients. 
 
The emergence of IPC management methods that prioritise pleurodesis, e.g. daily 
drainage regimens and talc slurry delivery via IPCs, is likely to result in a further 
reduction in the number of people who have a functioning IPC in place for a sustained 
period of time.(41, 266) This will place additional limitations on recruitment to a full-






Finally, developments in the field of MPM treatment since TILT was initiated are likely to 
impact on recruitment to a future full-scale trial. In April 2020, there was a pivotal 
breakthrough relating to first-line therapy for MPM, in the form of the CheckMate-743 
trial.(267) This phase III RCT compared standard chemotherapy (pemetrexed and 
cis/carboplatin) with a combination of two immune checkpoint inhibitors (ipilimumab 
and nivolumab) and showed a clinically meaningful extension in overall survival in the 
immunotherapy arm.  The full paper is awaited and, once published, a thorough 
evaluation will be necessary to determine whether the survival benefit outweighs the 
potential toxicity associated with combination ICI.  However, this trial is likely to lead to 
a change in the standard of care for frontline treatment of MPM. This could negatively 
impact on the number of patients eligible for a full-scale trial as more people are likely 
to accept frontline immunotherapy than chemotherapy.  Additionally, the safety of 
treating people who have received prior immunotherapy with further immunotherapy 
at a later date is unknown. Most immunotherapy trials excluded people who had 
received prior immune-based treatments and therefore offering intra-pleural bacterial 
agents to people after frontline immunotherapy is not advisable.(17, 49-51, 82) 
 
6.3.6. Clinical responses to intra-pleural bacterial agents: key finding 6 
 
Key Finding 6 – Intra-pleural bacterial agents were associated with significant local and 






All three participants who received an intra-pleural bacterial agent experienced 
remarkably similar systemic inflammatory responses.  The response began within 1 day 
of IMP administration and consisted of an increase in chest pain and breathlessness, 
with fevers and sweats occurring some days later.  The reaction was accompanied by a 
rise in serum inflammatory markers.  Usually the reaction resolved within a fortnight 
with simple analgesia and anti-inflammatory medication, however for one participant, 
symptoms persisted for the remaining 12 weeks of the study and a prolonged course of 
oral steroids. Two participants experienced reactions of such severity that hospital 
admission was necessary. 
 
This type of reaction is consistent with a cytokine release syndrome (CRS).  The 
syndrome describes a constellation of symptoms that result from the rapid release of 
inflammatory cytokines into the bloodstream following activation of immune cells, 
specifically T cells.  It is increasingly recognised as a potential complication of 
immunotherapy.  Classical symptoms and signs include fevers, breathlessness, nausea, 
fatigue and malaise, tachycardia and deranged liver function, all of which can range 
from mild to life threatening in severity.(268)  Unfortunately, and somewhat counter-
intuitively, neither the presence of CRS nor the severity of the reaction appear to 
correlate with clinical response to immunotherapy.  Data from the field of 
haematological malignancies (where immunotherapy has revolutionised the treatment 
landscape) have described many patients who experienced complete remission with no 
overt symptoms of CRS, and just as many who developed severe CRS in the absence of 






The reaction observed in TILT participants who received intra-pleural bacterial agents 
was also reminiscent of the pleural inflammatory effects seen with several pleurodesis 
agents.(270)  A network meta-analysis of interventions for MPE reported that all agents 
induced some degree of fever, chest pain and breathlessness following instillation into 
the pleural cavity.(271)  Essentially, anything that causes irritation of the pleural 
mesothelium leads to the release of chemokines such as interleukin-8 (IL-8) that attract 
neutrophils to the pleural space.  The presence of activated neutrophils induces the 
mesothelium to secrete further pro-inflammatory cytokines, such as TGF-β and basic 
fibroblast growth factor, which perpetuate the inflammatory pathway.(272) 
 
It was, therefore, unsurprising that combining a non-selective immunotherapeutic agent 
with intra-pleural administration led to profound local and systemic CRS and 
inflammatory responses.  Similar reactions have been described following intra-pleural 
administration of oncolytic viruses and viral vectors for gene therapy in people with 
MPM. A phase I trial of intra-pleural adenovirus vector encoding human IFN-α (Ad.IFN-
α2b) required dose-reduction after the first 3 patients treated all experienced severe 
flu-like symptoms with high systemic and pleural interferon-α (IFN-α) levels.(273)  
Symptoms began within 8 hours of administration and, in some patients, lasted for 7-10 
days.  The subsequent 6 participants, treated with a lower dose, similarly experienced 






The subsequent trial of Ad.IFN-α2b added an anti-inflammatory medication in the form 
of 14 days of celecoxib (a COX II antagonist) to be given alongside the viral vector.(263)  
Despite this, there were 39 episodes of CRS recorded in 40 participants who received 
the Ad.IFN-α2b, although all were mild, with no events more serious than Grade 2.  
Most CRS symptoms resolved within 48 hours.  However, 8 participants declined to 
receive a second dose of Ad.IFN-α2b due to the side effects of the initial administration. 
The researchers identified a sub-group of participants who experienced mild but 
persistent symptoms of malaise, anorexia and low-grade fevers that endured for several 
days.  This was assumed to be secondary to systemic effects of IFN, based on the 
similarity with side effects seen when intravenous IFN was used in other conditions.  
 
Another study used an oncolytic mutant of herpes simplex virus administered intra-
pleurally.(274)  Analysis of pleural fluid samples from the first 9 patients revealed 
increased levels of interferon γ (IFN-γ), TNFα and interleukin 6 (IL-6) in most people, as 
well as the IFN-γ associated cytokines IFN-γ-induced protein 10 (IP-10) and monokine 
induced by IFN-γ (MIG). Some participants also demonstrated rises in pleural fluid 
concentration of VEGF, interleukin 2 (IL-2), interleukin 10 (IL-10) and interleukin (IL-12) 
after virus administration, but these responses were less consistent.  
 
Future trials of intra-pleural immunotherapies should be aware of the likely systemic 
inflammatory response/CRS associated with their use.  Participants should be counselled 
about the risk of this side effect, particularly participants with MPM in light of their 





trials should consider the addition of a regular anti-pyretic, with or without a concurrent 
anti-inflammatory to mitigate the risk and severity of possible inflammatory reactions. 
 
6.3.7. Patients’ priorities with mesothelioma: key finding 7 
 
Key finding 7 – People with MPM were highly motivated by quality of life rather than 
longevity, and this influenced their decision-making with regard to systemic anti-cancer 
treatment and clinical trial participation. 
 
Several participants in TILT had chosen not to receive chemotherapy, despite being 
medically suitable to receive it.  Universally, this decision was based on a desire to 
maintain quality of life and concern that chemotherapy side effects would impact 
negatively on this.  This was combined with an appreciation that chemotherapy was 
associated with relatively limited survival benefit in MPM, and therefore the risk-benefit 
balance was not in its favour. 
 
This finding replicated an earlier observational study from our centre describing the 
characteristics and motivations of people with MPM who declined chemotherapy.  Of 
139 patients offered chemotherapy, 46 (33.1%) chose not to receive it.(48)  Reasons 
included concern that the benefits of chemotherapy did not outweigh the risks of 
treatment, and patients who were asymptomatic wishing to maintain their quality of life 






Initially, this decision seems justified, as chemotherapy has been shown to impact 
negatively on certain symptom-specific aspects of quality of life.  In another 
observational study from our group in Bristol, people with MPM who were receiving 
chemotherapy reported higher scores for nausea, vomiting, alopecia and sore mouths, 
as well as lower global health and social function scores during treatment, compared 
with patients who had elected not to receive treatment.(275)  In contrast to the beliefs 
of participants in TILT, however, symptoms did not affect quality of life, which remained 
stable over the 16 week study period.  Furthermore, quality of life improved in people 
who responded to chemotherapy, presumably due to a combination of improvement in 
tumour-related symptoms and the heartening knowledge that they were responding to 
treatment.  However, it is worth noting that patients were relatively symptomatic at 
baseline, so it is not known whether the same improvements would be seen in 
asymptomatic people with MPM who received chemotherapy.  Equally, the longer-term 
impact of chemotherapy on quality of life is not known. 
 
Recent oncological trials in MPM have also included quality of life outcomes.  In the 
phase III randomised MAPS trial, 36% of 225 patients who received standard 
pemetrexed and cisplatin chemotherapy reported a deterioration in their global quality 
of life after 9 weeks of treatment, as did 30% of the 223 patients who received 
chemotherapy plus bevacizumab.(6)  Whilst similar numbers of people experienced 
improvements in their quality of life, (27% and 29% for chemotherapy and 





speculation inherent to the decision to embark on systemic anticancer therapy.  As this 
thesis shows, some people with MPM are unwilling to take this gamble. 
 
The survival benefit of two to three months offered by chemotherapy in MPM was not 
deemed worth the risk of side effects by TILT participants.  In the literature, there is 
significant variation in the overall benefit that is perceived sufficient to make 
chemotherapy worthwhile.(276-279) In interviews with 83 women with early breast 
cancer, in which women were presented with four validated, hypothetical, trade-off 
situations, Duric and colleagues discovered that over 50% would be willing to receive 
adjuvant chemotherapy in exchange for a survival benefit of just 1 day.(280) Tellingly, 51 
of these women had a dependent child or children, and this factor was strongly 
associated with the likelihood of accepting smaller survival benefits.  Several women 
stated that “every day matters, especially because of my children”.  
 
Age differences and stage-of-life differences between people with MPM and women 
with breast cancer may explain their contrasting opinions on the benefits required to 
make chemotherapy worthwhile.  However, a systematic review by Jansen et al 
examining the determinants of uptake of adjuvant chemotherapy (i.e. chemotherapy 
given after curative tumour resection) did not find age or type of cancer to be related to 
decision-making.(278) However, as a cancer with no surgical or adjuvant chemotherapy 
options, no people with mesothelioma were included in the review and the findings may 
not be completely comparable with chemotherapy given in the first-line setting and with 





Toxicity and the risk of side effects have been shown to play a large role in patients’ 
decisions around chemotherapy with other cancer types. In their systematic review, 
Jansen et al demonstrated that people were more willing to accept chemotherapy with 
fewer side effects, and would generally do so for a lower chance of a cure.(278)  When 
Irwin and colleagues presented 46 women with breast cancer with a choice between 
chemotherapy regimens, impact on quality of life and side effect profile were two of the 
most important factors affecting their decision-making.(281)  Overall, therefore, people 
with MPM appeared to have similar priorities to other people with other cancers and 
were influenced by the same factors when making decisions about whether to receive 
chemotherapy. 
 
The decision to participate (or not) in TILT was also influenced by the desire to maintain 
quality of life and minimise the risk of side effects.  This also corresponded with clinical 
trial decision-making in patients with other cancer types. A systematic review of 51 
studies evaluating the factors affecting research participation in people with cancer 
found that 19% reported “concern about side effects” as a key factor in patients’ 
decisions not to participate in a trial.(282) Anxiety about the trial intervention (which 
presumably involved a degree of overlap with concern about side effects) was noted as 
a factor in the decision in 25% of studies. In one study that was included in the 
systematic review, people with different cancer types were asked to complete a 
questionnaire in which they scored how strongly they agreed or disagreed with certain 
statements.(283)  Of the 51 people who had declined to participate in a trial, 88.2% 






Interestingly, oncologists were less concerned about side effects, and appeared to 
underestimate their importance to patients as a deciding factor in clinical trial 
participation.  In a survey of 137 oncologists and 170 patients, patients ranked the fear 
of side effects as the most influential factor in their decision whether to join a trial, 
whilst oncologists ranked it fifth (out of seven possible options).(284) Oncologists were 
not interviewed as part of TILT, although this would be an interesting avenue for future 
research, particularly given the toxicity profile of many of the new combination 
immunotherapy regimens being investigated in MPM.(15, 17)   
 
The findings of this thesis suggested that, in keeping with studies of people with other 
cancer types, people with MPM placed great emphasis on the risk of side effects when 
deciding whether to participate in clinical trials.  The importance of quality of life to 
people with MPM, and their resultant disinclination to risk side effects should be noted 
by clinicians and triallists, and taken into consideration when planning future clinical 
trials and in communicating with patients, both about trials and about planned 
treatments.   
 
6.3.8. Communicating uncertainty and risk: key finding 8 
 
Key finding 8 – People with MPM valued certainty and were uncomfortable with 
uncertainty and unpredictability.  This has important consequences around risk 






The qualitative study highlighted that people with MPM sought certainty and were 
frustrated by perceived ambiguity.  In part, this reflected their high levels of 
engagement and pursuit of knowledge about all elements of their condition.  Equally, 
the fondness for numerical values and statistical expressions of probability was 
potentially grounded in their occupational backgrounds.  As a whole, men with MPM 
had worked in professions dictated by numbers and precision, e.g. engineering, 
plumbing, construction.  It was predictable, therefore, that they should feel comfortable 
in the realm of figures and would seek recourse to that domain wherever possible.  
(Clearly this is association rather than causation; it is equally possible that job choice 
was influenced by a pre-existing enjoyment of numbers rather than numerical familiarity 
being a result of vocational experience.  However, the end result remains the same, 
these were men with a preference for and familiarity with numerical information).  
 
A wish for certainty and discomfort with uncertainty is not specific to men with MPM, 
though. As Keren and Gerritson described in their experiments, aversion to ambiguous 
information is a universal human trait and one of the most consistent determinants of 
decision-making behaviour.(285, 286)  However, people with MPM were subject to 
several other factors that could have increased their wish for certainty, specifically the 
incurable nature of their disease.(287) 
 
Receiving a diagnosis of a chronic or terminal condition has been described by Michael 





are thrown into disarray.(287)  The future story of that person’s life is abruptly changed, 
requiring complete re-evaluation.  In their seminal book about awareness and dying, 
Glaser and Strauss discuss the various types of ‘work’ that need to be done to achieve 
acceptance of death.(288) This includes ‘biographical work’, in which a person’s life 
story is reconstructed to account for and encompass the new future.  When a person’s 
plans for the future, which have strengthened in certainty over years of their life, are 
suddenly removed, the desire to replace them with something equally concrete is 
understandable. Unfortunately, a fundamental part of biographical disruption is the 
unavoidable uncertainty that comes with it. 
 
Uncertainty comes in many forms, and the word itself can refer to an internal emotion 
or an external state of affairs.  Internal or psychological uncertainty is the feeling a 
person experiences if they lack information or have an unresolved decision. 
Psychological uncertainty is the personal experience of not knowing and the emotion 
associated with that experience.  Most human beings are inherently averse to the 
sensation of psychological uncertainty.(286) 
 
Psychological uncertainty can be created by external uncertainty, i.e. it may be an 
awareness that objective information or knowledge is lacking.  Fox and Ülkümen 
described two types of external uncertainty – epistemic and aleatory.(289)  Epistemic 
uncertainty is uncertainty relating to numbers, facts and science due to limited 
knowledge, and is the main uncertainty that men in this study were trying to overcome. 





could be filled in some way or at some point in the future.  This is in contrast to aleatory 
uncertainty, where unknowns are a result of randomness or chance and can never be 
predicted or converted to certainty, for example the uncertainty of where a roulette ball 
will land on its wheel.   
 
People in our study were exposed to both types of uncertainty: aleatory uncertainty 
relating to the date of their death and their individual trajectory over future months, 
and epistemic uncertainty about whether BCG was an effective treatment option for 
MPM.  These uncertainties overlapped in that they both related to survival and, sadly, 
neither uncertainty would be addressed for these participants during their lifetime.  
However, it is possible that the uncertainty about BCG efficacy could be resolved at 
some point in the future following further research, hence it represented a form of 
epistemic uncertainty. In contrast, the ability to predict the exact date of someone’s 
death is unlikely to ever be possible, hence that uncertainty is aleatory. 
 
Participants were also exposed to a combination of aleatory and epistemic uncertainty 
in regard to the adverse reactions experienced during the trial.  Whilst information was 
available about the likelihood of an adverse reaction and what form that reaction could 
take, the absolute (epistemic) figures were not known.  Added to that was the aleatory 
uncertainty of how severe the reaction might be for a specific individual and whether it 
would ultimately shorten or lengthen their life.  Although men in the trial were provided 





much as possible, this was perceived as insufficient, probably because the aleatory 
uncertainty remained unaddressed.  
 
In clinical research, particularly where investigational medicinal products are involved, 
uncertainty is inextricably linked with risk.  According to Steven Sloman’s Dual Process 
Theory, risk and the response to it can be processed in two ways; analytically or 
emotionally.(290)  Emotional processes are usually dominant, as an evolutionary 
remnant from when risk decisions were required quickly and in high stakes situations.  
These instinctive reactions remain at the forefront of our risk assessment processes, and 
continue to play the biggest role in decision-making.(291)  It was interesting to note, 
therefore, that men with MPM tended to be less emotional, demonstrating a highly 
pragmatic and analytical approach to their disease and decision-making.  Had they 
suppressed their emotional risk response in favour of the analytic pathway, and this was 
why they were disappointed when they subsequently experienced harm? 
 
The qualitative findings raised important questions about communication of risk, which 
had implications for both clinical and academic work.  Men in this study described 
experiencing “unexpected” adverse reactions, despite having been provided with 
information beforehand that detailed the possibility of a reaction.  In clinical practice, 
we routinely provide people with information about procedures and treatments that 
have potential side effects or risk of complications.  Is that information sufficient and do 
patients feel adequately forewarned if they subsequently experience a complication?  






How can this communication gap be addressed? It is our duty as doctors and 
researchers to ensure that patients and participants are fully informed before we 
subject them to any clinical procedure or academic process.  However, communicating 
uncertainty is complex and is made up of multiple elements that contribute to the 
eventual outcome.  Van der Bles and colleagues summarised the complexity of the 
process when they noted that the seemingly straightforward task of imparting 
information from one person to another actually involved multiple factors, namely who 
is communicating what, to whom, in what form and to what effect?(285) These factors 
will be considered in turn over the remainder of this section. 
 
In a clinical trial or medical procedure, the ‘who’ is usually pre-determined and 
unchangeable.  The responsible clinician or researcher should ensure they appreciate 
the complexities of risk communication specific to the relevant population and take 
every possible measure to ensure the communication is successful.  
 
The ‘what’ of risk communication should also be clear in terms of the object to which 
the uncertainty relates (in this study intra-pleural BCG, in other studies the trial 
intervention).  However, to fully understand the ‘what’, further interrogation is 
required.  What is the source of the uncertainty and to what level does it relate? For 
BCG, the uncertainty arose from an absence of established knowledge about its effects 
when used intra-pleurally.  But this wasn’t due to an absolute lack of information; 





papers reduced the level of uncertainty a little, by providing some information about the 
effects of BCG.  However, the studies were poorly reported and did not provide robust 
data that could be applied to the current trial, hence a moderate level of uncertainty 
remained.   
 
When designing a clinical trial, the degree of uncertainty relating to the intervention is 
established during the early research phases when the existing scientific literature is 
reviewed and evaluated.  In clinical research, this uncertainty informs equipoise and is 
usually the primary motivation for performing a trial.  In contrast, for clinical procedures 
and established treatments, the evidence base is generally stronger and the level of 
uncertainty about the intervention lower.  However, clinicians are still required to 
familiarise themselves with the literature and evaluate its strengths and weaknesses in 
order to communicate an accurate level of risk to their patients.    
 
The next consideration relates to how uncertainty is communicated. The manner in 
which the communication takes place should span media, i.e. paper-based, verbal, web-
based, etc. to ensure maximum appeal and accessibility, whilst the content will depend 
on the information available. Numerical data are often helpful and pictorial 
representations alongside numbers can enhance understanding.(292) However, 
interpretation of numerical risk can depend on how it is presented, as demonstrated in 
one study by Slovic and colleagues.  They presented experienced forensic psychologists 
with a theoretical case of a patient with a psychiatric diagnosis whose risk of performing 





discharge the patient into the community when the risk was described as a probability 
(i.e. “Patients similar to Mr. Jones are estimated to have a 10% chance of committing an 
act of violence”) than when it was described in terms of the actual frequency of the 
event happening (i.e. “of every 100 patients similar to Mr. Jones, 10 are estimated to 
commit an act of violence”).  They hypothesised that risk presented as a probability 
created a benign image of an individual who was unlikely to harm anyone, whilst 
reporting frequencies of actual events caused people to imagine the events and these 
“affect-laden images” created a higher perception of risk.  For people with MPM, the 
latter approach may be preferable as it could encourage people to imagine the reality of 
experiencing an adverse reaction and its potential impact on them as an individual. 
 
Risk communication becomes harder where numerical data is not available.  In these 
situations, verbal descriptors such as “rarely” and “likely” are required.  However, whilst 
these labels feel more natural to use in conversation and may be easier for people to 
understand, their interpretation is highly subjective.  Interpretation of verbal descriptors 
of risk can vary both between people, depending on their particular frame of reference, 
and within individuals depending on the circumstances and context.(294, 295)   
 
The people to whom uncertainty is being communicated cannot be changed in a trial or 
clinical setting.  It is important, therefore, to understand the characteristics of the 
population involved and appreciate how those characteristics may influence how the 
communication is received.  Perception and understanding of uncertainty varies 





and general degree of optimism.(285)  Prior or existing attitudes and beliefs are also 
important as people are more likely to assimilate uncertainty that concords with their 
own beliefs.(291)  The findings of the qualitative study provided important insight into 
how people with MPM process information, and made a strong case for presenting 
uncertainty and risk clearly and in numerical form wherever possible.  In a clinical trial, 
this approach could be used to address factual (epistemic) uncertainties, but since the 
ultimate aleatory uncertainty about survival persists, perhaps this too should be tackled 
explicitly, for example with the following statement:  
“We do not know what effect this drug will have on you personally or on your 
underlying disease.  This leaflet contains the current knowledge that exists 
about this drug, but there is still an inherent uncertainty involved with 
participating in this (or any) trial.” 
Being overt and upfront about uncertainty may appeal to people with MPM who 
preferred their doctors to be direct, clear and upfront when delivering 
information.   
 
The final consideration in communicating risk is the effect of the communication. For 
potential trial participants to be fully informed, knowledge of the potential risks must be 
accompanied by an appreciation of how those risks apply to them.  Assimilating 
information about risk is an individual process that varies depending on people’s 
backgrounds, experiences and belief systems.(291)  This highly personalised process can 
be particularly challenging in a clinical trial where the trial requirements may prioritise 





blinding of clinicians to the treatment their patients are receiving.  Many people, 
including several TILT participants, struggled to appreciate that trial participation may 
limit the degree of personalised care they receive, a phenomenon that Appelbaum and 
colleagues labelled the “therapeutic misconception”.(296, 297)  As a result of this 
phenomenon, people consistently underestimated the risks associated with 
participating in research, whilst overestimating the potential benefits.(298-300)  A 
specific and frequent manifestation of the therapeutic misconception was the belief 
that a trial intervention would only be offered if it carried some potential benefit and 
would not be offered if it was associated with significant risk.(300) This belief was 
expressed by several participants in TILT and their relatives. 
 
In this study, the surprise and distress described by participants who experienced a 
reaction made it clear that risk communication had been unsuccessful. If the above 
considerations and interventions are implemented, future trials may avoid this pitfall. 
 
6.3.9. Research participation and the TwiC methodology: key finding 9  
 
Key finding 9 – Participants and their relatives were engaged and well-informed about 
MPM and about research. People chose to participate in TILT due to a combination of 
altruism, scientific interest and potential personal gain and all participants found the 






Surveys undertaken by the charities Mesothelioma UK and the British lung Foundation 
(BLF) in 2012 and 2013 demonstrated that people with mesothelioma were keen to 
know about research and to participate wherever possible.(301, 302)  This, alongside 
the enthusiasm to participate in patient support groups and PPI events,(260, 303) 
illustrates an engaged and motivated patient group.  
 
An active approach to information gathering can be a useful coping strategy and has 
been shown to reduce anxiety levels and increase feelings of control in people recently 
diagnosed with cancer.(304, 305)  Cassileth et al asked 256 people with a diagnosis of 
terminal cancer to complete an assessment about their information level, followed by a 
survey about hopelessness.(306) They found that people who were well-informed about 
their condition were more likely to be hopeful about the future, regardless of their 
expected prognosis. Most people expressed a wish to be provided with as much 
information as was available, and for communication to be open and honest.(306)  
Similar feelings were expressed by 56 patients receiving palliative care for a terminal 
diagnosis who completed a Likert scale questionnaire about their information 
needs.(307)  100% of patients wanted their doctors to be honest, 98.2% wanted to be 
informed about changes in their disease status, 89.3% wanted to know about new 
treatment options and 80.4% wanted to be told the expected course of their 
disease.(307) This corresponds with the conclusion of this thesis regarding the 






It must be noted, however, that not everyone is as eager for information as the people 
described in the above study. Some people may find it upsetting to be reminded of the 
short life-expectancy associated with MPM,(260, 308) and indeed one of the 
participants in TILT (who unfortunately died before she could participate in a qualitative 
interview) was adamant throughout her diagnostic and treatment journey that she did 
not wish to know her prognosis.  Previous qualitive work with people with 
mesothelioma has highlighted the varying amounts of information that different 
patients desire and are able to process.(232, 308) In line with the findings of this thesis, 
however, most people expressed a wish for honest and direct communication.(232)   
 
There is a clear tension here, in how to balance honesty and appropriate information 
transfer with the preservation of hope and optimism.  The same issue was raised in the 
questionnaire study mentioned above, where despite 100% of patients stating that they 
wanted honesty from their doctors, 91% also wished their doctors to be optimistic.(307)  
Is it possible to be optimistic when communicating about a terminal disease with limited 
treatment options, like MPM?  Probably, as long as information is provided in a caring 
manner, rather than abruptly and with a sense of the physician “washing their hands” of 
the patient.(304)  The RADIO-meso study confirmed this. Patients with MPM were 
interviewed about the experience of receiving the diagnosis and many commented that 
the shock of the news was mitigated if it was communicated in a warm and sensitive 
fashion.(232) Respondents to the Mesothelioma UK patient survey described similar 
experiences, whereby the sensitivity of the staff helped relieve some of the trauma of 





being led by their information requirements and ensuring information is provided 
sensitively and carefully have been highlighted as key factors in communicating bad 
news to people with MPM.(232) 
 
Another consideration in communicating information to people with MPM relates to the 
specificity of the information.  In a qualitative study consisting of focus group sessions 
and one-to-one interviews, caregivers of people with terminal cancer expressed 
frustration when the initial information they had been given (e.g. high chances of cure 
with treatment) later transpired to be incorrect.(304) This echoed the findings of this 
thesis that patients and relatives wanted certainty about the specific effects of 
treatment for them as an individual, and is an important consideration when 
communicating information to patients and relatives (as discussed in Section 6.3.8.). 
 
Participants in TILT sought information from several different sources.  This corresponds 
with the BLF patient survey, which revealed that most people with mesothelioma 
received information from their doctor or specialist nurse, but that many also 
considered their local patient support group or social media to be their main source of 
information.(302)  Participants in the Mesothelioma UK survey also mentioned doing 
their own research on the internet and reading up about official guidance, including the 
Government’s 2011 White Paper on improving cancer outcomes.(301, 309) 
 
When it came to trial participation, MPM patients were knowledgeable about research 





sources.(301) Being well-informed about research may have informed the decision to 
participate and may have contributed to the confidence TILT participants expressed in 
their decision after the event. In a study of 118 people who were participating in cancer 
trials, Stryker et al reported that patients who scored highly on information assessments 
about the trial were less likely to express regret at their decision to participate.(310) 
 
Longitudinal qualitative interviews with participants in a MPM surgical trial (the second 
Mesothelioma and Radical Surgery trial; MARS2) revealed that, similar to TILT, people 
often chose to join the trial in the hope of receiving a treatment that was not otherwise 
available.(172)  Other motivating factors for joining MARS2 included recognition that 
participation brought with it an enhanced level of care and support from the research 
team.(172)  Most MARS2 participants mentioned altruism and the desire to improve 
treatment options for future patients, as well as acknowledging that participating in a 
trial offered hope, and enabled them to take a positive approach to their illness.(172) 
These reasons for participating in research resonated strongly with the findings of the 
TILT qualitative study, and confirm that people with MPM are as motivated by altruism 
and the greater good as they are by potential personal gain from research. 
 
Altruism is a recurring motive behind clinical trial participation in people with cancer.  In 
a systematic review of 51 quantitative and qualitative studies examining oncology 
clinical trials, altruism was identified as a key facilitator to participation, mentioned in 
25% of studies included in the review.(282)  The similar “desire to help others” was cited 






Potential personal gain has also been reported frequently in studies examining people’s 
reasons for participating in research in the context of incurable cancer.  “Perceived 
personal benefit” and “hope for a cure” were often quoted as motivating factors in 
oncology trials.(282)  In one questionnaire study, patients with cancer alluded to limited 
alternative treatment options and a belief that the trial treatment was the best option 
available to them as their primary motivation for joining a trial.(283) Again, there are 
clear similarities with the motivations described by people with MPM in TILT. 
 
TILT participants were often motivated to take part in the trial due to scientific interest 
and an ability to understand the rationale behind the research.  This observation has not 
been reported previously, either in people with MPM or in people with other types of 
cancer.  In part, this is likely to reflect the slightly restrictive study designs that were 
used, historically, to explore this area.  Specifically, most studies relied on data collected 
through surveys or questionnaires. If the specific instrument did not include an option 
about scientific interest, then this motive would not have been detected.  Recent 
qualitative work in MPM patients in MARS2 employed a more inductive approach to 
data collection, however this theme was not identified.(172)  Perhaps the concept of 
surgically resecting a tumour was less scientifically intriguing than that of bacterial 
immunotherapy.  Nevertheless,  some participants who expressed a preference for the 
surgical arm in MARS2 did so on the basis that they were keen to have the tumour 





and chemotherapy, suggesting that understanding the rationale behind the treatment 
did contribute to people’s enthusiasm to participate.(172) 
 
Another theme that recurred between the MARS2 qualitative study and the findings 
from this thesis was a sense from some participants that they felt abandoned or 
neglected by the trial team.(172)  Although most people in MARS2 felt well-supported 
during the trial, some commented that they would have preferred more frequent 
contact to reassure them that they had not been forgotten or overlooked, particularly at 
the point of transition from the tertiary surgical centre back to their local hospitals.  This 
replicates the experience of one TILT participant and highlights the importance to 
people with MPM of regular and frequent interactions with clinical and healthcare 
professionals. 
 
As the first clinical trial in MPM patients to use the TwiC design, there was no prior 
literature regarding its acceptability to this population.  Equally, as a relatively newly 
described trial methodology, there was no existing data about its acceptability in other 
participant groups.  However, other trial designs that use randomisation without 
consent, for example the Zelen design, have been criticised in the past for being 
unethical. The main criticism rests on randomisation being research activity that should 
not occur unless the person has explicitly consented to participate in research.(138)  A 
similar argument has been made about the TwiC methodology in its original format (i.e. 






The acceptability of the Zelen design and other types of randomisation without consent 
trials has been explored previously.  McNulty et al undertook a cluster-randomised 
modified-Zelen trial of an educational intervention for chlamydia screening uptake in 
primary care.(312) GP practices were randomly allocated to implement the educational 
programme or not, and consent to participate was only sought from practices allocated 
to the intervention.  Once the trial had ended, all practices were provided with 
information about the modified-Zelen design, their allocation and the consent process, 
and were invited to participate in qualitative interviews about the methodology.(313)  
Overall, the design was highly acceptable to those involved, with many people 
expressing approval for the “realistic” picture the research would generate as a result of 
the pragmatic design. GPs found the consent process acceptable and several people 
who worked in practices who had not been approached for consent described gratitude 
that they had not been burdened with additional governance processes when their day-
to-day practice had not changed.  For many people, the trial design was reminiscent of 
service evaluation and monitoring, and thus felt like a familiar concept.  Interestingly, 
most people believed that the trial design should be made explicit to all participating 
practices once the trial had finished, and some stakeholders suggested the need for a 
national ethical approval process specifically for trials that involved randomisation 
without consent.  The only perceived disadvantage of the method was the potential 
damage in trust between individual GP staff and the Primary Care Trusts (PCT) who had 
provided consent on their behalves.  However, this is the usual process for cluster 
randomised trials based on PCTs or GP practices and did not relate to the Zelen design 






The concept of randomisation without consent (or post-randomisation consent) has also 
been explored in lay people.  In a large US study, 3739 members of the public were 
selected from an existing database (known to be representative of the general US 
population) and invited to complete an online survey about clinical trials in which the 
control arm did not provide consent.(314)  Two separate theoretical trials were 
presented - a high stakes scenario of survival in leukaemia and a low-stakes scenario of 
blood sugar monitoring in diabetes, with two different types of wording – standard RCT 
language vs minimising language that emphasised the lack of change to care in the 
control arm.  Of 2004 analysable responses, 75.4% of participants stated they would 
definitely or probably recommend an ethics panel to approve the study design, whilst 
20.4% would probably not recommend approval and 4.2% definitely would not.  
Recommendation rates did not change when the trial was presented in the high or low 
setting, nor if it were presented using the different wording.  Interestingly, people were 
less accepting of the design on a personal level, with only 53.2% of people stating they 
would be OK with being randomised to the control arm and not informed about it.   
 
All participants in the TILT qualitative study said they were happy with the idea of 
control participants being blinded to the trial, as did their relatives.  However, blinding 
had been breached in all control patients, so it was not possible to hear from someone 






Previous qualitative work with people participating in trials has highlighted that 
participants can struggle with the concept of randomisation.(315-317) Qualitative 
interviews with people with breast cancer showed that they found it hard to understand 
why randomisation was necessary and disliked the idea of placebos.(318)  Other studies 
have consistently demonstrated that people do not believe that randomisation is truly 
random, often believing allocation decisions are based on individual characteristics or 
responses to prior treatment.(315-317)   People with MPM interviewed longitudinally 
during participation in the MARS2 trial, demonstrated variable understanding of 
randomisation.(172)  The majority of people had a good appreciation of random 
allocation to the treatment arms, however several people believed that the doctors 
decided their treatment and others thought that the decision was based on their 
individual situation and responses to previous treatment.  In general, TILT participants 
revealed similar levels of understanding to MARS2 participants, with the majority 
demonstrating a good understanding and acceptance of randomisation.  It may be that 
people with MPM are more able to understand and accept the concept of 
randomisation, perhaps as a result of being well-informed about research in general. 
 
6.3.10. Anxiety about the future and coping strategies: key finding 10 
 
Key finding 10 – For people with MPM and their relatives, thoughts of the future were 
associated with anxiety and grief for lost opportunities.  Whilst people with MPM tended 





for their family member.  The specific needs of both groups should be catered for in the 
provision of routine clinical care. 
 
As discussed in Section 6.3.8., being diagnosed with a terminal condition creates 
fundamental challenges to a person’s sense of self and personal narrative.(319)  
Unwanted changes to a previously-imagined future are difficult to accept and are often 
met with a combination of grief, anger and frustration.(287)  The unpredictability of 
what the new future holds is a source of anxiety, with patients and relatives concerned 
about potential symptoms and physical deterioration.  In a survey of 56 people receiving 
palliative care for a terminal condition, 41.4% were afraid of the dying process, with 
64.3% expressing concern about being in pain in future.(307) Similar fears were 
articulated by participants in the TILT trial.  Respondents to the survey study also 
reported anxiety about whether their dignity would be respected (76.8%) and what they 
would do if they became unable to care for themselves (53.6%), although these 
concerns were less frequently mentioned by people with MPM.(307)  People with MPM 
in the TILT qualitative study were more likely to focus on the practical elements of their 
conditions and the limitations placed on their day-to-day lives.   
 
Some of practical factors mentioned by people with MPM were the lost opportunities 
and plans that were no longer possible as a result of the disease. Their relatives also 
described sadness about future events and experiences that would no longer happen.  
This theme was noted by Dr Helen Clayson in her interviews with 15 people with 





included retirement plans that had been scuppered and hoped-for holidays that had 
been cancelled.  Grief for the loss of a future that was previously taken for granted has 
been reported in other cancer types and is likely a common experience across several 
terminal disease conditions.(320) 
 
The tendency of people with MPM to respond to their loss with practical and stoical 
behaviour has been well-described in previous qualitative studies.(174, 213, 321)  
Similarly, the observation that relatives and carers respond differently to the emotional 
demands of the disease is not novel.  In her work described earlier, Clayson noticed the 
“striking” difference between the acceptance and stoicism demonstrated by men with 
the disease and the “passionate anger” their wives displayed on their behalves.(174, 
213)  As described in this thesis, relatives of people with mesothelioma felt they had to 
fight on behalf of their loved one, either because their relative was too accepting of the 
situation or was too ill to fight for themselves.(174)   
 
Advocacy often focussed on the medical care received by people with mesothelioma. In 
the Mesothelioma UK patient survey, relatives sometimes described dissatisfaction with 
the care their partners received, as did family members in Clayson’s interviews.(213, 
301)  The dissatisfaction often related to organisational issues (as mentioned by Caroline 
in the TILT qualitative interviews) and a perception that medical interventions and 
investigations were not occurring in a timely fashion.(308) This pattern was not unique 
to people with mesothelioma, as Gribich and colleagues demonstrated in their 





with other terminal cancers.(304) They found a similar theme of relatives advocating on 
behalf of their unwell family member, particularly if they felt healthcare staff were not 
listening to the patient’s needs.  
 
The role of advocate was associated with (and potentially driven by) a heavy emotional 
burden for carers.  This thesis demonstrated that relatives were often living with an 
inescapable awareness of their loved one’s imminent mortality, often listening out to 
check that they were still alive.  Whilst this particular anxiety has not been described in 
the mesothelioma literature before, one Italian questionnaire study noted that carers of 
people with MPM were more likely to report intrusive or disabling fear compared to 
people who were not carers.(322)  
 
In less specific terms, the high emotional burden experienced by carers of people 
mesothelioma has been highlighted by multiple qualitative studies.(213, 214, 321, 323, 
324)  The change in role from partner to care-giver/nurse has been described as 
stressful and relatives often reported tiredness, sleep disturbance and feelings of 
helplessness as a result.(214, 322-324)  Carers often neglected their own health, and in 
one study, a number of carers for people with mesothelioma disclosed that they had 
started smoking again due to the stress of being a carer.(213)   
 
Relatives faced additional emotional challenges that were not shared with their 
partners.  Coping with their relative’s death was one such difficulty, as was managing 





bereavement.(174, 213, 321)  This topic was not addressed during this thesis, although 
several relatives referred to what their life might look like after their partner had died, 
either directly or indirectly. 
 
Clearly the needs of carers are significant and appear to be slightly different from those 
of people with MPM.  Fortunately, there are an increasing number of resources 
available to provide this, both in the UK and further afield. Charitable organisations such 
as Macmillan and Mesothelioma UK have provided funding for mesothelioma specialist 
nurses who provide a consistent point of contact and supportive option for patients and 
relatives affected by mesothelioma. In some older qualitative studies, carers reported 
feeling unsupported by healthcare workers,(323, 324) however more recent data 
describe a predominantly positive picture regarding the impact of dedicated 
mesothelioma nursing teams.(232, 301, 308)  Carers appreciated the regular close 
relationship that they developed with the specialist nurse and recognised the benefit of 
the nurse’s experience dealing with other people with mesothelioma, which enabled 
them to understand many of the nuances and complexities associated with this specific 
disease.(308) 
 
Patient support groups were mentioned by several patients and carers in TILT and were 
seen as a useful place to seek information and emotional support.  The value of support 
groups in mesothelioma has been demonstrated elsewhere,(303) and they are an 
increasingly popular venture, often run by the local mesothelioma specialist nurse.  





support group, that it highlighted the high mortality associated with the disease as 
group members inevitably died.  She said the support group sometimes felt like people 
were “sitting around waiting to die”. Nonetheless, that person often attended the 
support group, even when her husband was unable to, and she maintained that she 
found it helpful and derived support from it.  Patients and carers who did not have 
access to a support group stated that they would like to be able to attend one in their  
responses to the Mesothelioma UK survey.(301) In general, it seems that patient and 
carer support groups are a positive resource, and one that all people with mesothelioma 
should be able to access, even if they choose not to attend. 
 
6.4. Strengths and limitations of the research 
A major strength of this research was the use of mixed methods to tackle different 
aspects of the research question. By employing a quantitative observational 
methodology alongside a clinical trial with embedded qualitative interviews, the 
research has provided a multi-faceted perspective on the subject of intra-pleural 
bacterial immunotherapy in MPM and yielded broader and richer results than any single 
approach would have. 
 
The interplay between the qualitative study and the clinical trial was the most 
beneficial.  Qualitative interviews, analysed contemporaneously, enabled modifications 
to be made to the trial protocol to increase acceptability and improve the experience of 
subsequent participants.  Qualitative interviews with later participants allowed the 
changes to be reviewed, to determine whether they had improved the trial or not, with 






The findings of the quantitative and qualitative study complimented each other, with 
each element providing information of a different facet of the overall project.  It was 
useful to learn, from the qualitative study, that the TwiC design was acceptable, even 
though the trial demonstrated it not to be feasible to use in this context.  Chapter 1 
described the different approaches to mixed methods research and a diagram was 
provided to represent the relationship between the qualitative study and the feasibility 
trial.  The diagram is recreated below (Figure 6.2) with annotation describing the specific 
way the two methods interacted to inform the findings. 
 
6.4.1. Systematic review 
A strength of the systematic review was the robust methodology, conducted in 
accordance with the Cochrane Handbook for Systematic Reviews.  The search  
strategy was thorough and undertaken with the support of an information scientist from 
the University of York.  Study selection, data extraction and risk of bias assessment were 
undertaken by two independent reviewers, with any discordance resolved by discussion. 
 
Unfortunately, five papers that were deemed eligible for inclusion were not available for 
full text review.  Multiple attempts were made to source these manuscripts, including 
contacting the British Library and personal correspondence (written and email) with the 
relevant authors, however to no avail.  Whilst this is perhaps unsurprising given almost 3 
decades had passed since publication in some cases, the missing papers may have 












TILT was acceptable to participants and 
relatives but was not feasible in this 
population. 
Participant experienced a reaction after administration 
of trial drug and said he felt “neglected” by the trial 
team. In response, protocol changed to include: 
• Daily phone calls for 1 week  
• Additional visit at Day 3 
• Regular anti-inflammatories  
• Option for half-dose IMP  
Workstream 3 – Feasibility trial 
Informs 
Quantitative:  
• TILT was not feasible due to poor recruitment, 
attrition and inability to blind controls. 
• Trial drug created significant inflammatory reaction. 
 
Qualitative:  
• Trial design was acceptable to participants. 
• Inflammatory side effects were unpleasant. 
• People chose not to participate because of concerns 
about side effects. 




Workstream 4 – Qualitative study 
Interpretation 
Figure 6.2 Schema of a parallel, concurrent, interactive model of mixed methods research with subsequent convergence, annotated to demonstrate 





Although not a limitation of the systematic review itself, the quality of the literature 
available for inclusion was poor.  As described in Chapter 2, approximately half of the 
included studies were non-randomised, observational studies, at high risk of 
confounding and selection bias.  Few studies were designed with survival as a primary 
outcome, and consequently reporting of survival endpoints was imperfect.  Measures of 
variance were rarely provided, which prevented interpretation of survival estimates.  
Additionally, survival outcomes were rarely adjusted for other variables, raising the very 
high risk of confounding due to patient or tumour characteristics. 
 
There was a high degree of heterogeneity between the papers included in the 
systematic review.  Not only is MPE a heterogeneous disease, caused by multiple 
different pathologies with different prognoses, but there are also several different 
bacterial products that have been studied in clinical trials, at different doses and 
regimens.  As previously discussed, this heterogeneity made synthesis of study findings 
difficult, particularly in terms of evaluating the overall effect of any specific bacterial 
products in a single disease process. 
 
6.4.2. Population-based cohort 
The population-cohort study had several strengths. The use of data from a resource with 
universal coverage of activity in NHS hospitals across England minimised selection bias. 
Similarly, the use of standardised coding within HES, using ICD-10 and OPCS-4, ensured 
that identification of study participants was comprehensive.  Compared with national 





94.3% and 100% of patients diagnosed with mesothelioma in England each year.(325)  
Similarly, the number of deaths recorded for the years 2006 to 2014 in the study 
represented 92% to 98% of the total mesothelioma deaths recorded by the Health and 
Safety Executive in England for those years.(33)  Finally, the 1-year survival rate for 
patients diagnosed in 2014 was comparable to that reported in the National 
Mesothelioma Audit (38.8% vs 43.1%) as was the proportion of patients diagnosed after 
2008 who received chemotherapy (36.0% vs 36.5%).(38)  It is likely, therefore, that the 
study population was a reliable representation of the mesothelioma population in 
England during this period. 
 
Unfortunately, there is less certainty regarding identification of pleural infection.  The 
incidence of pleural infection in patients with mesothelioma has not been reported 
previously, and so it was impossible to know whether case identification was 
comprehensive.  Since the same method of identifying cases was used, it was hoped 
that detection of pleural infection was as sensitive as it was for mesothelioma.  It could 
be argued that mesothelioma was more likely to be correctly coded than pleural 
infection, given it is a legally notifiable disease.  However, the lack of alternative data 
sources to validate pleural infection rates against made it impossible to evaluate the 
sensitivity of pleural infection identification within the cohort.   
 
The incidence of pleural infection in the general population is 6-22 per 100,000 - much 
lower than the incidence observed in mesothelioma patients in this study.(326, 327)  





they undergo multiple pleural interventions, each carrying a risk of infective 
complications.  It may be that the higher incidence observed here is a reflection of that 
risk.  An alternative possibility is that pleural infection was a misdiagnosis in a 
proportion of people with mesothelioma.  As part of the disease process, someone with 
mesothelioma could present with fevers and sweats, alongside a loculated pleural 
effusion, which may well have a low pH.  Several of these features would also be found 
in pleural infection, so misdiagnosis, particularly at first presentation, is conceivable.  
However, patients were only entered into the cohort study once mesothelioma had 
been diagnosed and episodes of pleural infection had to occur after the diagnosis had 
been made.  Diagnostic confusion was less likely to occur once mesothelioma had been 
confirmed, and therefore, misdiagnosis is unlikely to explain the increased rates of 
pleural infection seen. 
 
Another strength of the study was the statistical analysis plan.  Splitting follow up at 
infection and at 30 days reduced the risk of immortal-time bias affecting the results, i.e. 
patients with pleural infection had to have lived long enough to have developed pleural 
infection.  Handling pleural infection (as well as chemotherapy and thoracic surgery) as 
time-varying covariable removed this potential bias. 
 
The cohort study was affected by a major limitation, namely the lack of information 
available about potential confounding variables.  Specifically, patients’ performance 
status and tumour histological sub-type were not available.  These factors are known to 





infection as well, thus creating confounding.(1, 44)  For example, it is possible that 
pleural infection was more likely in patients with worse performance status, and the 
higher mortality related to their performance status rather than infection.  To adjust for 
this, the variable “comorbidities” was created, as a surrogate marker for performance 
status.  This approach was imperfect, though, as performance status is a global measure 
of functional status that encompasses more than just co-existent medical conditions.  
Nonetheless, it was reassuring that the mortality hazard did not change greatly when 
adjusted for comorbidities and age, the two factors most likely to reflect overall 
performance status. 
 
HES also lacked data on the causative organisms driving pleural infection.  As previously 
described, different bacterial species elicit differing immunological responses, and it 
would have been useful to be able to analyse the effects of different infective 
aetiologies on survival.(242, 243)  Additionally, certain bacterial species secrete 
virulence factors known as superantigens, which bypass classic antigen-binding 
pathways and induce dramatic inflammatory responses, including polyclonal T cell 
proliferation and activation, and cytokine storm.(328)  It is possible that evaluating all 
aetiologies of pleural infection en masse may have masked a true effect related to one 
single organism or species (e.g. staphylococcal infections only).   
 
Where HES collected information on a variable, missing data were rare.  However, it was 
noted that patients with missing socioeconomic data had dramatically better survival 





these patients had missing data for other variables, including date of death.  This would 
have resulted in these patients appearing to live much longer.  Post-hoc investigation 
revealed that patients in these groups were more likely to have been right-censored 
than other groups, supporting this theory.  However, patient numbers were small, and a 
sensitivity analysis omitting these patients resulted in near-identical results to the 
primary analysis.   
 
6.4.3. TILT trial 
A strength of TILT was that it faithfully recreated the processes required to undertake a 
TwiC of intra-pleural immunotherapy in MPM.  Like all well-executed feasibility studies, 
this enabled identification of potential challenges that could affect a full-scale trial, 
saving significant time and money compared to a definitive trial.  Because TILT 
replicated the exact methodology of a potential full-scale trial, the difficulties 
encountered during trial delivery would be equally likely to affect the full-scale trial.  
Based on the results of TILT, a full-scale trial of intra-pleural bacterial immunotherapy 
should not be based on the TwiC design and would require a large number of recruiting 
centres and/or an extended recruitment period to ensure a suitable number of 
participants were enrolled. 
 
Another strength of TILT was the qualitative interviews embedded within the trial 
design.  Because these were analysed contemporaneously, the research team were able 
to respond to themes as they were identified and modify the trial design to optimise 





the first participant experienced an SAE.  A theme arose from his and his wife’s 
interviews about feeling “abandoned” and “isolated” in the days after IMP 
administration.  This was discussed at the next Trial Steering Committee meeting and 
the protocol was amended to add daily phone calls for a week after IMP administration 
and an extra trial visit at day 3.  Subsequent participants commented on feeling well 
supported and looked after by the trial team.   
 
The changes made to the trial processes in response to the qualitative findings were 
relatively easy to make but had an important impact on participants’ experiences. The 
responsiveness afforded by using an integrated mixed-methods approach meant that 
the final processes that we used in the trial were the most acceptable they could be to 
participants and their relatives.  Although other elements of TILT rendered a full-scale 
trial non-feasible, the assimilation of qualitative outcomes into the trial design 
maximised the acceptability of the trial and we can be as confident as possible that lack 
of acceptability was not a key barrier to trial delivery.  Additionally, the qualitative 
findings are likely to inform the design of future trials in MPM patients, even if the TwiC 
methodology is not utilised. 
 
A final strength of the trial was the use of validated measures for all secondary outcome 
measures.  Although, as a feasibility trial, TILT was powered to detect a pre-determined 
feasibility outcome (attrition) and not to evaluate efficacy outcomes, use of these 






There is, however, a recognised limitation to the performance of cross-sectional imaging 
in the evaluation of MPM.  CT scans have been shown to have a low sensitivity for 
detecting MPM, particularly in early stage disease.(329)  Additionally, evaluating 
radiological TNM (Tumour, Node, Metastases) stage is difficult on CT, with a high degree 
of inter-observer variability, particularly relating to subtle changes such as invasion of 
the diaphragm.(330) Magnetic resonance imaging (MRI) is more sensitive for detecting 
MPM with minimal pleural thickening and for assessing invasion of soft tissue, however 
assessment of response remains problematic.(331)  The circumferential growth pattern 
of MPM makes 3-dimensional assessment more important but also more challenging 
than for more commonplace rounded tumours.  mRECIST relies on multiple 
measurements of tumour thickness taken at different levels and positions within the 
chest cavity to ascertain whether progression has occurred, with disease progression 
defined as an increase in the sum of these measurements of 20% or more.(208) 
However, this approach is vulnerable to inconsistency in tumour measurement as well 
as in choice of site to measure.(332)  Additionally, a tumour could become significantly 
bulkier in all dimensions without a 20% increase in the areas where the specific 
measurements were taken.  Finally, there is poor correlation between TNM stage and 
mRECIST as serial markers of disease status.  It is perfectly possible for a tumour to be 
upstaged on TNM without meeting the mRECIST criteria for disease progression, for 
example via new invasion of the diaphragm. 
 
Tumour volume, assessed on CT or MRI, provides a more accurate evaluation of MPM 





MPM in several academic centres and shown to be reliable and consistent, if time-
consuming.(333)  The development of artificial intelligence software (AI) to perform 
automated 3-dimensional evaluation of MPM tumours is likely to have a dramatic 
impact on the radiographic assessment on MPM, and should be included in any future 
full-scale trial. 
 
Another consideration for a full-scale trial relates to the open-label nature of both trial 
arms.  Although with the TwiC design, the intention is for controls to be blinded, this 
was not possible in the TILT population.  This could have introduced assessment bias, 
particularly in the completion of patient-reported outcome measures – data that are 
inherently subjective.  People who received an IMP may have been more aware of 
symptoms and therefore more likely to score them highly.  Alternatively, participants in 
the control arm may have been so disappointed not to receive an IMP that it impacted 
on their quality of life. The conclusion not to proceed to a full-scale TwiC and to consider 
a modified approach of a classical, double blind RCT embedded in a cohort removes this 
limitation.   
 
The longer survival observed in TILT participants compared to national figures highlights 
a frequent issue affecting MPM trials, that of selection bias.  The fact that both control 
participants and people who received an IMP lived longer than expected meant that the 
positive outcome could not be credited to IMP efficacy.  Nor was it likely that the act of 
participating in the trial conferred a survival benefit.  Instead, it is probable that the 





reflected in their enhanced survival.  The enrolment of a skewed population to the trial 
may be due to the eligibility requirements, e.g. good performance status, or may be a 
result of healthier people being more likely to participate in a trial.  Whilst this bias 
often cannot be avoided, it should be acknowledged.  This finding also serves to 
emphasise the importance of having RCT data to evaluate any intervention: had TILT 
been a single-arm study of OK432 or BCG, the longer survival could have been 
misattributed to the IMP.  Having a control population with a similarly long survival 
clearly signified that this outcome was affected by bias.   
 
Another bias that was likely to have affected TILT (and contributed to the selection bias 
described above) is survivorship bias.  Participants enrolled in TILT were not required to 
be newly diagnosed, indeed only two people were randomised within a month of 
receiving their diagnosis.  The remaining participants were enrolled between 3 months 
and 30 months after diagnosis.  MPM is a heterogeneous disease and whilst the 
prognosis is poor for most, there is a recognised sub-group of long survivors who have 
very indolent disease.(1, 44)  The participant who joined TILT 30 months after his 
diagnosis had already outlived the predicted 12 month life-expectancy for MPM by a 
substantial margin and was, therefore, almost certain to be a “long survivor”.  It was not 
a surprise, therefore, that he remained alive 15 months later when survival was 
censored.  The receipt of an IMP in the latter third of his overall recorded survival could 
not possibly explain his prolonged survival prior to joining the trial, but nor should it be 
assumed to be the cause of ongoing survival.  Both phenomena are most probably 





Survivorship bias is a particular risk in post-front line therapy trials.  By definition, 
participants must have survived long enough to complete first-line therapy, which 
precludes patients with more aggressive disease phenotypes.  This is a potential 
explanation for the recurrent pattern of positive single-arm phase II trials being followed 
by negative phase III RCTs in MPM.(50, 51)  
 
As well as affecting outcomes, the selection and survivorship bias that affected TILT 
would limit the external validity of full-scale trial using this methodology.  The trial 
population was not representative of the UK MPM population and this is also likely to be 
the case for a subsequent full-scale trial.  Therefore, the results of a full-scale trial would 
not be generalisable to the wider patient group.  This undermined one of the 
fundamental aims of TILT, which was to be a pragmatic trial that closely resembled real-
world care and had high external validity.  
 
6.4.4. Qualitative study 
Embedding qualitative research within the TILT trial allowed rich and holistic data to be 
collected about the acceptability of the trial design, augmenting the quantitative 
feasibility data.  In addition, the qualitative interviews provided a detailed depiction of 
the attitudes, expectations and experiences of people with MPM and their relatives in 
regard to both the trial and MPM.  The inductive and flexible nature of qualitative 
research enabled identification of previously unreported themes (e.g. certainty and risk 
communication) and provided the space to explore these themes with subsequent 






Several themes identified in the qualitative study have been described in previous work 
relating to the experience of living with MPM. The theme of physicality and the value 
placed on health and strength was reported by Dr Clayson in interviews with men with 
mesothelioma and focus group sessions with their wives.(174)  She described the 
deterioration in body-image as damaging to men’s sense of self, as their prior fitness 
had been a major asset during physically demanding jobs.  She also noted the stoicism 
and acceptance with which men responded to the diagnosis of mesothelioma, and 
contrasted this with the responses of bereaved wives, which were characterised by 
“intense passion, anger and fierce determination” to fight on behalf of their husbands.  
The TILT qualitative study noted similarly contrasting responses between the two groups 
and this replication of previous qualitative outcomes increased the credibility of other 
findings from this study. 
 
6.4.4.2. Sample size & information power 
The purposive sampling strategy was robust, with the different aspects of trial 
participation reflected in the qualitative data.  Specifically, people who participated in 
both active and control arms were interviewed, and the views of participants who 
declined to participate were also represented.  Based on Malterud’s theory, the 
specificity of the TILT qualitative study population, the narrow study objective and the 
quality of the dialogue meant that the sample size had high information power to 
address the study aim.(231)  Certainly the data collected was interesting, insightful and 





work.  The aim of the study was addressed satisfactorily and several additional findings 
were uncovered that had relevance to current and future clinical and academic work in 
MPM. 
 
Notwithstanding the high information power of the sample, it must be acknowledged 
that the qualitative sample size was vulnerable to being influenced by recruitment to 
TILT.  Had interviews been limited to TILT participants and their immediate family 
members, the fact that TILT underrecruited could have limited the qualitative findings. 
However, the addition of snowball sampling to enable additional relatives, friends and 
carers to be invited to interview overcame this potential limitation. Ultimately, snowball 
sampling was not required and, aside from the wife and daughter of one participant, 
only one relative of each TILT participant was interviewed for the qualitative study. 
However, the option to recruit additional relatives and friends if a larger sample size 
were needed was a strength of the study design. 
 
6.4.4.3. Transferability 
Unfortunately, not everyone who was invited to participate in the qualitative study 
agreed. Of the trial participants, two did not participate in an interview; in both cases 
this was because the person was nearing the end of their life and was too unwell.  One 
lady had actually agreed to take part in the qualitative study but deteriorated rapidly 
and died before the interview took place.  This meant that the study did not include any 
experiences of people in the terminal phase of their disease.  The daughter-in-law of 





account of his experience from her perspective.  The husband of the lady who died prior 
to interview was invited to participate in the study but he did not respond to the 
invitation. He was the only relative to be bereaved during the study.  
 
The qualitative findings may not reflect the views of people who are in the final stages 
of MPM, therefore. These people may have had specific experiences and perspectives 
that were not shared or reported by people who were not in the terminal phase.  For 
example, people who were dying from MPM may have felt the trial processes to be 
more burdensome, or they and their relatives may have felt resentful that the limited 
time they had left together was being spent on the research trial.  Alternatively, people 
may have been comforted by the idea that they were contributing to something with 
long-lasting impact, and the research may have given them a sense of purpose during 
their final days. All of these views have been reported previously in interviews with 
patients dying of other cancers and their bereaved carers.(334, 335)   
 
Clearly, the experiences of people participating in research during the terminal stages of 
MPM are important and interviews with people in this situation would provide valuable 
information. However, research is difficult to conduct in this population. Potential 
participants are likely to have reduced mobility, low energy levels, poor concentration, 
and active symptoms such as breathlessness and pain. These create practical and ethical 






Despite the absence of people in the terminal phase of MPM, many of the experiences 
reported in the qualitative interviews will have been shared by others with MPM, 
whatever stage of the disease they are in. The ‘biographical disruption’ described by 
Bury was apparent in the narratives of TILT participants and will have been experienced 
by many people with MPM.(287, 319) Similarly, the thirst for information and desire for 
certainty are unlikely to be unique to interviewed participants. Therefore, although the 
data reported here did not specifically include people in the terminal stages of MPM, 
many of the findings should resonate with their experiences, nonetheless. 
 
The study sample was entirely made up of white British participants in late middle age 
or older.  TILT trial participants who were interviewed were all male.  Although this 
sample may not be representative of the general population, it is a typical reflection of 
the UK population of people with MPM.(38)  Therefore, the findings are likely to be 
transferable to the wider UK MPM community. That said, people with MPM from other 
racial, ethnic and cultural backgrounds may describe different experiences of living with 
MPM and of participating in research, as may women with MPM.  The views and 
experiences of these groups of people should not be ignored simply because they 
represent a minority of the MPM population.  Indeed, their minority status makes a 
stronger case for understanding their experiences to obtain a full picture of the 







Reflexivity is an important element of all qualitative research, and a poor appreciation of 
the impact of the researcher and their individual characteristics on data collection and 
analysis can undermine the credibility of the results.(336)  In the TILT qualitative study, 
all interviews took place between participants and myself.  I kept a diary of reflections 
during the study to capture my experience of the process and reflect on my positionality 
within the interviews and data analysis, as advised in several qualitative method 
guides.(228, 337)  There were three areas where my personal experience, role and 
background intersected with qualitative study processes.  These areas are described in 
turn below and their potential effect on the work considered. 
 
The first reflexivity point related to my role as a MPM clinician and PI for the TILT trial.  I 
had met all of the qualitative participants at least once prior to their interviews and all 
were aware of my position within the trial.  In her article on qualitative research, Prof 
Nicky Britten stated that clinicians should not interview their patients, as participants 
may be more likely to say what they think their doctor wants to hear.(240)  However, 
she goes on to recommend that if this situation cannot be avoided, patients should be 
given permission to speak freely and should not be corrected if they express a view or 
opinion that the doctor disagrees with. This was the approach I adopted. 
 
However, despite encouraging participants to speak openly and honestly about their 
experiences, it must be considered that my clinical and research roles may have 
influenced participants’ responses during the interviews.  Specifically, it is perhaps not a 





few suggestions for improvement or change, given that they knew the trial had been 
designed by the person sat in front of them.  To overcome this, interviews were 
presented as a collaborative effort to improve future research for other people with 
MPM, rather than a specific critique of TILT.  Additionally, I approached the interviews 
with a humble and receptive manner, and all comments, positive or negative, were 
received with interest and encouragement.  This approach appeared to be successful, as 
two participants were particularly forthcoming and spoke at length about their 
perceived criticisms of the trial.  This suggested that my manner encouraged negative as 
well as positive feedback.  
 
My role as a clinician with MPM experience and pre-existing clinical relationships with 
many of the participants may have had some beneficial impact on the study.  For 
example, I have received extensive training in communication skills during my medical 
training and have been involved in difficult conversations e.g. breaking bad news and 
discussing end of life issues, on a regular basis since qualifying as a doctor.  These 
experiences were extremely useful when conducting interviews and enabled me to 
discuss potentially upsetting issues in a sympathetic and sensitive manner.  Additionally, 
the pre-existing clinical relationship between several participants and me meant that 
dialogue was potentially easier because a level of trust and mutual respect had already 
been established. 
 
The second important area of reflexivity related to my inexperience as a qualitative 





interview technique, specifically how comfortable I felt with silence and allowing people 
time to formulate their own thoughts.  Reflecting on this behaviour led me to William 
Whyte’s guidance on conducting qualitative interviews, which included techniques such 
as reflecting back remarks made by the participant and asking for expansion on 
comments of interest.(338) Adopting these methods strengthened my interview skills 
and, listening to the audio-recordings of the interviews, it is clear by the third interview 
that my practice was much improved.   
 
Finally, I became increasingly aware during the qualitative study that interviews with 
female relatives were longer, richer and more open than the interviews with male 
participants.  In part, this may have been a reflection of the different behaviours of the 
two groups, i.e. that men tended to be stoical and down-play events, whilst their wives 
and daughters were more vocal and likely to advocate on their behalves.  It must be 
considered, however, that my own gender may have been a factor in encouraging 
female participants to talk freely.  The corollary is that men may have felt less able to 
open up to me, as a woman, although based on discussions in PPI groups and the overall 
experience of working with men with MPM, it seems unlikely that male participants 
would have been any more forthcoming with a male interviewer.   
 
Another possible explanation for the quality of data obtained from interviews with 
female relatives relates to my own experience of bereavement.  Prior to the study I was 
aware that I felt great sympathy for people with MPM and their relatives, but the 





study progressed.  I suspect that this empathy contributed positively to interviews with 
relatives.  This phenomenon has been described previously, by Dr Jenny Bozenski, who 
interviewed 12 clinical psychologists about the experience of bereavement on their 
work.(339)  They described increased empathy towards clients in the aftermath of 
bereavement and greater sensitivity to their grief.  In many cases this enhanced 
therapeutic interactions, as it is likely to have done in the TILT qualitative interviews. 
 
6.4.5. Co-production and patient & public involvement 
The work undertaken in this thesis was planned and designed in close collaboration with 
patients and the public during dedicated co-production meetings and patient and public 
involvement (PPI) group sessions.(340)  This ensured that the content and overall aim of 
the research was consistent with the priorities and values of the people at the heart of 
the thesis, i.e. people with MPM.  The close involvement of the dedicated PPI group, 
who reviewed the protocols, consent forms and all patient-related resources for TILT 
and the qualitative study, was likely a crucial factor in the overall acceptability of the 
trial to participants and relatives.  
 
The suggestions made by the PPI group and the changes made to the study protocols 
following their recommendations have been described in the relevant sections.  Briefly, 
the trial follow-up regimen, the choice of patient-reported outcome measures, the 
decision to include friends as well as family in the qualitative study, the appropriateness 





interviews over focus groups for people with MPM and the qualitative topic guide were 
all strongly informed by the PPI group. 
 
The opportunity for mutual learning was evident during the PPI sessions. The academics 
and clinicians enjoyed meeting patients outside the usual hospital setting and felt it 
allowed a more holistic view of patients as “real people”, each with their own 
knowledge, skills and experience to bring to the trial.  Participants in the PPI groups, 
which included people with MPM, carers of people with MPM and bereaved relatives of 
people who had died from MPM, were interested to learn about the processes that take 
place ‘behind the scenes’ in academic research, and said how much they appreciated 
the opportunity to contribute to the process.  Overall, everyone involved in the PPI work 
experienced a sense of partnership, with a shared purpose and joint commitment to try 
& improve knowledge and treatment in MPM. 
 
There are two rationales for including PPI input in the design and implementation of 
clinical research.  The first is a moral argument, i.e. the people most affected by the 
condition being studied should be involved in deciding what research is done in the 
area, and how.  This argument stems from the accepted premise that it is not acceptable 
to research to, on or about people, rather it should be done with or by them.(341)  The 
second argument is consequentialist and relates to the fact that PPI can improve the 
quality, efficiency and dissemination of clinical trials.(342)  Both arguments are 
compelling and will appeal to different stakeholders, for example, funders may be more 





prefer the moral reasoning.  Either way, there are indisputable benefits from PPI, which 
make non-inclusion difficult to justify. 
 
There are challenges in PPI work, however, including the practical demands on 
participants.(343)  For people with MPM who may have troublesome symptoms, this 
should not be underestimated.  Additionally there is an emotional burden of re-visiting 
issues relating to their illness (which men with MPM were often reluctant to do based 
on the findings of our qualitative work).(343)  Finally, and of particular pertinence to 
people with MPM, there is the issue that contributing to PPI and the types of discussions 
held during PPI meetings may serve as an unwelcome reminder to patients about the 
poor prognosis of MPM and the lack of treatment options available.  Mesothelioma 
researchers have described patients and relatives becoming upset or even leaving 
meetings where research is being discussed, as a result of the sheer volume of negative 
information presented.(260) The authors of that report suggest a novel approach to 
mesothelioma PPI analogous to a speed-dating event, where patients and carers rotate 
in groups around stations or tables where a researcher is sat.  Discussions can take place 
on a more personal level, with information exchange tailored to the people in each 
group.  A similar approach has been trialled at one of the Bristol patient and carer 
update days, with positive feedback from all involved.  PPI for future MPM trials will 






6.5. Future research 
There remains uncertainty regarding the role of intra-pleural bacterial products as 
immunotherapeutic agents in MPM.  The systematic review highlighted the need for 
well-designed, suitably powered, RCTs to determine whether these agents prolong 
survival.  Such a trial would require certain methodological decisions to be made upfront 
and the finding of this thesis may inform those decisions. 
 
6.5.1. Choice of bacterial agent 
The systematic review did not identify any single bacterial agent that was likely to be 
more effective in the treatment of malignant pleural disease.  However, certain 
difficulties encountered during the set-up of the TILT trial could guide the choice of 
agent for future trials.  Unfortunately, several bacterial agents are no longer 
commercially available, despite initially promising clinical trial data.  Unavailable agents 
include Lactobacillus casei, Nocardia rubra and Corynebacterium parvum.   
 
OK432 was obtained for the TILT trial, albeit with some logistical difficulty and at 
considerable expense.  Although an established procurement pathway has now been 
established and a reliable importation company identified, the costs associated with 
obtaining OK432 remain high, with no expectation of bulk savings if a larger trial were 
planned.  It should also be noted that OK432 failed to demonstrate any positive effect 






The other bacterial agent studied was BCG, a drug that has an established role in 
bladder cancer and is therefore easily obtainable through NHS procurement pathways.  
In the systematic review, BCG was associated with a survival benefit in both studies that 
employed it, although they were non-randomised and at high risk of bias in several 
domains.  These findings are in keeping, however, with the established anti-neoplastic 
effect of intra-vesical BCG in bladder cancer.(108-113)  BCG also exerts a cytotoxic effect 
in melanoma, inducing tumour regression and significant prolongation of survival 
following intra-lesional administration.(115)  The exact mechanism of action is 
unknown, but is likely to involve activation of CD4+ and CD8+ T lymphocytes and release 
of cytokines, such as interferon-gamma and tumour necrosis factor.(105, 106, 344, 345)  
The scientific rationale, pre-clinical data and clinical evidence is strongest, therefore, for 
BCG, and it certainly induced significant inflammatory responses in patients who 
received it in the TILT trial.   
 
Further information is needed regarding the frequency and severity of BCG-related 
inflammatory responses in people with MPM. There is an interesting question to be 
answered regarding immunological memory to M. Bovis and whether people who react 
strongly to tuberculin skin testing are more likely to experience severe reactions to 
intra-pleural BCG.   Given the priorities of people with MPM, as described in this thesis, 
the risk of potential reactions following intra-pleural BCG would need to be balanced 
against its potential efficacy (and clearly stated in the PIS) if a future full-scale trial were 
planned.  Fear of side effects may limit recruitment to a trial and, ultimately, BCG 






6.5.2. Participant recruitment 
If a full-scale trial of intra-pleural bacteria in MPM were planned, the challenge of 
recruitment would need to be addressed.   It is now clear that the population of people 
who would be eligible for the trial is smaller than was anticipated at the beginning of 
this PhD.  One option to overcome this would be to increase the number of recruiting 
sites and establish participant identification centres (PIC) to refer people into the trial 
from distant hospitals.  However, given the small number of cases of MPM seen in most 
hospitals, this is unlikely to radically increase numbers.  Extending the recruitment 
window would be another option, but this would be associated with higher costs and 
resource requirements. Additionally, there is an element of urgency in undertaking this 
work in order to find an effective treatment before MPM incidence falls to such a 
degree that the treatment is no longer required.  A trial period of several years is not 
ideal in this context. 
 
An alternative approach would be to relax the inclusion criteria.  The factor that most 
frequently rendered people ineligible for TILT was the lack of an IPC, or absence of a 
pleural effusion.  An ongoing trial of an intra-pleural oncolytic adenovirus has attempted 
to avoid this issue by including the option for patients to have an IPC inserted surgically, 
in the absence of a pleural effusion (NCT03710876).  However, given the increasing age 
of the MPM population and associated co-morbidities, it seems likely that a reasonable 






The presence of non-expandable lung and loculations in the pleural cavity must remain 
as exclusion criteria for two reasons. Firstly, in order to stimulate an immune response, 
the bacterial agent must be able to come into contact with the pleura, rather than 
simply gather in a discrete locule.  Secondly, we have shown that intra-pleural bacterial 
agents are highly inflammatory and, if delivered to patients with non-expandable lung, 
are likely to result in a complex, multi-loculated effusion which could cause symptoms 
but could not be drained.  This would clearly be unacceptable. 
 
Another eligibility criterion that cannot be changed is that of no concurrent 
chemotherapy.  Whilst some clinicians (including us) may feel braver about 
administering inactivated and killed bacteria alongside immunosuppressant medication 
such as chemotherapy, the most promising bacterial agent, BCG, is a live-attenuated 
bacteria, and would be carry a high risk of uncontrolled infection if administered in the 
context of chemotherapy.  The phenomenon of disseminated BCG-osis that has been 
reported after intra-vesical use of BCG in bladder cancer supports our concerns in this 
regard.(346, 347) 
 
A final consideration regarding the feasibility of a future full-scale trial of intra-pleural 
bacterial immunotherapy is the evolving treatment landscape and increasing number of 
competing clinical trials in MPM.  As the evidence grows for the use of systemic 
immunotherapy agents in MPM, more patients are keen to receive them, whether as 
part of routine clinical care (depending on the formal results of CHECKMATE-743), in a 





over the next few years, patients will increasingly elect to pursue one of these 
treatments, rather than receive an unproven intrapleural bacterial agent.  Additionally, 
it is important to note that most of the clinical trials of checkpoint inhibitors excluded 
people who have previously received immunotherapy.  There is an ethical dilemma 
about recruiting patients to a clinical trial that may preclude them from receiving an 
effective treatment at a later date. 
 
6.5.3. Trial methodology 
The work described in this thesis has shown that the TwiC methodology is not feasible 
for future trials in the MPM population, due to an inability to maintain blinding of the 
control arm and attrition from the intervention arm after randomisation.  However, 
elements of the design remain attractive and of potential benefit to future MPM trials, 
specifically the possibility to increase recruitment efficiency by screening within a cohort 
and the option to collect long-term outcome data on both trial participants and people 
who decline trials.   
 
On this basis, I propose a modified TwiC methodology for MPM, consisting of a standard 
double-blinded, placebo-controlled RCT embedded within the ASSESS-meso cohort.  
Screening for trial eligibility could take place at regular cohort assessment visits, and if a 
person is found to be eligible, they are approached in the usual fashion and standard 
RCT process followed.  With this approach, all ASSESS-meso centres could function as 
PICs, with patients being offered the option to travel to one of the main trial sites if they 





patients would be less likely to withdraw from the study after randomisation.  On 
completing the trial at the trial centre, they could return to their local centre for ongoing 
data collection as part of ASSESS-meso.  In this way, the benefits of the TwiC are 
maintained, whilst the challenges encountered during TILT are eliminated. 
 
6.5.4. Qualitative studies 
The qualitative work undertaken as part of this thesis highlighted several areas of 
interest for future research studies.  Most pressingly there is a need to understand more 
about perception of risk in people with MPM and the most effective way of 
communicating uncertainty to patients, in both the clinical trial setting and in the 
context of clinical care.  A reasonable starting place for this work would be to review 
existing clinical documents that discuss benefits and risk, e.g. patient information sheets 
about biopsies and thoracoscopy, and explore how they are perceived and interpreted 
by patients and their relatives.  This could be done using a cognitive interviewing 
approach.(348)  This is a technique that is usually applied to the development of 
questionnaires or surveys but could equally be applied to patient information leaflets.   
Participants are encouraged to think aloud as they read the document, whilst an 
interviewer may ask additional questions to enable initial thoughts to be expanded 
upon.  The participant’s responses are collected and analysed qualitatively.      
 
The finding that participants were ill prepared for adverse reactions, despite being 
warned of the possibility in the trial PIS, makes a compelling case for greater amounts of 





dedicated MPM PPI group was established, and this group should be maintained and 
capitalised on for future studies, potentially using novel techniques such as “Meet the 
Researcher” that have been well-received in other patient research events in MPM (see 
Section 6.5.4.).(260) 
 
Although the TwiC methodology was not feasible for use in future MPM trials, it may 
have a role in other respiratory illnesses.  In order to shape and inform potential future 
trials, qualitative interviews with the research team and clinicians involved in TILT could 
provide useful information about the acceptability of this methodology to the people 
delivering the research.  One observation of interest was that all ASSESS-meso 
participants who declined to be considered for TwiCs were enrolled at the same study 
site.  Was the trial methodology explained in a different way at that centre?  Or were 
the trial team less enthusiastic about the methodology and this was communicated to 
patients, either explicitly or sub-consciously?  Given the novelty of the TwiC design and 
its potential use in other clinical settings, there is value in undertaking further work to 
delineate the acceptability and feasibility of its use as much as possible. 
 
People with MPM were clear that the survival benefit offered by current treatment 
options were not sufficient to risk the adverse events associated with those treatments.  
To understand people with MPM’s decision-making and to help tailor future treatment 
offers, it would be interesting to investigate the relative importance of survival benefit 
against potential side effects using a discrete choice experiment (DCE).  Initially designed 





choice experiments present a series of hypothetical scenarios where single elements are 
altered sequentially to evaluate people’s priorities and the level at which their decision 
changes.(349)  In MPM, DCE could be used to determine what survival benefit 
chemotherapy would have to offer to make it acceptable or attractive to patients. 
Similarly, given the known side effect profiles of the newer immunotherapy agents, 
what level of clinical efficacy would people require before they contemplate receiving 
treatment?  Do these decisions vary depending on patient characteristics, and if so, 
what are those characteristics?  Further qualitative work could shed important light on 
these questions and help MPM clinicians and researchers understand patients’ priorities 
and thus offer a more personalised approach to their care. 
 
6.6. Conclusion 
This thesis presents evidence about the role of intra-pleural bacterial immunotherapy in 
pleural malignancy, specifically MPM.  Although intra-pleural bacterial agents have been 
studied as potential treatments for pleural malignancy for several decades, evidence for 
their anti-cancer activity is weak and beset by methodological issues. Bacteria arising in 
the pleural space due to pleural infection were not associated with improved survival in 
people with mesothelioma, in fact the opposite outcome was observed and people with 
pleural infection were more likely to die than those without.  It was clear that 
randomised trial data was required to reliably determine the efficacy (or lack thereof) of 
intra-pleural bacteria in MPM. 
 
The TILT trial was designed as a feasibility study of two intra-pleural bacterial agents, 





first CTIMP to employ the TwiC design and demonstrated that the methodology could 
comply with the necessary clinical trial regulations and obtain the requisite approvals 
from the HRA and MHRA.  Participants in TILT found the trial processes and 
methodological design acceptable, but ultimately the trial was unfeasible for several 
reasons.  Recruitment was challenging due to a smaller eligible population than initially 
expected and the TwiC methodology added further restrictions to recruitment, for 
example the trial could not be advertised on clinical trial registers or patient support 
websites.  Additionally, one of the fundamental premises of the TwiC approach, that 
control participants were unaware of the trial’s existence, could not be maintained in 
people with MPM.  Finally, attrition after randomisation occurred in both arms of the 
trial and this could have important implications for bias if a full-scale TwiC were 
planned.  Both intra-pleural agents generated significant systemic inflammatory 
responses, and dose-reduction was necessary to attenuate this reaction.  
 
Qualitative interviews revealed that people with MPM tended to be practical, stoical 
and well-informed about their disease and about research.  Their desire for certainty in 
the face of an uncertain future created challenges in the communication of risk, which 
has potential implications for current clinical work and future research trials.  People 
with MPM were motivated to participate in research by a combination of altruism and 
potential personal gain.  In contrast, their relatives were more anxious about the future 
and felt protective of their family member and, as a result, were more reluctant for 






Effective treatment options are still required for MPM.  Based on the findings of this 
thesis, a full-scale TwiC of intra-pleural OK432 or BCG in MPM is not recommended. 
However, future research approaches could involve embedding a traditional RCT within 
the ASSESS-meso cohort.  This would facilitate more efficient recruitment and enable 
collection of long-term outcome data, whilst avoiding some of the challenges 
encountered by TILT.  The work presented here will help inform future MPM trials and, 
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Appendix 1 – Search strategy for the systematic review 
 
i) Medline Epub Ahead of Print, In-Process & Other Non-Indexed Citations, 
Ovid Medline (R) Daily and Ovid Medline (R) <1946 to 2017 week 09> 
1 malignant pleural effusion.mp. or exp Pleural Effusion, Malignant/ 3988 
2 malignant pleura$ effusion$.mp     2267 
3 malignant pleura$ effusion$.m_titl     1191 
4 pleural effusion.mp. or exp Pleural Effusion/    25996 
5  (pleura* adj5 (effusion* or fluid*)).mp     30742 
6 1 or 2 or 3 or 4 or 5       30742 
7 exp Neoplasms/ or neoplas*.mp       3005820 
8 (cancer* or tumor* or tumour* or carcinom* or malignan*).mp.  2896188 
9  7 or 8         3778969 
10 6 or 9         3795436 
11 intra-pleura$.mp.       99 
12 intra-pleura$.m_titl.       28 
13 intra pleura$.mp.       99 
14 intra pleura$.m_titl.       28 
15 intrapleura$.mp.       2926 
16 intrapleura$.m_titl       1209  
17 11 or 12 or 13 or 14 or 15 or 16      2992 
18 OK432.mp. or exp Picibanil/      1599 
19 OK-432.mp.        1485 
20 OK 432.mp.        1485 
21 OK432.m_titl.        85 





23 OK-432.m_titl.        849 
24 18 or 19 or 20 or 21 or 22 or 23       1880 
25 corynebacterium parvum.mp. or exp Propionibacterium acnes/  3785  
26 corynebacterium parvum.m_titl.     672 
27 25 or 26        3785 
28 BCG.mp. or exp Mycobacterium bovis/     31283 
29 bacille calmette guerin.m_titl      653 
30  28 or 29        31300 
31 exp Adjuvants, Immunologic/ or exp Lactobacillus casei/ or LC9018.mp. 157064 
32 superantigen.mp. or exp Superantigens/    5264 
33 exp Superantigens/ or exp Bacterial Toxins/ or exp Staphylococcus aureus/ or  
exp Staphylococcal Infections/ or exp Lymphocyte Activation/ or staphylococ* 
superantigen.mp. or exp Enterotoxins/     348842 
34 exp Staphylococcal Infections/ or superantigen.mp. or exp Streptococcus  
pyogenes/ or exp Staphylococcus aureus/ or exp Superantigens/ or exp  
Streptococcal Infections/      170762 
35 exp Staphylococcus aureus/ or exp Bacterial Proteins/ or exp Membrane  
Proteins/ or exp Bacteria/ or exp Bacterial Infections/ or bacteri*.mp. or exp  
Bacterial Toxins/       3580177 
36 Gram-Negative Aerobic Bacteria/ or Gram-Negative Bacteria/ or Gram- 
Negative Anaerobic Bacteria/ or Gram-Positive Endospore-Forming Bacteria/  
or Bacteria, Anaerobic/ or Gram-Negative Chemolithotrophic Bacteria/ or  
Bacteria, Aerobic/ or Gram-Positive Bacteria/ or exp Bacteria/ or bacteria.mp.  
or Endospore-Forming Bacteria/     
 1304044 
37 lipopolysaccharide.mp. or exp Lipopolysaccharides/   97434 
38 Enterotoxin.mp or enterotoxin.m_titl     11746 
39 immunotherapy.mp. or exp Immunotherapy, Active/ or exp Immunotherapy/  
or exp Immunotherapy, Adoptive/     267316 
40 coley.mp. or exp Cancer Vaccines/     11960 
41 24 or 27 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40   





42 10 and 17 and 41       404 
43 limit 42 to human       316 
 
Once duplicates removed – 312 
 
ii) EMBASE via OVID <1974 to 2017 February 28>    
1 malignant pleural effusion.mp. or exp Pleural Effusion, Malignant/ 3991 
2 malignant pleura$ effusion$.mp.     2267 
3 malignant pleura$ effusion$.m_titl.     1191 
4 (pleura* adj5 (effusion* or fluid*)).mp.     30749 
5 pleural effusion.mp. or exp Pleural Effusion/    26003 
6 1 or 2 or 3 or 4 or 5       30749 
7 exp Neoplasms/ or neoplas*.mp.     3006214 
8 (cancer* or tumor* or tumour* or carcinom* or malignan*).mp.  2897416 
9 7 or 8         3780252 
10 6 or 9         3796720 
11 intra-pleura$.mp.       99 
12 intra-pleura$.m_titl.       28 
13 intra pleura$.mp.       99 
14 intra pleura$.m_titl.       28 
15 intrapleura$.mp.       2927 
16 intrapleura$.m_titl.       1209 
17 11 or 12 or 13 or 14 or 15 or 16      2993 
18 OK432.mp. or exp Picibanil/      1599 
19 OK-432.mp.        1485 
20 OK 432.mp.         1485 





22 OK 432.m_titl.         849 
23 OK-432.m_titl.         849 
24 18 or 19 or 20 or 21 or 22 or 23       1880 
25 corynebacterium parvum.mp. or exp Propionibacterium acnes/   3786 
26 corynebacterium parvum.m_titl.      672 
27 25 or 26         3786 
28 BCG.mp. or exp Mycobacterium bovis/      31289 
29 bacille calmette guerin.m_titl.       653 
30 (BCG or Mycobacterium bovis or bacille calmette guerin).m_titl.   12984 
31 exp Adjuvants, Immunologic/ or exp Lactobacillus casei/ or LC9018.mp.  157068 
32 superantigen.mp. or exp Superantigens/     5264 
33 exp Superantigens/ or exp Bacterial Toxins/ or exp Staphylococcus aureus/ or exp 
Staphylococcal Infections/ or exp Lymphocyte Activation/ or staphylococ* 
superantigen.mp. or exp Enterotoxins/      348863 
34 exp Staphylococcal Infections/ or superantigen.mp. or exp Streptococcus pyogenes/ or 
exp Staphylococcus aureus/ or exp Superantigens/ or exp Streptococcal Infections/ 
          170782 
35 exp Staphylococcus aureus/ or exp Bacterial Proteins/ or exp Membrane Proteins/ or 
exp Bacteria/ or exp Bacterial Infections/ or bacteri*.mp. or exp Bacterial Toxins/ 
                              3580690 
36 Gram-Negative Aerobic Bacteria/ or Gram-Negative Bacteria/ or Gram-Negative 
Anaerobic Bacteria/ or Gram-Positive Endospore-Forming Bacteria/or Bacteria, 
Anaerobic/ or Gram-Negative Chemolithotrophic Bacteria/ or Bacteria, Aerobic/ or 
Gram-Positive Bacteria/ or exp Bacteria/ or bacteria.mp. or Endospore-Forming 
Bacteria/                                  1304276 
37 lipopolysaccharide.mp. or exp Lipopolysaccharides/    97462 
38 Enterotoxin.mp. or enterotoxin.m_titl.      11746 
39 immunotherapy.mp. or exp Immunotherapy, Active/ or exp Immunotherapy/ or exp 
Immunotherapy, Adoptive/       267361 
40 coley.mp. or exp Cancer Vaccines/      11960 





42 10 and 17 and 41        403 
43 limit 42 to human        315 
 
Once duplicates removed – 311 
Removing duplication with MEDLINE search - 0 
 
iii) Cochrane Central Register of Controlled Trials and Cochrane review 
database   
#1 MeSH descriptor: [Pleural Effusion, Malignant] explode all trees   117 
#2 malignant pleura* effusion*:ti,ab,kw (Word variations have been searched) 386 
#3 #1 or #2         386 
#4 MeSH descriptor: [Picibanil] explode all trees     94 
#5 OK432 or OK-432 or OK 432:ti,ab,kw (Word variations have been searched) 146 
#6 #4 or #5         159 
#7 MeSH descriptor: [Propionibacterium acnes] explode all trees   104 
#8 corynebacterium parvum:ti,ab,kw (Word variations have been searched) 99 
#9  #7 or #8         154 
#10 MeSH descriptor: [Mycobacterium bovis] explode all trees   84 
#11 MeSH descriptor: [BCG Vaccine] explode all trees    745 
#12 BCG or 'bacille calmette guerin':ti,ab,kw (Word variations have been searched) 1518 
#13 #10 or #11 or #12        1531 
#14 MeSH descriptor: [Bacteria] explode all trees     12403 
#15 MeSH descriptor: [Bacterial Toxins] explode all trees    2115 
#16 MeSH descriptor: [Superantigens] explode all trees    10 
#17 MeSH descriptor: [Bacterial Proteins] explode all trees    1612 
 #18 MeSH descriptor: [Enterotoxins] explode all trees    120 
#19 MeSH descriptor: [Membrane Proteins] explode all trees   15673 





#21 MeSH descriptor: [Immunotherapy] explode all trees    7799 
#22 MeSH descriptor: [Cancer Vaccines] explode all trees    279 
#23 superantigen or enterotoxin or lipopolysaccharide or Coley:ti,ab,kw  (Word variations 
have been searched)        982 
#24 MeSH descriptor: [Adjuvants, Immunologic] explode all trees   1956 
#25 MeSH descriptor: [Lactobacillus casei] explode all trees    143 
#26 LC9018:ti,ab,kw (Word variations have been searched)    4 
#27 #6 or #9 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or 
#24 or #25 or #26        39181 
#28 #3 and #27         35 
 
Removing duplicates with previous searches – 24 (16 excluded) 
 
iv) US National Library of Medicine at www.Clinicaltrials.gov  
Searched on 01/03/2017 
Search terms:   "intra-pleural" and "malignant pleural effusion" 
Study Type:    all studies  
Study Results:    all studies 
Recruitment:    all studies 
Eligibility Criteria: Adult (18–65) and Senior (66+) 
21 results (all excluded) 
 
v) International Standard Randomised Controlled Trial Number Registry at 
www.isrctn.com.  Searched on 01/03/19. 
Text search:  blank 
Condition:  malignant pleural effusion 
Interventions:  blank 
Funder Name:  blank 






vi) EU Clinical Trials Register www.clinicaltrialsregister.eu. 
Searched 01/03/2017 
 
1. Malignant pleural effusion     122 
2. Intrapleural       15 
3. Intrapleural immunotherapy    0 
4. Malignant pleural effusion AND intrapleural   4 
5. Malignant pleural effusion AND immunotherapy  11 
6. Malignant pleural effusion AND bacteria   0 
7. Malignant pleural effusion AND OK432   0 
8. Malignant pleural effusion AND Corynebacterium parvum 0  
9. Malignant pleural effusion AND BCG   0 
10. Malignant pleural effusion AND lactobacillus casei  0 
11. Malignant pleural effusion AND Coley   0 
 
TOTAL – 152 (all excluded) 
 
 
vii) iSystem for Information on Grey Literature in Europe – SIGLE and the Open 
University Grey Literature site  
Pleural    140 
Intrapleural   4 
Intra pleural   4 
Intra-pleural   1 
Pleural effusion   8 





Appendix 2 – Papers excluded from the systematic review at full-text stage 
and reasons for exclusion 
 
Full-text article not available: 
• Feixue SO, Xiaxia PE, Qimei JI, Yan PE, Jun ZH, Ji XI. Clinical effect of 
pseudomonas aeruginosa injection on malignant pleural effusion. Chinese 
Journal of Clinical Oncology. 2013:1127-9. 
• Ikehara M, Oshita F, Suzuki R, Saitoh H, Yamada K, Noda K. Phase II study of OK-
432 intrapleural administration followed by systemic cisplatin and gemcitabine 
for non-small cell lung cancer with pleuritis carcinomatosa. Journal of 
Experimental Therapeutics & Oncology. 2004;4(1). 
• Wang J, Zhang H, Wang Y. Results of phase III clinical trial of Pseudomonas 
jinanensis vaccine injection (PVI) in the treatment of malignant pleural effusion. 
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]. 1995;17(6):458-60. 
• Fukuoka M, Takada M, Tamai S, Negoro S, Matsui K, Ryu S, Sakai N, Sakaguchi K. 
Local application of anti-cancer drugs for the treatment of malignant pleural and 
pericardial effusion. Gan To Kagaku Ryoho. Cancer & Chemotherapy. 
1984;11(8):1543-9. 
• Urata A, Nishimura M, Ota K. Randomized controlled study of OK-432 in the 
treatment of cancerous pleurisy. Gan To Kagaku Ryoho. Cancer & 
Chemotherapy. 1983;10(6):1497-503. 
 
Survival outcomes not reported, or not reported separately for patients with MPE: 
• Foresti V, Scolari N, Villa A, Parisio E, De Filippi G, Guareschi G. Malignant pleural 
effusions: meaning of pleural-fluid pH determination. Oncology. 1990;47(1):62-4. 
• Kan N, Kodama H, Hori T, Takenaka A, Yasumura T, Kato H, Ogawa H, Mukaihara 
S, Kudo T, Ohsumi K, Mise K. Intrapleural adaptive immunotherapy for breast 
cancer patients with cytologically-confirmed malignant pleural effusions: an 
analysis of 67 patients in Kyoto and Shiga Prefecture, Japan. Breast cancer 
Research and Treatment. 1993;27(3):203-10. 
• Ran ZA. Intracavitary infusion of Huachansu injection combined with 
polysaccharide nucleic acid fraction of Bacillus Calmette Guérin (BCG-PSN) or 
cisplatin in the treatment of malignant pleural and peritoneal effusions. Tumor. 
2008;6:017. 
• Salomaa ER, Pulkki K & Helenius H. Pleurodesis with doxycycline or 
Corynebacterium parvum in malignant pleural effusion. Acta Oncologica. 
1995;34(1):117-121. 
• Yasumoto K, Yamamura Y. Randomized clinical trial of non-specific 
immunotherapy with cell-wall skeleton of Nocardia rubra. Biomedicine & 
Pharmacotherapy. 1984;38(1):48-54. 
• Yew WW, Chan SL, Kwan SY. Comparison of efficacy of mitomycin-C and 
corynebacterium parvum in the management of malignant pleural effusion. 






Duplicate publication of data 
• Kan N, Kodama H, Hori T, Takenaka A, Yasumura T, Kato H, Ogawa H, Ohsumi K, 
Kudo N, Mukaihara S. Intrapleural treatment of breast cancer patients with 
pleural effusions: an analysis of 13 institutes in Kyoto and Shiga Prefectures. 
Kyoto and Shiga Breast Cancer Study Group. Gan to kagaku ryoho. Cancer & 
Chemotherapy. 1992;19(10 Suppl):1632-5. 
• Yasumoto K, Ichinose Y, Yaita H, Tanaka K, Hara N, Ohta M, Hirota N, Nomoto K, 
Inokuchi K, Yamamura Y. Effect of adjuvant immunotherapy with Nocardia rubra 
cell-wall skeleton in lung cancer. Nihon Geka Gakkai Zasshi. 1983;84(4):321-7. 
 
No participants with pleural effusions 
• Holmes EC, Hill LD, Gail M. A randomized comparison of the effects of adjuvant 
therapy on resected stages II and III non-small cell carcinoma of the lung. The 
Lung Cancer Study Group. Annals of surgery. 1985;202(3):335. 
 
Review article 







Appendix 3 – Additional analyses from population-cohort study 
 
Variable of 
interest Interacting variable 
P 
value* 
Sensitivity analysis controlling 
for interacting variable 
RR 95% CI P value 
Comorbidities 
Age 0.018 1.17 1.13-1.20 <0.001 
IMD quintile <0.001 1.17 1.13-1.20 <0.001 
Diagnosed after 2008 <0.001 1.19 1.15-1.22 <0.001 
No of pleural procedures <0.001 1.19 1.16-1.23 <0.001 
No of hospital episodes per year <0.001 1.20 1.16-1.23 <0.001 
IMD quintile 
Age 0.360 0.95 0.90-1.00 0.061 
Comorbidities 0.132 0.96 0.90-1.01 0.080 
Diagnosed after 2008 0.732 0.93 0.88-0.98 0.005 
No of pleural procedures <0.001 0.92 0.87-0.98 0.006 
No of hospital episodes per year 0.053 0.96 0.91-1.02 0.180 
No of pleural 
procedures 
Age 0.056 1.54 1.46-1.63 <0.001 
Comorbidities 0.013 1.57 1.48-1.65 <0.001 
IMD quintile 0.269 1.61 1.52-1.70 <0.001 
Diagnosed after 2008 0.828 1.51 1.43-1.60 <0.001 
No of hospital episodes per year <0.001 1.54 1.46-1.63 <0.001 
Diagnosed 
after 2008  
Age 0.043 1.03 0.86-1.23 0.765 
Comorbidities 0.016 0.95 0.80-1.14 0.595 
IMD quintile 0.650 1.11 0.93-1.32 0.250 
No of pleural procedures 0.355 1.03 0.86-1.23 0.757 
No of hospital episodes per year 0.190 1.02 0.99-1.04 0.186 
No of hospital 
episodes per 
year  
Age 0.190 1.02 0.99-1.04 0.186 
Comorbidities 0.021 1.01 0.98-1.03 0.681 
IMD quintile 0.868 0.99 0.97-1.02 0.558 
Diagnosed after 2008 0.827 1.01 0.99-1.03 0.465 
No of pleural procedures 0.006 1.00 0.98-1.02 0.774 
Appendix Table 3a Mantel Haenszel test for interactions between pre-specified variables on the 
association with pleural infection  
Abbreviations: CI – confidence interval, IMD – index of multiple deprivation, RR – relative risk 











 Adjusted analysis 
 HR 95% CI p 
Pleural infection            Pre-infection/no infection 
First 30 days post- infection 





1.51 to 2.36 




Male gender 1.27 1.22 to 1.32 <0.001 











1.12 to 1.23 
1.27 to 1.39 
1.50 to 1.65 


















0.91 to 0.99 
0.90 to 0.98 
- 
0.92 to 1.01 
0.95 to 1.04 








Urban ≥10,000 population 
Town and Fringe 
Village 








0.99 to 1.09 
0.95 to 1.06 
















1.04 to 1.25 





Diagnosed after 2008 0.87 0.85 to 0. 90 <0.001 
No. of comorbid codes 0.97 0.97 to 0.98 <0.001 
Non-pleural mesothelioma 0.94 0.91 to 0.96 <0.001 
Documented asbestos exposure 1.10 1.06 to 1.15 <0.001 












1.17 to 1.27 
0.85 to 0.94 
1.06 to 1.14 






Total no. of pleural procedures 0.87  0.85 to 0.89 <0.001 
Average no. of hospital episodes per year 0.98 0.98 to 0.99 <0.001 






0.95 to 1.02 
0.87 to 1.18 




Abbreviations: CI – confidence interval; HR – Hazard ratio for mesothelioma-specific mortality; 
IMD – index of multiple deprivation. 
  
Appendix Table 3b Factors associated with mesothelioma-specific mortality in 22,149 
patients with mesothelioma, from adjusted Cox proportional hazards models.  All listed 





 Adjusted analysis 
 HR 95% CI p 
Pleural infection 
Pre-infection/no infection 
First 30 days post- infection 







1.31 to 2.35 





Male gender 1.29 1.23 to 1.36 <0.001 











1.05 to 1.19 
1.18 to 1.33 
1.36 to 1.53 


















0.86 to 0.98 
0.89 to 1.00 
- 
0.92 to 1.04 
0.93 to 1.05 








Urban ≥10,000 population 
Town and Fringe 
Village 








0.97 to 1.10 
0.96 to 1.11 
















0.87 to 1.12 





Diagnosed after 2008 0.87 0.84 to 0.91 <0.001 
No. of comorbid codes 0.99 0.98 to 0.99 0.005 
Documented asbestos exposure 1.07 1.02 to 1.13 0.004 












1.07 to 1.19 
0.80 to 0.90 
1.01 to 1.10 






Total no. of pleural procedures 0.91 0.88 to 0.93 <0.001 
Average no. of hospital episodes per year 0.99  0.98 to 0.99 <0.001 






0.51 to 0.57 
0.74 to 1.13 





Appendix Table 3c Factors associated with all-cause mortality in 11,401 patients with pleural 
mesothelioma, from adjusted Cox proportional hazards models, in which all listed variables 
were included.   
 








Variable VIF Tolerance R2 
Pleural infection 1.08 0.926 0.074 
Male gender 1.03 0.968 0.032 
Age at diagnosis                        1.20 0.830 0.169 
IMD quintile 1.04 0.964 0.036 
Rural/urban location 1.03 0.972 0.028 
Mode of initial attendance 1.10 0.907 0.093 
Diagnosed after 2008 1.10 0.905 0.095 
No. of comorbid codes 1.22 0.817 0.182 
Non-pleural mesothelioma 1.08 0.927 0.073 
Documented asbestos exposure 1.08 0.926 0.075 





















Total no. of pleural procedures 4.57 0.219 0.781 


















Appendix Table 3d Test for collinearity within multivariable survival analysis.  
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   MM 
  
YYYY DD 
CLINICAL ASSESSMENT (BASELINE)  
 
1. TILT ELIGIBILITY & PARTICIPATION  
 
 
If you have not assessed their eligibility for TILT, please do so, using form 
TILT01 or the trial database. 
If the participant is eligible for TILT, please complete data collection for this 
visit, and refer to the TILT protocol for instructions on what to do next. 
 
2. PARTICIPANT INFORMATION  
Sex MALE FEMALE 
Age years 
Weight  kgs 
Height m 
Performance status 0 1 2 3 4 
 
Date diagnosis of MPM was confirmed at MDT DD/MM/YYYY 
Method of diagnosis Clinico-radiological Cytology Histology 
If ‘Histology’, what was 
the diagnosis? Epithelioid Sarcomatoid Biphasic Desmoplastic 










Side of disease Bilateral Left Right 
IPC in situ? YES NO 
Date of IPC insertion DD/MM/YYYY 
Side of IPC  Bilateral Left Right 
 
Have you assessed the participant’s eligibility for TILT? YES NO 
Are they eligible to participate in TILT? YES NO 
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What symptoms did the participant have at presentation? (Tick all that apply) 






Weight loss  
Other (please specify:______________________________)  
Duration of symptoms at presentation <1 month 1-2 months > 2 months 
 
4. PREVIOUS MEDICAL HISTORY 
Does the participant have a history of any of the following conditions? 
 
CANCER 
Previous or current malignancy (other than MPM) YES NO 
Previous or current? Previous Current 
What malignancy?  
RESPIRATORY DISEASE Asthma/COPD YES NO 
Interstitial lung disease (ILD) YES NO 
Bronchiectasis YES NO 
Pulmonary hypertension YES NO 
Pulmonary emboli/ DVT YES NO 
Pleural infection YES NO 
(If yes, which side?) Left Right 
Other respiratory condition (specify:____________) YES NO 
CARDIAC DISEASE Ischaemic heart disease YES NO 
 Atrial fibrillation YES NO 
Heart failure YES NO 
Valvular disease YES NO 
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Other cardiac condition (specify: _______________) YES NO 
OTHER SIGNIFICANT CONDITION Diabetes YES NO 
(If yes, are you on insulin?) YES NO 
Chronic kidney disease YES NO 
Gastrointestinal condition (specify:______________) YES NO 
Neurological condition (specify:________________) YES NO 
Endocrine/hormone condition (specify:__________) YES NO 
 
5. PREVIOUS PLEURAL INTERVENTIONS  
Procedure Undertaken? No of times 
performed 
Diagnostic tap YES NO  
Therapeutic aspiration YES NO  
Chest drain (excluding post-thoracoscopy drains) YES NO  
Talc slurry pleurodesis YES NO  
Image-guided percutaneous pleural biopsy YES NO  
Local anaesthetic thoracoscopy YES NO  
Surgical thoracoscopy or other surgical procedure YES NO  
Talc poudrage YES NO  
Intra-pleural fibrinolytics YES NO  
Other (please specify)________________________ YES NO  
 
Please complete the boxes below for each pleural procedure. 
If they have not had any previous pleural procedures, go to Section 6. 
 
DIAGNOSTIC TAP 
What date was the diagnostic tap? DD  MM YYYY 
Which side was the diagnostic tap? Left Right 
What was the pleural fluid LDH? U/L 
What was the pleural fluid total protein? g/L 
What was the pleural fluid glucose? mmol/L 
What was the serum LDH? U/L 
What was the serum total protein g/L 
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What was the predominant cell type on the first tap?  
 
THERAPEUTIC ASPIRATION 
What date was the therapeutic aspiration? DD  MM YYYY 
Which side was the therapeutic aspiration? Left Right 
What was the volume aspirated? mls 
 
CHEST DRAIN (excluding post thoracoscopy drains) 
What date was chest drain inserted? DD  MM YYYY 
Which side was the chest drain? Left Right 
What was the total volume drained? mls 
 
TALC SLURRY PLEURODESIS 
What date was the talc slurry pleurodesis? DD  MM YYYY 
Which side was the talc slurry pleurodesis Left Right 
 
IMAGE GUIDED PERCUTANEOUS BIOPSY 
What date was the biopsy? DD  MM YYYY 
Which side was the biopsy? Left Right 
 
LOCAL ANAESTHETIC THORACOSCOPY 
What date was the thoracoscopy? DD  MM YYYY 
Which side was the thoracoscopy? Left Right 
 
SURGICAL PROCEDURE 
What was the surgical procedure?  
What date was the surgical procedure? DD  MM YYYY 
Which side was the surgical procedure? Left Right 
 
TALC POUDRAGE 
What date was the talc poudrage? DD  MM YYYY 
Which side was the talc pleurodesis? Left Right 
 
INSERTION OF AN INDWELLING PLEURAL CATHETER 
What date was the IPC inserted? DD  MM YYYY 
Which side was the IPC? Left Right 
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REMOVAL OF AN INDWELLING PLEURAL CATHETER 
What date was the IPC removed? DD  MM YYYY 













 TpA DNAse 
Which intrapleural fibrinolytics (circle all that apply) Streptokinase Urokinase 
 Other:__________________ 
What was the start date for the intrapleural 
fibrinolytics? 
DD  MM YYYY 





Were any of the above procedures felt to be 
necessary but not carried out, or attempted but not 
completed? 
YES NO 
(e.g. Patient required therapeutic aspiration, but procedure not undertaken as 
patient anticoagulated). If yes, please provide details below.  If no, go to Section 6. 




DD MM YYYY  
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6. PLEURAL DRAINAGE 
If the participant has an IPC in situ, please complete the table below with 
the date and volume of every drainage in the past 4 weeks, or since the IPC 
was inserted if less than 4 weeks (including today’s drainage). If the 
participant does not have an IPC in situ, please go to Section 7. 
Date Volume drained 
(mls) 
 Date Volume drained 
(mls) 
DD MM YYYY      DD MM YYYY  
DD MM YYYY  DD MM YYYY  
DD MM YYYY  DD MM YYYY  
DD MM YYYY  DD MM YYYY  
DD MM YYYY  DD MM YYYY  
DD MM YYYY  DD MM YYYY  
DD MM YYYY  DD MM YYYY  
DD MM YYYY  DD MM YYYY  
DD MM YYYY  DD MM YYYY  
DD MM YYYY  DD MM YYYY  
 
7. PREVIOUS MESOTHELIOMA TREATMENT 
Treatment Received
? 














 (DD/MM/YY) (DD/MM/YY) 









X   
Bevacizumab YES NO 
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Has the patient chosen not to receive a specific treatment at 
any point? 
YES NO 
If yes, what treatment did they chose not to 
receive? 
 






8. MEDICATION HISTORY 
Please list all medications that the participant is currently taking: 
 
Drug 












(Doses per day - if PRN 
give approx. frequency) 
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CHECKLIST  DONE 
Please uploaded this data onto the study database. 
 
Please complete eCRF AM08 ‘Blood tests’ for this visit. 
 
Please complete eCRF AM09 ‘Imaging’ for this visit. 
 
Have you asked the participant to complete an EQ-5D-5L QoL questionnaire 
(eCRF AM10) for this visit? 
 
Have you asked the participant to complete symptom VAS scores (eCRF 
AM11) for this visit? 
 
Does participant have a date for their next trial visit? 
(nb this should correspond with their next clinic appointment, if within 3 
months) 
 
If the participant is eligible for TILT, they are now ready for randomisation.   
Please log on to REDCAP & complete eCRF TILT-07a - Randomisation 
 
 
If the participant is eligible for TILT, please complete the checklist below: 
Please randomise the participant using the randomisation module in 
REDCAP.  You may wish to use cribsheet TILT-07a to collect the data for 
randomisation. 
 
DO NOT INFORM PARTICIPANT ABOUT RANDOMISATION AT THIS STAGE 
Provide participant with VAS booklet (AM12)   
Please arrange next trial visit appointment   
 
 
This checklist is intended to assist with data entry onto the electronic CRF.  
Once completed, this checklist can be stored in the patient’s notes as 
source data, stored securely in the participant’s trial file or destroyed. 
  
  DD MM YYYY 
Researcher completing form Signature Date 
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9. BLOOD TESTS 
 
 Result Date   Result Date 
Haemoglobin (g/dL)    Sodium (mmol/L)   
WCC (x109/L)    Potassium (mmol/L)   
Neutrophils (x109/L)    Urea (mmol/L)   
Lymphocytes (x109/L)    Creatinine (mmol/L)   
Platelets (x109/L)    eGFR (mL/min/1.73M2)   
       
CRP (mg/L)    Bilirubin (µmol/L)   
INR    AST (U/L)   
Albumin (g/L)    ALT (U/L)   







 DD MM YYYY 
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1. CHEST X-RAY 
Did the participant have a chest x-ray today? YES NO 
If not, why not? (please tick one) Participant declined  
 Not clinically indicated  
 Participant too frail  
 Other  
 
Is the x-ray normal? YES NO 
If not normal, which side are the abnormalities? LEFT RIGHT 
What are the abnormalities? (Tick all that apply) 
Pleural plaques  
Pleural thickening  
Pleural opacification/ fluid covering < 25% of the hemithorax  
Pleural opacification/ fluid covering 25-50% of the hemithorax  
Pleural opacification/ fluid covering >50% of the hemithorax  
Loculated pleural effusion  
Hydropneumothorax/ trapped lung with < 50% pleural apposition  
Hydropneumothorax/ trapped lung with >50% pleural apposition  
Other abnormality (please specify:_____________________________)  
 
2. CT THORAX 
Has the participant had a CT chest since their last assessment? YES NO 
What was the date of their last CT chest? DD MM YYYY 
What is the radiological staging on the most recent CT scan? T      N             M 
What is the disease status on the most recent CT scan? 
Disease progression  
Stable disease  
Partial response  
Complete response  
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YYYY DD 
3. THORACIC USS - To be completed only if the participant has a pleural effusion. 
Which side is the effusion BILATERAL LEFT RIGHT 
Was thoracic ultrasound performed today? YES NO 
If not, why not? (please tick one) 
                                                                                              Participant declined  
Not clinically indicated  
Participant too frail  
Other (please specify:_______________________________)  
 
Please grade the degree of septation/loculation for the effusion.  If the participant has 




Free-flowing: Non-loculated, no visible septations 
  
 
Mild: Non-loculated, up to 3 septations visible at 
maximally septated area  
 
Moderate: Fluid separated into locules. Between 4 




Heavy: Fluid separated into locules. More than 10 
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I have no problems in walking about      
I have slight problems in walking about     
I have moderate problems in walking about     
I have severe problems in walking about     




I have no problems washing or dressing myself    
I have slight problems washing or dressing myself    
I have moderate problems washing or dressing myself   
I have severe problems washing or dressing myself    
I am unable to wash or dress myself      
 
 
USUAL ACTIVITIES (e.g. work, study, housework,  
family or leisure activities) 
I have no problems doing my usual activities     
I have slight problems doing my usual activities    
I have moderate problems doing my usual activities    
I have severe problems doing my usual activities    
I am unable to do my usual activities      
 
 
PAIN / DISCOMFORT 
I have no pain or discomfort       
I have slight pain or discomfort      
I have moderate pain or discomfort      
I have severe pain or discomfort      
I have extreme pain or discomfort      
 
 
ANXIETY / DEPRESSION 
I am not anxious or depressed      
I am slightly anxious or depressed      
I am moderately anxious or depressed     
I am severely anxious or depressed      
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• We would like to know how good or bad your health is 
TODAY. 
• This scale is numbered from 0 to 100. 
• 100 means the best health you can imagine. 
0 means the worst health you can imagine. 
• Mark an X on the scale to indicate how your health is 
TODAY.  
• Now, please write the number you marked on the scale 
in the box below.  
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Please place a single vertical mark on each line to show how severe your 
symptoms have been in the past 24 hours.  An example is shown below, but 
if you are unsure, please ask a member of the research team to help you. 
 





 IN THE PAST 24 HOURS 






 IN THE PAST 24 HOURS 






 IN THE PAST 24 HOURS 
 HOW MUCH SWEATING HAVE YOU EXPERIENCED?  
 
 














No pain at all 
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Dear [insert name] 
 
I am writing to express my sincere sympathy following the sad loss of your husband/ 
wife.  
 
I also wanted to tell you how grateful I am for ____________’s involvement in our 
research.  I recognise that taking part made demands of both of your time and energy, 
and I wanted to let you know that those efforts were appreciated.   
 
_________’s experience of taking part in research is important to us, as is your 
experience of helping him/her take part.  If you, or a member of your family, wanted to 
share your thoughts about _____________’s involvement in research, we would be very 
interested to hear about it, in a face-to-face meeting.  I have included an information 
sheet with this letter so you can read about what that meeting would involve.  If you 
would like me to give you a call and tell you a bit more about it, please return the 
enclosed form with your telephone number and the best time of day to call. 
 
If you do not want to do this, I completely understand, and we will not contact you 
about it again.  I would like to thank you once more for _____________’s and your 
contribution to our research and let you know that my thoughts are with you at this 
difficult time. 
 




Dr Anna Bibby 





Dear Dr Bibby 
 
Re: Invitation to take part in a one-to-one interview 
 
I am considering meeting to talk about my relative’s participation in research and/or I 
am interested in hearing more about what it would involve.   I would like to be 
















___________________________________   ________________________ 




Appendix 6 – Topic guide for qualitative interviews 
 
Interview topic guide  
 
 
The interviewer will use this guide as a flexible template for interview topics and 
questions.  However the interviewer will also respond to participants’ answers and 




Explain that the interview will be recorded and discuss issues of confidentiality and 
anonymisation.  Explain that the aim of the research is to understand participants’ 
experiences of having mesothelioma and taking part in a research study.  The information 
will be used to improve future research studies, and our interactions with patients in 
clinical care. 
 
Reaffirm consent, and check that the participant is happy to take part in the interview.  
Check whether the participant has any questions prior to starting the interview. 
 
 
Part 1 – participating in research 
I’d like to talk about your participation in research. 
• Overall experience of pleural service 
• Initial thoughts on ASSESS-meso 
• Factors affecting decision to take part 
• Discussed with anyone? 
o Who and what? 
• Did potential for trials affect decision? 
o Positive or negative? Agree to be considered for future trials? 
• ASSESS-meso assessments  
o Frequency 
o Ease of completion 
o Blood tests & IPC drainages 
• Anything particularly good? 
• Anything particularly difficult? 
 
Part 2 – receiving OK-432/BCG (for TILT participants only) 
• Initial invitation to join TILT 
• Thoughts, feelings or concerns about OK-432/BCG 
• Experience receiving OK-432/BCG 
• Any problems after OK-432/BCG? 





Part 3 – reasons for not participating (people who declined any element of the study) 
• Reasons for not participating 
• Anything that would have changed your decision? 
• Any other considerations? 
 
Part 4 – TWIC methodology 
• Explain RCT design – any thoughts?  
• Explain TWICS – what thoughts? 
• More or less fair? 
• How would you feel if you found out other people in ASSESS-meso had been invited to 
join a trial and you had not? 
 
Thank you and close 
• Any other thoughts about research? 
• Any other comments about mesothelioma? 
• Any questions for me? 
Thank you for taking part. 
 
